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ABSTRACT
The behaviour of morphine and morphine glucuronides has 
been defined in an attempt to overcome the confusion 
surrounding the pharmacokinetics of morphine and the 
potential contribution of the active metabolite 
morphine-6-glucuronide (M6G), to the clinical effects 
observed after morphine treatment.
Differential RIAs for the quantitation of morphine, M6G, 
and morphine-3-glucuronide (M3G) in a range of biological 
fluids have been developed. A specific M6G antiserum, 
suitable for use in an immunoassay, has been successfully 
raised.
Pharmacokinetic parameters for morphine and M6G have 
been established in volunteers treated with morphine. Similar 
quantities of morphine and M6G were. observed after 
intravenous dosing. Bioavailabilities of enteral morphine 
preparations ranged between 19% and 24%. There was little 
difference between these routes with respect to the relative 
quantities of morphine and M6G measured, with quantities of 
M6G exceeding those of morphine by up to 7-fold.
Data obtained following intravenous morphine or M6G 
revealed similar elimination half-lives for both compounds. 
M6G was less widely distributed and not significantly bound 
by plasma proteins. Significant biliary concentrations of 
morphine and morphine glucuronides suggested the presence of 
an enterohepatic circulation, but no secondary plasma peaks 
or prolonged elimination half-lives were apparent.
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After systemic administration, significantly less M6G 
than morphine entered the central nervous system (CNS). In 
rats, the mean brain:serum ratios for morphine and M6G were
0.4:1 and 0.2:1 respectively. A mean cerebrospinal fluid 
(CSF):plasma morphine ratio of 0.9:1 was found in patients 
receiving intravenous morphine; no M6G was detected in the 
CSF. After oral morphine, mean CSF:plasma ratios were 0.6:1 
and 0.3:1 for morphine and M6G respectively. A similar rate 
of disappearance from the CNS was observed for both morphine 
and M6G. Following intravenous M6G, the mean M6G CSF:plasma 
ratio was 0.1:1. Morphine was absent from the CSF and plasma 
indicating that the clinical effects observed are due to M6G 
alone.
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CHAPTER ONE
LITERATURE REVIEW
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1.1. GENERAL INTRODUCTION
Opium, the dried latex from the unripe seed capsules of 
the poppy, Paoaver somniferum, has been used medicinally as 
an analgesic for over 5000 years. Indeed, to date it is still 
the drug of choice for the treatment of severe pain, in 
particular that associated with advanced cancer.
Opium is known to contain at least 23 different 
alkaloids of which morphine possesses the most marked 
analgesic activity. It was the German pharmacist, Friedrich 
Serturner, who first isolated morphine from opium in 1805, 
although its chemical structure was uncertain until 1925 
(Fig.1.1(a)). Interest in the mode of action of morphine has 
remained since these times, and its pharmacology has been 
extensively studied, particularly in animals. However, 
despite this, many aspects of its metabolism and pharmacology 
are still not clearly understood, particularly in the 
clinical situation. One of the major reasons for this has 
been the lack of suitable analytical techniques. It is only 
since 1974 that techniques of adequate sensitivity have been 
available to study the metabolism and pharmacokinetics of 
morphine after conventional doses in man. Since this time, a 
large number of studies have been carried out and more 
details on the pharmacokinetics of morphine after the common 
routes of administration have become available. However, 
attempts to establish a pharmacodynamic/pharmacokinetic 
relationship between the plasma levels of morphine measured 
and the clinical effects observed have been far from
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successful. This may be due to a number of factors including 
the problem of morphine tolerance and the difficulties 
experienced in assessing pain in the clinical situation. 
Another problem that has more recently become apparent is the 
potential contribution to morphine's clinical effects of 
analgesically active metabolites. Of particular interest is 
the importance of the contribution of morphine-6-glucuronide 
(M6G) (Fig.1.1(b)) to the analgesia and toxicity of morphine, 
a factor that has only recently become appreciated as better 
analytical techniques have begun to provide a more complete
picture of the overall metabolic fate of morphine in man.
In this chapter, an attempt has been made to review the
present knowledge about morphine in terms of the methods
available for its detection in biological fluids, its 
metabolic fate and pharmacokinetics, and its
pharmacodynamics.
In the majority of studies published to date, values for 
morphine and its metabolites have been expressed in mass 
units. However, more recent studies have adopted molar units 
and these have been used throughout this thesis, and where 
possible results from other studies have been converted.
In the present studies, morphine alkaloid base in 
association with one molecule of water has been used 
(monohydrate). The molecular weight of this complex is 303.4 
and for conversion purposes Ing/ml = 3.30 nmol/1.
For clinical use, morphine is only prescribed in the 
form of its two water-soluble salts:
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1) Morphine sulphate - occurs as a dimer in association with 
five molecules of water. The molecular weight is 758.84 and 
the conversion factor is Ing/ml = 2.64nmol/l.
2) Morphine hydrochloride - is used in the form of the 
trihydrate which has a molecular weight 375.86. For 
conversion purposes, Ing/ml = 2.66 nmol/1.
Morphine-6-glucuronide and morphine-3-glucuronide were 
available as single molecules in association with two water 
molecules. The molecular weight is 497.53 and Ing/ml = 
2.Olnmol/1.
1.2. THE METABOLIC FATE OF MORPHINE.
The pathways involved in the metabolism of morphine in 
humans are summarised in Fig.1.2. Morphine undergoes 
extensive biotransformation predominantly by phase II 
conjugation to M3G, M6G and small quantities of 
morphine-3,6-diglucuronide (Boerner &1., 1975). The enzyme 
responsible, uridinic pyrophosphoglucuronyl transferase 
(UDPGT), is known to occur in a number of different forms, 
and it has been suggested that two different forms are 
responsible for M3G and M6G formation (Boerner and Abbott, 
1973). The vast majority of data on the in vivo interaction 
of morphine and UDPGT has involved the study of M3G 
production, although it has recently been shown that the 
formation of morphine glucuronides in rat and human liver is 
enantioselective and involves more than one UDPGT isoenzyme
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Fig.1.2. Metabolism of morphine and related compounds
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(Miners si. si»/ 1988; Coughtrie et al., 1989). It would also 
appear that the glucuronidation of morphine, codeine and 
naloxone in human liver are under the control of similar 
UDPGTs (Wahlstrom et al., 1989).
UDPGT activity has been investigated in a number of 
human and animal tissues. Jacqz and colleagues (1986) 
observed that, in dogs, morphine was glucuronidated to 
approximately the same extent by both hepatic and 
extrahepatic glucuronyl transferases. Studies of human 
microsomal fractions of liver and intestinal mucosal cells 
have provided a wide range of results for UDPGT activity, 
mainly arising from the considerable inter-individual 
differences observed (Sawe et ^ . , 1982). Pacifici et al.
(1986) observed that the average rate of morphine 
glucuronidation was 0.58 and 0.27nmol/min/mg of protein in 
homogenates of liver and intestinal mucosa respectively. 
However, their results were based on mean rates measured in a 
limited number of randomly selected intestinal sections and, 
as such, their validity is questionable in the light of the 
findings by Roster gt aJL. (1985a) that glucuronidation 
capacity varied considerably along the gut.
The majority of these early studies were unable to 
address the question of M6G formation. However, since a 
method capable of measuring this metabolite became available 
(Svensson et al., 1982), more interesting information has 
been forthcoming. To date, no quantitative studies 
investigating the production of morphine-3,6-diglucuronide
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have been published. Svensson and colleagues (1982) reported 
that when human liver microsomes were incubated with morphine 
and uridine diphosphoglucuronic acid, M3G and M6G were 
synthesised in the same proportions as were found in plasma. 
In a more detailed study carried out in six cancer patients, 
Sawe et (1985) showed a clear correlation between UDPGT
activity in liver biopsy specimens and M3G;morphine ratios in 
plasma. More recently, it has been shown that in children the 
capacity to glucuronidate morphine slowly increases from 
birth, and that the pathways controlling the production of 
M3G and M6G subsequently develop in parallel (Choonara et 
al., 1989). The results of Shelly gt âl» (1988) are also of
interest since they indicated that the technique used for 
anaesthesia could influence metabolite production by altering 
splanchnic blood flow.
Although there has been much interest in the extent to 
which glucuronidation of morphine occurs extrahepatically, 
particularly in the kidney, reliable information is sparse. 
Schali and Roch-Ramel (1982) ■ demonstrated the formation of 
morphine glucuronides in isolated rabbit kidney proximal 
tubules iû vitro but were unable to distinguish between M3G 
and M6G. In two chronically cannulated cows, the hepatic 
extraction ratio decreased from 0.7, at portal vein plasma 
levels above 2jumol/l, to zero at 200nmol/l (Bullingham et 
âi. , 1984), although the clinical relevance of these findings 
is dubious. A more recent study by Yue ^1* (1988) has
provided in vitro evidence for the formation of M3G and M6G
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from morphine by human kidney microsomes. The above findings 
are in contrast to those reported by Merrell et aJL. (1990) 
who recorded a negligible extraction ratio of morphine across 
the dog kidney in vivo and also those of Bodenham ^  al. 
(1989) who concluded that the liver is the primary site for 
morphine metabolism in patients undergoing hepatic 
transplantation.
Human CNS tissue has been shown to have a minor capacity 
for glucuronidating morphine (Wahlstrôm et , 1988). In
another study, no evidence for pulmonary metabolism of 
morphine in patients was found (Ratcliffe, 1989).
The biotransformation of morphine also involves a number 
of other minor metabolic pathways (Boerner et sJL. , 19 75). 
Normorphine is produced by N-demethylation of morphine and 
the majority of this is converted to
normorphine-3-glucuronide and normorphine-6-glucuronide, both 
of which have been identified in human urine (Yeh et al., 
1977). The importance of normorphine as a metabolite of 
morphine is still under debate, although it may account for 
more than 5% of an administered dose of morphine (Yeh, 1973), 
and this figure may be higher after oral dosing than after 
i.v. dosing (Brunk and Delle, 1974), or may be reduced in 
addicts (Hahn aJL. , 1977). Other groups have been unable to 
demonstrate the presence of significant levels of 
normorphine, even after chronic oral dosing with morphine 
(Sawe et &1., 1983a; Joel S.P., personal communication).
Evidence for the importance of codeine as a metabolite
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of morphine is similarly conflicting. Its formation by the 
3-0-methylation of morphine has been demonstrated in dogs and 
rats (Elison and Elliott, 1964) and significant quantities 
were observed in man by Boerner and Abbott (1973). However, 
Yeh (1974) found no evidence for its production from morphine 
in man.
The formation of 3-ethereal and 6-ethereal sulphates of 
morphine is also likely to be of significance in man, 
although only the former metabolite has been detected (Yeh, 
1973). The production of morphine-N-oxide may also
represent another minor metabolic pathway (Woo ^  &À., 19 68).
The above pathways represent the current knowledge 
available on the metabolic fate of morphine. Nonetheless, 
this process has still not been completely elucidated and 
Boerner ^  §1. (1975) stated that 10-20% of a given dose
remains unaccounted for. In their attempts to explain this 
loss, Quinn et (1988a) investigated the in vitro
metabolism of morphine in samples of whole blood and plasma 
prior to analysis. They were unable to demonstrate any 
metabolism, but suggested that some morphine may possibly be 
retained in the centrifuged blood cells. More detailed 
information on this topic is still required.
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1.3. THE DETECTION OF MORPHINE AND MORPHINE GLUCURONIDES IN 
BIOLOGICAL SAMPLES
1.3.1. Introduction
Until the early 1970s, there was a lack of assay 
procedures capable of detecting morphine after conventional 
doses in man, and this largely explains why reliable 
information on its metabolism and pharmacokinetics has only 
recently become available. Early studies investigating the 
metabolism of morphine relied on colorimetric techniques 
using the principle of an organic base forming a soluble 
complex with an organic acid. These methods were extremely 
labour-intensive and lacked specificity. The availability of 
radiolabelled morphine (notably 14C) allowed more accurate 
metabolism studies to be performed and some useful 
information was provided by these investigations. Limitations 
with such techniques include the difficulties involved in 
achieving direct quantitative measurements and the ethical 
problems associated with the administration of these isotopes 
to humans. Early attempts to measure morphine by photometry 
and fluorometry failed to achieve adequate sensitivity. 
Eventually, a fluorometric method, with greater sensitivity, 
became available (Kupferberg êt al., 1964), which allowed the 
determination of high nanogram levels of morphine. 
Unfortunately, this method was relatively non-specific and 
extensive extraction of biological samples was still 
required.
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significant advances have been made in the field of drug 
analysis over the last 20 years, and whilst many of these 
techniques (e.g. thin-layer chromatography (TLC) Wang et 
al.r 1986) are only suitable for qualitative or 
semi-quantitative analysis, other methods with much improved 
sensitivity have allowed the quantitation of morphine in a 
wide range of biological fluids (see Holder, 1986). 
Nevertheless, a fundamental limitation of studies
investigating the pharmacokinetics of morphine has remained
i.e. many of the standard assay techniques used have, until 
recently, been unable to reliably distinguish morphine from 
its metabolites. This has severely hampered attempts to 
investigate the in vivo fate of the drug. Indirect estimates 
of morphine glucuronide metabolites have been made by 
measuring free morphine and total morphine after hydrolysis 
of the sample. However, the relative stability of M6G 
(Yoshimura &t âi*/ 1968) may have rendered these measurements 
inaccurate, and has highlighted the need for methods capable 
of direct quantitation of morphine and its metabolites.
Three major assay techniques are currently in use for 
the determination of morphine, namely gas-liquid 
chromatography (GLC), high-performance liquid chromatography 
(HPLC) and immunoassays, generally those employing 
radiolabels (radioimmunoassay) (RIA). In this section the 
assays available will be reviewed and, where appropriate, 
their application to the additional measurements of morphine 
metabolites is also considered.
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1.3.2. Gas Liquid Chromatography (GLC^
The versatility of GLC in being able to separate a wide 
range of organic compounds of relatively low molecular weight 
has made it a powerful technique in the identification and 
quantitation of drugs. For the operation of GLC, the 
chromatographic column is packed with a stationary phase that 
consists of a finely divided support coated with a 
non-volatile liquid. An inert gas is passed through this 
system and the components of a volatile mixture are separated 
by distribution between the gas phase and the stationary 
phase, the principle separation parameter being the nature of 
the stationary phase and its percentage coating onto the 
inert support. The major advance in GLC has been in the 
development of capillary columns which can reduce analysis 
time and improve the reproducibility at low concentrations.
Until recently, the sensitivity and specificity of GLC 
made it the most attractive method for the determination of 
morphine in biological samples. GLC chromatographic 
separation of morphine was first described by Lloyd et al. 
(1960), and since then a large number of different methods 
have been described. Recently, some of these methods have 
been adapted for use with capillary columns (Edlund, 1981; 
Lora-Tamayo et ^ . , 1987). The low volatility and relative
high polarity of morphine renders it difficult to analyse at 
low levels by GLC. For this reason, a range of derivatives 
have been prepared by reacting morphine with an organic 
molecule usually an acid anhydride. Originally,
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trimethylsilyl derivatisation was employed (Wilkinson and 
Way, 1969; Cone ^  , 1983), but the tendency now is to use
molecules containing fluorine, such as the trifluoroacetyl 
derivative (Yeh, 1973; Wallace and Hamilton, 1974), the 
pentafluoropropionic derivative (Dahlstrom and Paalzow,
1975a; Garrett and Gurkan, 1978), or the heptafluorobutyryl 
derivative (Lora-Tamayo ^  r 1987).
Following chromatographic separation, morphine has been 
detected in a number of different ways. The comparatively 
non-selective flame-ionisation detector (FID) has been used 
(Wilkinson and Way, 1969) but it has been surpassed by 
electron capture detection which offers increased sensitivity 
down to levels between 2 and lOnmol/1 (Wallace and Hamilton, 
1974; Dahlstrom and Paalzow, 1975a). The use of nitrogen 
specific detectors alone, or in combination with FID, has 
also been reported (Vu-Duc and Vernay, 1990). As a method of 
detection with GLC, mass spectrometry (MS) offers exquisite 
sensitivity and specificity and is the most suitable assay 
for the unequivocal identification of drugs. Morphine has 
been quantitated by MS using the stable isotope method 
(Ebbinghausen et al., 1973) and by selected ion monitoring
(Drost Qt al., 1984; Bowie and Kirkpatrick, 1989; Chen et
al., 1990).
Of these methods, the one described by Dahlstrom and 
Paalzow (1975a) has been proven to be the most popular; it is 
more straightforward and less expensive than the GC/MS
techniques, and is apparently the most sensitive of the GLC
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methods currently in use with a detection limit of lnmol/1.
Overall, GLC provides a sensitive and accurate method 
for the detection of morphine. However, direct analysis of 
its metabolites is not possible. This drawback, together with 
the requirement for time-consuming extraction and 
derivatisation procedures, has led to GLC being less widely 
used for morphine pharmacokinetic studies, being superceded 
by HPLC and RIA.
1.3.3. High Performance Liquid Chromatoaraphv fHPLCl
HPLC is a technique that has arisen from the application 
to liquid chromatography of the theories and instrumentation 
that were originally developed for GLC. In HPLC, separation 
of a mixture of solutes is achieved due to differences in 
their partition coefficients between the stationary phase and 
the liquid mobile phase.
The use of HPLC has become extremely attractive as an 
analytical tool in drug analysis. This stems from the fact 
that chromatography with a liquid mobile phase is more 
appropriate for most compounds of biological origin than GLC 
because these compounds are usually non-volatile and, in the 
case of many drugs and metabolites, are relatively polar. Due 
to the problems encountered in the analysis of morphine by
the methods discussed so far, it comes as no surprise to
learn of the large number of HPLC methods that have been
published for the measurement of morphine in biological
fluids. Some of these methods involve the analysis of
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morphine alone, whilst others have been developed to allow 
the simultaneous measurement of morphine with other alkaloids 
and/or metabolites.
1.3.3.1. Sample Preparation
Morphine is an alkaloid that exhibits an amphoteric 
character (pKa= 8.2), and has been extracted from biological 
fluids by a variety of different procedures. Both 
liquid-liquid and liquid-solid extraction techniques have 
been developed and it is now possible to selectively 
concentrate morphine, relatively free from contaminants, from 
a number of biological fluids. A number of these methods have 
included a suitable internal standard in the sample that is 
subjected to the same extraction process, and enables the 
efficiency of the procedure to be monitored. Generally, a 
morphine-like molecule has been used with nalorphine proving 
to be a popular choice (Wallace et al., 1980; Nelson et al ;, 
1982; Kim and Kats, 1984; Tagliaro e^ a%., 1985).
Although a number of organic solvents with a wide range 
of polarities have been used for the extraction of morphine, 
the most popular choice has been a mixture of a chlorinated 
hydrocarbon and an alcohol used over an optimum pH range of 
8.5 and 9.0 (Jane and Taylor, 1975; Wallace, et âlw 19 80; 
Nelson et ai-, 1982; Tagliaro êt &1., 1985). Other groups 
have simply used chloroform (Vandenberghe et âiw 1982; Kim 
and Kats, 1984; Turner and Murphy, 1988), although Dahlstrom 
et al. (1977) found that the inclusion of an alcohol improved
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recoveries due to reduced adsorption losses. When more 
selective extraction has been required, multiple-stage 
procedures have been used involving back-extraction from the 
organic solvent into an aqueous phase (Tagliaro ei al., 1985; 
Chen et al., 1989).
A number of traditional liquid-solid extraction 
techniques have been used for morphine in the form of columns 
or cartridges containing Dowex or Amberlite XAD-2 resins 
(Yoshimura et ^ . , 1969; Misra et al., 1970). More recently, 
small columns containing new solid phases that possess a wide 
variety of surface properties have become available. By 
choosing an appropriate phase to match the physicochemical 
properties of the compounds for extraction, the material of 
interest is retained on the solid support. As many 
potentially interfering substances as possible are eluted^ 
and the solute of interest is then desorbed leaving further 
unwanted endogenous material behind. This procedure offers 
advantages over liquid-liquid extraction techniques in that 
the problems associated with emulsion formation are avoided, 
and it is considerably easier to automate. The potential use 
of this technology for the extraction of morphine and/or its 
metabolites has been investigated and a number of methods 
have been reported. The method of Moore et al. (1984a), using 
non-polar octadecasilyl (C18) bonded silica columns with 
methanol as the eluting solvent, represents the simplest 
example of this technique for morphine and claims an 
extraction efficiency of > 95%. Similar procedures have been
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used for extraction of morphine from whole blood and/or urine 
by other groups (Abbott et al., 19 87; Tebbett, 1987).
In 1982, Svensson and co-workers published a complicated 
but valuable extraction procedure employing Cl8 solid-phase 
columns which WOvf able to selectively extract morphine, M3G, 
M6G and normorphine from samples of plasma and urine. The 
extraction efficiency of this method was found to be 84% for 
morphine and 9 0% for M3G at high nanomolar concentrations, 
with no data at lower concentrations available. They were 
unable to assess the extraction efficiency for M6G due to the 
lack of the raw metabolite. However, this procedure has 
recently been automated (Joel et , 1988) leading to a
subsequent improvement in the extraction efficiencies, 
reported to be at least 80% for morphine and M6G at levels > 
40nmol/l and M3G at levels > 400nmol/l. This method has found 
widespread use, but is not without its drawbacks as it is 
very labour-intensive and expensive. No data on the 
extraction efficiencies at low levels are available and, in 
the absence of a suitable internal standard or other quality 
control, the method still requires further validation. In 
their recent report, Venn and Michalkiewicz (1990) describe 
the use of a simpler extraction procedure for the same 
compounds using C2 solid-phase columns and quote excellent 
recoveries. However, as above, data at low levels is lacking 
and there is no internal standard or other quality control.
An alternative approach to sample preparation using 
on-line plasma sample clean-up has recently been proposed by
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Konishi and Hashimoto (1990). This method employed 
N-ethylnormorphine as an internal standard and apparently 
gave rise to excellent assay precision at levels down to 
approximately lOnmol/1 for morphine and M6G and 80nmol/l for 
M3G.
1.3.3.2■ Chromatographic Procedures
HPLC methods for the measurement of morphine employing 
several different forms of stationary phase have been 
published. A limited number of these methods have made use of 
normal-phase chromatography, employing a polar stationary 
phase in the form of microparticulate silica together with a 
relatively non-polar mobile phase (Jane and Taylor, 1975: 
White, 197 9; Gourlay et al., 19 85; Zoer et 1986).
However, the more versatile reverse phase chromatography, in 
which the stationary phase is less polar than the mobile 
phase, is far more suitable for the chromatographic 
separation of polar compounds. For this reason, the majority 
of HPLC methods available for these compounds are based on 
this technology (Wallace ^  âiw 1980; Nelson al., 1982; 
Raffa al. , 1982; Todd êt alw 1982; Owen and Sitar, 1983; 
Kim and Kats, 1984). In general, these methods use a mobile 
phase consisting of an aqueous buffer solution and a low 
percentage of a relatively polar organic modifier (e.g. 
methanol or acetonitrile). For ionisable compounds, such as 
morphine, further refinements have been reported using the 
technique of ion-pair chromatography (Olieman et al., 1977;
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Svensson et âl*/ 1982; Vandenberghe et , 1982; Moore et
al., 1984a; Turner and Murphy, 1988; Harris et al., 1988; 
O'Connor et &1., 1989; Schneider and Ravenscroft, 1989). This 
procedure involves suppressing the ionisation of the 
compounds of interest by adjusting the pH, followed by the 
formation of an "ion-pair" complex with a counter ion usually 
present in the mobile phase. This complex may then be 
chromatographed as a neutral polar molecule by reverse phase 
HPLC on a C18 column. The method of Svensson and co-workers 
(1982), based on that developed for codeine by Kubiak and 
Munson (1980), has found the most widespread use as it allows 
the simultaneous separation of morphine, M3G, M6G and 
normorphine. In order to achieve this finely tuned 
separation, the concentration of the pairing ion was modified 
and the pH of the mobile phase was adjusted to 2.1, in order 
to completely suppress the ionisation of the glucuronic acid 
moiety (pKa= 3.3). In another recent report, Tagliaro and 
coworkers (1988) adopted a different approach by using 
reverse phase HPLC with a polymeric column and a basic mobile 
phase (pH 9.5) to chromatograph morphine.
1.3.3.3. Detection and Quantitation
A number of detection systems are available for use with 
HPLC, and several of these have been successfully adapted for 
the quantitation of morphine. However, a number of problems 
have been encountered in attempting to quantify low levels of 
morphine and  ^its metabolites after chromatographic
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separation. Early methods relied upon the detection of 
ultra-violet (U.V.) absorption (Knox and Jurand, 1973; 
Svensson et aj,.. , 1982) with an optimum detection limit of 
lOnmol/1 for morphine. Attempts have been made to improve the 
specificity of U.V. detection by the use of dual wavelength 
detection (Baker et aJ.., 1979 ), and U.V. detection is still 
used in forensic studies (Tebbett, 1987).
In order to improve upon the sensitivity offered by U.V.
absorbance, attempts have been made to quantify morphine and 
its metabolites by fluorescence detection. Despite the 
findings of Glasel and Venn (1981), it was generally 
accepted that, although M3G is readily detectable by this
method, morphine and M6G are only weakly fluorescent. Minor 
improvements in sensitivity have been made by derivatising 
morphine to its fluorescent dimer, pseudomorphine (Jane and 
Taylor, 1975; Nelson Qt 1982), or by using pre-column
dansyl derivatisation (Tagliaro et âiw 1985). Nevertheless, 
methods employing this detection technique for morphine and 
its metabolites in their native states have recently been
published with detection limits of 6nmol/l for morphine (Chen 
et al., 1989; Schneider and Ravenscroft, 1989) or between 1
and 4nmol/l for morphine, M3G, M6G, normorphine and codeine 
(Venn and Michalkiewicz, 1990).
As White (1979) had reported that nanomolar quantities 
of morphine could not be reliably detected by fluorescence, a 
number of groups proceeded to investigate the potential of 
electrochemical detection (ECD). It was subsequently found
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that morphine could indeed be specifically quantified using 
ECD in the oxidative mode, and sensitivities down to 3nmol/l 
have been claimed (White, 1979; Wallace âl*/ 1980; Todd et 
al., 1982). In the light of this information, Svensson 
adapted his original method (1982) to enable morphine, M6G 
and normorphine to be detected by HPLC with ECD and claimed 
improved assay reproducibility and a sensitivity of lnmol/1 
(Svensson, 1986). Unfortunately, the absence of the 
electroactive group, believed to be at the 3-phenolic 
hydroxyl position on the morphine molecule, renders M3G 
undetectable by this method and this compound has to be 
detected using either U.V. absorbance or fluorescence (Joel 
et al., 1988). The advantages of using ECD for the detection 
of morphine and/or its metabolites after chromatography are 
reflected in the large number of methods using this technique 
that are currently available (Raffa ^  al,, 1982;
Vandenberghe et al., 1982; Owen and Sitar, 1983; Moore et 
âJLw 1984a; Gourlay al. f 1985; Zoer si al. , 1986; Shah and 
Mason, 1987; Tagliaro et al.. , 1988; Turner and Murphy, 1988). 
In their method, Harris and coworkers (1988) report the use 
of two EC detectors in series, leading to better 
discrimination between morphine and the contaminants present 
in human plasma samples.
Other techniques that have been used for the detection 
of morphine after HPLC separation include the potentially 
very sensitive chemiluminescence technique, described by 
Abbott and coworkers (1987) and the use of immunoassay to
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assess the fractions collected from an HPLC column (Nelson et 
al.r 1980). The potential of these techniques requires 
further investigation.
In conclusion, a number of HPLC methods are available 
for the detection of morphine in biological samples (see 
review by Tagliaro et al., 1989). However, the methods
described by Svensson and co-workers (1982; 1986), and
subsequently improved by Joel et al. (1988), represent the 
only HPLC methods for the direct, simultaneous determination 
of morphine and its metabolites that have so far gained wide 
acceptability. Unfortunately, these methods require multiple 
extraction procedures and complex chromatographic systems to 
ensure reproducibility and resolution and are therefore 
time-consuming, expensive and difficult to master. For this 
reason, the potential of the method recently published by 
Venn and Michalkiewicz (1990) needs further investigation and 
the need for a simple, robust, sensitive, specific and 
relatively inexpensive HPLC method for the quantitation of 
morphine and its metabolites is still apparent.
1.3.4. Radioimmunoassay fRIAt
Historically, radioiodinated antigens and antibodies 
were first used by immunologists in the study of 
antigen-antibody reactions in the early 1950s. Yalow and 
Berson were the first to point out the remarkable sensitivity 
possible when unlabelled antigens are measured by their 
ability to competitively inhibit the binding of highly
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radiolabelled antigens by antibody, and they subsequently 
published the first radioimmunoassay (RIA) method for plasma 
insulin (Yalow and Berson, 1960). RIAs for other protein and 
polypeptide hormones rapidly became available, and the 
concept of RIA was soon extended to compounds of smaller 
molecular weight, notably drugs. However, , it was not until 
later that its full potential in the fields of pharmacology 
and toxicology was recognised (Marks si al., 1974). With an 
antibody of high affinity for the antigen, and a labelled 
antigen or antibody of high specific activity, picogram 
quantities of the antigen can be measured. The success of 
this technique, therefore^lies in its sensitivity. Few other 
assay procedures can match the additional qualities of 
versatility, convenience and speed of throughput that RIA 
also offers. A further attraction that sets RIA apart from 
the majority of chromatographic methods is that it permits 
the direct measurement of a particular substance in a complex 
mixture, such as plasma, thereby obviating the need for 
tedious preliminary extraction procedures unless
cross-reacting substances are found to be present.
RIAs depend upon the principle of saturation analysis. 
The RIA of a drug involves the incubation of a fixed amount 
of radiolabelled form of the drug with standards or samples 
containing the drug with a limited number of antibody binding 
sites. Following the required incubation period, during which 
equilibrium is reached or approached, the antibody bound 
fraction is separated from the unbound (or free) fraction so
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that the amount of radiolabelled drug in either fraction may 
be quantitated. This sequence of events is summarised below.
Ab + Ag + Ag*
Ag*-Ab + Ag-Ab + Ag* + Ag 
Phase separation
Ag*-Ab 
+
Ag-Ab
Ag’
+
Ag
Bound fraction Free fraction
Compounds of relatively low molecular weight, such as 
morphine and other drug molecules, are not naturally 
immunogenic. In order to produce antibodies to these 
compounds, immunogenic conjugates must first be prepared by 
covalently linking the compound (hapten) to a carrier 
protein. The most popular proteins used have been bovine 
serum albumin (BSA), ovalbumin, gamma globulins and 
thyroglobulin. Conjugation usually takes place through the 
lysine or carboxylic acid residues of the protein. The 
chemical reaction may be achieved by a number of methods.
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notably the mixed anhydride (Erlanger et al., 1957) or 
carbodiimide (Kurzer and Douraghi-Zadeh, 19 67) condensation 
reactions, or by the use of hydroxysuccinimide esters 
(Anderson et f 1964). The use of other bifunctional
reagents, such as glutaraldehyde (Reichlein et âi./ 1968) and 
N-(ffi-maleimidobenzoyloxy)-succinimide (MBS) (Kitigawa ^  al., 
1981), has also been described. The type of conjugation 
reaction used depends mainly upon the functional groups 
available on the hapten. Some haptens contain reactive groups 
such as carboxyl, amino, or hydroxyl, through which direct 
conjugation can take place, but often a more appropriate 
analogue or derivative of the compound has to be used. The 
specificity of a resulting antiserum will greatly depend upon 
the point of attachment of the protein to the hapten, since 
antibodies to haptens are directed primarily to determinants 
furthest away from the site of conjugation (Landsteiner, 
1945). Thus, the choice of conjugate requires careful 
consideration. A major shortcoming is that the resulting 
antibody is raised against, and therefore only recognises a 
specific portion of the hapten molecule. Other regions, not 
present on the hapten, may occur on structurally related 
molecules; these regions not^recognised by the antibody,
and the specificity of the interaction is consequently 
reduced. In this way, an antibody raised against one portion 
of a molecule may be unable to distinguish between that 
molecule and a derivative, such as a larger conjugate in 
which the additional material is outside the antibody
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recognition zone (epitope).
Following the production of a hapten-protein conjugate, 
purification by dialysis or gel fi&tration may be necessary
to remove any unreacted hapten. The conjugate is then
prepared for immunisation by émulsification with an adjuvant 
containing inactivated bacteria (Bacillus Calmette-Guerin 
(BCG)). When the animal receives this mixture as the primary 
immunisation, this adjuvant serves to sensitise the immune 
system, as well to ensure that the immunogen is released 
slowly. BCG is absent from any subsequent booster
immunisations, which are generally administered at 3 month 
intervals. However, once an immune response has been
identified, it appears to be advantageous to leave the animal 
for a period of up to 6 months to allow the antibody titre to 
fall to a low plateau before re-boosting (Aherne G.W., 
personal communication).
Each bleed obtained from the animal requires extensive 
characterisation by measurement of antibody titre, avidity 
and specificity. Titre is an indication of the concentration 
of antibodies present, and is defined as the dilution of the 
antiserum that achieves 50% of the maximum binding of a fixed 
amount of radiolabelled antigen. Of greater importance are 
the quality and specificity of the antiserum. Affinity is a 
measure of the energy with which the combining sites of the 
antibody bind the antigen. Avidity is the mean affinity of a 
polyclonal antiserum. These properties are, therefore, an 
indication of the quality of the antiserum. The specificity
page 27
of an antiserum is assessed by monitoring the extent to which 
structural analogues of the hapten cross-react with the 
antiserum. Detail on how these properties are determined, as 
well a description of the other stages involved in the 
optimisation and validation of an RIA is discussed in Chapter 
Two.
For heterogeneous assays, a method of separating the 
free from the antibody-bound fraction of the antigen, without 
disturbing the antigen-antibody equilibrium, is essential 
(phase separation). A number of methods are available for 
this purpose (Ratcliffe, 1974). Although an ideal separation 
procedure does not exist, those that offer a specific 
precipitation, such as immunoprécipitation using a second 
antibody reaction, or by the use of solid-phase reagents, are 
finding favour over the more traditional methods employing 
chemical precipitation, chromatography or adsorption. 
Nevertheless, in general, the use of dextran-coated charcoal, 
which functions as an adsorbent for the unbound antigen 
fraction, still offers a rapid, efficient and cheap method 
for phase separation. This procedure has been employed in the 
assays described in this thesis (Chapter Two).
Due to its widespread clinical use, morphine was one of 
the first drug molecules for which RIAs were developed. The 
first RIA for morphine was described by Spector and Parker 
(1970). The majority of morphine conjugates have been 
prepared by the attachment of the morphine hapten to the 
protein, usually BSA, through the 3-phenolic, the
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6-alcoholic, or the cyclic nitrogen positions. Predictably, 
these antisera were found to cross-react to varying degrees 
with the metabolites of morphine. In their method, Spector 
and Parker (1970) employed an antiserum that had been raised 
in rabbits to a 3-carboxymethylmorphine-BSA conjugate. 
Although early reports indicated that the resulting assay 
gave rise to similar results to those obtained using a 
fluorescent assay (Kupferberg et ^ . , 1964), this antiserum
was unable to distinguish between morphine, codeine or 
diamorphine, but no cross-reaction with M3G was reported 
(Spector, 1971). Similar results were obtained using antisera 
raised to the same conjugate by Gatlin si âi* (1973) and Van 
Vanukis si al. (1972), or with antisera raised to a
3-succinylmorphine-BSA conjugate (Wainer si alw 1972). In 
contrast to Specter's early findings, the additional problem 
of interference from M3G with these antisera was also 
observed (Stanski si al., 1982; Grabinski si al., 1983).
These findings agreed with those of Koida si al. (1974a) who 
prepared an antiserum using M3G as the hapten, and described 
its use in the combined measurement of morphine and M3G in 
urine. Due to these specificity problems, the use of such 
antisera in pharmacokinetic studies has been abandoned, 
although they are still widely employed in toxicological and 
forensic screening procedures.
In an attempt to leave the 3-phenolic position free to 
act as an antigenic determinant, different conjugates were 
prepared by attaching the protein either at the 'the
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2-position or the 6-alcoholic position on the morphine 
molecule. In 1973, Spector and coworkers described the 
production of an anti-morphine antiserum raised to a
2-(p-amino-phenylazo)morphine-BSA conjugate. This antiserum 
cross-reacted with codeine and heroin, although interference 
from M3G and normorphine was minimal. At the time, M6G was 
unavailable for assessment of its cross-reactivity, although 
it was not expected to interfere. In a later study. Gross and 
coworkers (19 74) prepared an antiserum to a similar 
conjugate, and found significantly lower cross-reactivity 
with codeine and normorphine. These antisera, therefore, 
appeared to offer considerable advantages over the antisera 
raised to the 3-conjugated morphine immunogens, but it was 
later found that the specificity varied between different 
batches (Gatlin, 1977) and further studies were discouraged. 
Despite these findings, one such antiserum is currently 
employed in a commercially available RIA for morphine 
(Goat-A-Gount Morphine RIA kit; Diagnostic Products Gorp., 
Los Angeles) that claims complete specificity with respect to 
its major metabolites (Matejczyk and Kosinski, 1985; Loeber 
ei al. / 1986; Hand at al./ 19 87a; Spiehler and Brown, 19 87 ). 
However, specific information is unavailable as to the
structure of the conjugate used and the cross-reactivity of 
this antiserum with M6G was only determined in one of these 
studies.
In their report, Spector and coworkers (1973) also
described the preparation of an antiserum raised to a
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6-morphenylhemisuccinate conjugate which cross-reacted with 
codeine, heroin, M3G and normorphine. Similar results were 
also reported by Koida et al* (1974b) and Wainer et al. 
(1973; 1974). The use of 6-succinylmorphine as a hapten, 
synthesised according to the method of Simon et al* (1972), 
has also been described (Aherne at al., 1975). The production 
of similar antisera demonstrating negligible cross-reaction 
with M3G have been reported, and these have been employed in 
RIAs for morphine in a number of pharmacokinetic studies 
(Steiner and Spratt, 1978; Aherne at al., 1979; Hahn et al., 
1979; Moore et al., 1984b). At the time it was widely
believed that, although M6G was likely to extensively 
cross-react with these antisera, this metabolite was only 
present in negligible quantities (Boerner at al./ 1975).
Since this time, more information on the importance of M6G as 
a metabolite following morphine treatment has become 
available (Svensson at al.a 1982). The failure of studies 
using these RIAs to recognise the significance of any 
cross-reaction with M6G has led to the publication of a 
number of misleading reports describing the pharmacokinetics 
of morphine (Aherne and Littleton, 1986; Osborne at al., 
1986; Savarese et âi. . 1986).
To date, the most useful anti-morphine antisera have 
been prepared using conjugates in which the hapten has been 
attached to the protein through the cyclic N-position of the 
molecule (Morris et al., 1974; Gintzler et al./ 1976; Findlay 
et ^ . , 1981). These antisera demonstrated insignificant
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cross-reactivity with any of morphine's major metabolites. 
The expected cross-reaction with normorphine was observed, 
but this is unlikely to be a problem since significant levels 
of this metabolite have not been measured, even after chronic 
morphine dosing (Section 1.2).
The majority of available RIAs for morphine are,
therefore, only suitable for pharmacokinetic studies if the
antiserum cross-reactivity is known, and any potentially 
cross-reacting substances are efficiently removed before 
analysis. This has generally been performed by the inclusion 
of a preliminary stage, using either solvent extraction 
(Grabinski et , 1983; Edwards Qt al,, 1986) or
liquid-solid extraction (Sandouk al., 1984; Quinn et al., 
1988b). A report published shortly after the start of this 
project describes the use of three different anti-morphine 
antisera, with a wide range of specificities to morphine and
its major metabolites, in a differential RIA method for the
determination of morphine, M3G and M6G (Hand et ai., 1987a). 
Reasonable correlation with spiked standards containing 
morphine and/or its metabolites was demonstrated. At present, 
this indirect approach offers the only available RIA 
technique for the quantitation of M3G and M6G. Because of the 
importance of M6G, further production of antisera capable of 
selectively detecting this metabolite offer the possibility 
of producing an assay that would enable the rapid, direct and 
specific quantitation of M6G.
In general, RIAs for morphine have employed tritiated
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radiolabels, although suitable iodinated radiolabels are now 
available (Mason et , 1981; Moore Qt , 1984b). Although 
dextran-coated charcoal has been frequently used to achieve 
phase separation, other methods have been used for this 
purpose, including immobilised antibodies (Steiner and 
Spratt, 1978; Hahn et ^ . , 1979) and solid phase second
antibodies (Moore &t i^.* / 1984b; Quinn ^  ai. ^ 1988b).
Alternative immunoassays, employing a range of different 
detection techniques, have been described. The majority of 
these were developed to enable the rapid screening of plasma 
and urine samples to be carried out, and, therefore, employed 
non-specific anti-morphine antisera. Antisera raised to the
3-conjugated immunogen described earlier have been used by 
Vanzetti &t (1983) in their haemagglutination inhibition
assay, and by Leute e£, §1. (1972) in their spin labelling
assay. Other techniques that have been reported include 
enzyme immunoassay (Schneider e1^  al. , 1973),
"enzyme-channelling" immunoassay (Litman al., 1983),
fluoroimmunoassay (Colbert et &1./ 1988), radioreceptor assay 
(Levi et al., 1987), and enzyme-linked immunosorbent assay 
(ELISA) (McDonald et al., 1988; Laurie gt al., 1989). The 
ELISA method of Laurie et (1989) employed an antiserum
raised to a morphine-N-butyryl-keyhole limpet haemocyanin 
conjugate which showed good specificity towards morphine.. 
However, the sensitivity achieved (0.2jumol/l) is unable to
compete with that offered by RIA.
The immunoassays discussed thus far have all employed
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morphine antisera consisting of a heterogeneous mixture of 
antibodies of varying specificity and affinity, known 
collectively as polyclonal antibodies. The development of 
antisera in which the antibodies are derived from a single 
cell line, first described by Kohler and Milstein, (1975), 
has been of considerable importance to the field of
immunoassay research. These (monoclonal) antibodies are 
produced by injecting specific strains of mice (or rats) with
the required immunogen. The lymphocytes from the spleens of
these animals are fused with appropriate myeloma cells and 
grown in culture. The hybrid cells are then selected out and 
propagated before being injected into the peritoneum of
sensitised rodents, in which they will produce an ascites 
tumour containing fluid rich in antibodies. The production of 
high affinity monoclonal antibodies directed against morphine 
has been described (Glasel ^  1983; Sawada et al..
1988). Despite the encouraging affinities calculated for 
these antibodies, their use in immunoassays was not 
advantageous compared to polyclonal antibodies either in 
terms of specificity or sensitivity. These findings, in 
addition to the increase in time and cost involved in the 
production of monoclonal antibodies, has so far limited their 
application in immunoassays for morphine.
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1.4. THE PHARMACOKINETICS OF MORPHINE AND MORPHINE 
GLUCURONIDES.
1.4.1. Distribution
A number of groups have investigated the tissue 
distribution of morphine and, to a limited extent, its
metabolites. The majority of experiments have been carried 
out in animals, and have been predominantly concerned with 
the passage of these compounds to their site of action,
namely the CNS. The transport of morphine into the CSF of 
rabbits in vivo, and its uptake into the choroid plexus and 
kidney tissue in vitro, have been demonstrated (Takemori and 
Stenwick, 1966; Hug, 1967; Wang and Takemori, 1972). It was
concluded that these processes involved a saturable active
transport mechanism that was carrier-mediated, acting against 
a concentration gradient. At the same time another experiment 
reported that the uptake of M3G by the choroid plexus in 
vitro was not performed by an active process, and on the 
basis of these experiments it was speculated that M3G could 
not penetrate into the CNS from the systemic circulation 
(Muraki, 1971). This hypothesis was later challenged by 
Yoshimura sLi.. ( 1973) who demonstrated the penetration of 
radiolabelled M3G and M6G into the brain of rats. A later 
study demonstrated the slow entry (compared to morphine) of 
unidentified morphine metabolites, thought to be 
glucuronides, into dog CSF following i.v. morphine (Hug et 
âiw 1981).
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Early experiments investigating the organ distribution 
of morphine and its surrogates were carried out using a wide 
range of analytical methods e.g. indicator techniques, and 
spectrophotometry (see review by Way and Adler, 19 60). The 
use of polarography, paper chromatography and radiolabelled 
tracers for the determination of morphine in rat tissues has 
also been described (Milthers, 1961; Johaness&n and Milthers, 
1962; Mulé and Woods, 1962; Oldendorf et al,. , 1972; Misra et 
al. , 1971). These studies provided some useful data but the 
techniques used were rather tedious and unreliable and also 
suffered from specificity and sensitivity problems. More 
recently, techniques with improved reliability, specificity 
and sensitivity, such as HPLC, GLC and RIA, have become 
available for the analysis of a wide range of biological 
matrices, notably serum and brain tissue (Spector and 
Vessell, 1971; Dahlstrom and Paalzow, 1975a; Raffa Qt al., 
1982; Bolander Qt ai., 1983). These techniques have enabled 
better designed and more reliable investigations to be 
carried out.
The majority of these studies have been performed in 
animals and have been particularly concerned with 
investigating the kinetics of absorption, disposition and 
excretion of morphine in reference to its activity within the 
CNS (Dahlstrom and Paalzow, 1975b; Hipps al. , I97C3; Lesher 
and Spratto, 1976; Mullis et al., 1979; McDougal et al.,
1981; Plomp et al., 1981; Bolander et gj,. , 1983). These
reports represent only a selection from the vast number of
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experiments investigating the disposition of morphine that 
have been reported. Although several animal species have been 
used, the rat has proven to be the most popular animal model. 
It is obvious, however, that large discrepancies exist with 
respect to concentrations of the drug at a given time 
interval. Part of this variation is due to the doses 
employed, the route of administration, and the time of 
sacrifice. However, the major problem arises from the use of 
different analytical techniques.
Despite the abundance of studies investigating the 
distribution of morphine in animals, little information is 
available on the distribution of morphine (or its 
metabolites) in human tissues and body fluids, in particular 
the CNS. This primarily reflects the difficulties in 
obtaining samples of human tissue, and the problems involved 
in interpreting the data obtained from the analysis of 
post-mortem tissues. Indeed, of the investigations that have 
been carried out, the majority have involved the analysis of 
tissues to obtain data of toxicological and forensic 
interest. For this purpose, samples of blood, excretory 
fluids, and organs, such as liver, kidney and brain, have 
been analysedj often using non-specific RIA methods (Cravey 
and Reed, 1977), although more reliable methods of detection 
have been used, notably GLC (Christopolous and Kirch 1971; 
Pare et , 19 84; Chan ej; al* / 19 86).
The relatively poor availability of systemically 
administered morphine to the brain has long been recognised
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and, consequently, more direct methods for the introduction 
of morphine into the CNS, by means of intrathecal or epidural 
injections, have become popular. As a result, a large number 
of studies have investigated the CSF pharmacokinetics of 
morphine. Large inter-individual variations in kinetics are 
evident in these studies. Terminal elimination half-life 
values from the CSF compartment, ranging from 108-363 min, 
have been found after intrathecal dosing (Moore et ,
1984c; Sjdstrom âi* a 1987a; Caute ej^  ^ .  , 1988; Bigler et 
al. , 1990), and from 120-369 min after epidural dosing (Todd
et al. , 1982; Sjôstrôm et ^ .  , 1987b*), A few
groups have also compared the kinetics of morphine following 
these routes with those after systemic administration using 
either animal or human models (Kaiko al., 1978; Bellanca
et al. / 1985; Nordberg et aJL. , 1985; Sandouk et âiw 1986;
Greene et aT. , 1987). Bellanca and colleagues|^found similar 
plasma kinetics after intramuscular (i.m.) and epidural 
administrations, with higher morphine levels in the CSF after 
the latter route. In their study, Nordberg et (19 85)
found a similar elimination half-life from both CSF and 
plasma after i.m. dosing, which was in direct contrast to the 
earlier findings of Hug al- (1981), who demonstrated
prolonged elimination of morphine from the CSF compared to 
plasma clearance following intravenous (i.v.) administration 
to dogs. Estimates for the availability of morphine to the 
CSF, during these studies, were found to be in the region of
2% after epidural dosing and 0.005% after i.m.
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administration. From this data it is obvious that CSF levels 
of the more polar glucuronidated metabolites of morphine are 
likely to be very low, as was evident from the 
systemic/intracerebroventricular potency ratios apparent in 
the early studies carried out in rats (Shimomura et al., 
1971). The lack of methods with adequate sensitivity has 
restricted the investigation of the availability of morphine 
metabolites to the CNS in man. Single sample studies of human 
CSF and plasma have confirmed that glucuronidation does 
result in impaired CSF entry. Hand et aj^ . (1987b) studied 
patients receiving single doses of morphine. Plasma and CSF 
samples were taken 140 minutes after oral dosing or 95 
minutes after i.m. dosing; significant levels of morphine, 
M3G and M6G were detected in the CSF. CSF levels of morphine 
were 4%-7.5% of those found in the plasma, with the higher 
levels occurring after i.m. dosing. By comparison, CSF M6G 
levels were only 0.7%-2.3% of those found at the same time in 
plasma, with similar levels found after both routes. 
Consistent results were obtained in an identical study 
carried out in a larger number of patients (Claffey, 1988). 
Equivalent data is unavailable for M6G after chronic morphine 
treatment, but results from a single study of five patients 
at steady-state on chronic oral morphine found CSF M3G levels 
to be 7.5% of those measured simultaneously in plasma (Sawe, 
1986). M6G behaves in a similar fashion to M3G (Hand st al., 
1987b), and this data appears to indicate that morphine 
glucuronide accumulation may occur during chronic oral
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morphine dosing. This is of particular interest, as it is in 
this situation that the role of M6G in the analgesic activity 
of morphine has been emphasised (Hanks et a%., 1987), and
clearly more quantitative data is required.
The extent to which a compound is bound to plasma 
proteins has an important effect on its distribution within 
the body. This is of particular importance when considering 
the availability of the compound to the CNS, as only the free 
drug is able to pass across the blood-brain barrier. The 
binding of morphine by plasma proteins has been investigated 
by Olsen (1975). Values in the region of 34-37% have been 
reported by this group, although they have shown that this is 
significantly reduced in renal failure (Olsen ^  al., 1975).
1.4.2. Excretion
On the basis of the findings of Boerner et al* (1975), 
it has generally been accepted that the major route for the 
excretion of morphine is through the kidney by glomerular 
filtration and, to a minor extent, tubular excretion. 
However, Wolff êt al. (1988) have questioned the predominant 
role of glomerular filtration in the elimination of 
unconjugated morphine in the light of data on elimination 
rates observed in renal failure patients, and based on their 
inability to find any significant correlation between 
morphine clearance and glomerular filtration rate. Estimates 
of the proportion of unchanged morphine excreted in the urine 
range from 2% to 12% of an administered dose, and this value
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is .‘independent ' of dose. Morphine glucuronides represent the 
major excretory metabolites accounting for up to 7 0% of an 
administered dose, with smaller quantities of the other 
metabolites evident (Yeh, 1975; Yeh et , 1977). In the
study of Brunk and Delle, (1974), 5% of the administered dose 
was excreted as unchanged morphine over the first 2 hours, 
rising to 8.5% after 24 hours and 9.3% at 48 hours, after 
which time the urinary excretion of free and conjugated 
morphine comprised 70-80% of the administered dose. Similar 
findings were also reported by Berkowitz (1976) and 
Patwardhan ei (1981).
Although the major proportion of an administered dose of 
morphine is excreted in the urine, the role of biliary 
excretion is less well documented. The importance of this 
route of elimination (Yoshimura et a_l. , 1969), and the
resulting enterohepatic circulation pathway, has been clearly 
demonstrated in animals (Walsh and, Levine, 19 75; Dahlstrdm 
and Paalzow, 1978). The evidence for enterohepatic
circulation in man is less compelling, although between 1% 
and 10% of an administered dose of morphine has been detected 
in the faeces of normal volunteers and addicts after
parenteral dosing (Boerner et al., 1975). An earlier
experiment, using 14C-morphine, had indirectly inferred that 
approximately 7.4% of an intramuscular dose appeared in the
gastrointestinal tract (Elliot et al., 1954). More recently, 
Watson et ai* (1985) recovered only 3.4% of the total
administered dose in the bile after 8 hours, probably in the
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form of free and conjugated morphine. The importance of this 
route as a means of eliminating morphine and its metabolites 
requires detailed investigation.
The possibilty that the lung may contribute to the 
clearance of an i.v. dose of morphine was disproved by the 
findings of Roerig et (1987) or Persson &t &1 - (198(j).
Low levels of morphine have been detected in the breast milk 
of lactating women (Feilberg et ad., 1989). However, there is 
no evidence that significant excretion of morphine, or its 
metabolites, occurs by other minor routes in man (Boerner et 
^., 1975).
1.4.3. Morphine Pharmacokinetics
Morphine has been clinically administered by a number of 
different routes, and this wide range of use has encouraged 
investigation of its pharmacokinetic behaviour. There are a 
number of factors that need to be taken into consideration 
when interpreting and comparing the results from these 
studies. Perhaps the most important factor, and one that has 
already received attention in this review, is that of assay 
specificity. The use of non-specific assays, notably RIAs 
that cross-react with metabolites, has severely compromised 
the data from a number of these studies, and has consequently 
cast doubt on many of the conclusions that have been reached. 
The majority of the studies employing these assays have 
therefore been excluded from the following discussion. 
Another important factor is that the majority of studies have
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investigated the metabolism and pharmacokinetics of morphine 
following the administration of single doses, rarely more 
than lOmg, to normal volunteers or post-operative, 
morphine-naive surgical patients. This situation is a poor 
reflection of the treatment required when morphine is used to 
control chronic cancer pain. Such patients require large 
doses of morphine or diamorphine (often several grams daily) 
to effectively control their pain, and may suffer from the 
problems associated with the influence of disease on drug 
handling, in particular, hepatic and renal insufficiencies 
that are commonly associated with advanced cancer.
1.4.3.1. Parenteral Administration
Mean pharmacokinetic parameters, following the 
administration of an i.v. bolus or an i.m. dose of morphine, 
in normal volunteers or patients are presented in Tables 1.1 
and 1.2 respectively. These parameters have been followed in 
a wide range of subjects, and, consequently there is great 
inter-individual variability in the results.
In general, the data obtained in the normal volunteer 
studies (Patwardhan et âl-/ 1981; Owen et ^ .  , 1983; Mazoit 
£t al., 1987) is best described by a two-compartment model 
with rapid distribution occurring from the plasma 
compartment. Wide inter-study variation is apparent for the 
values reported for volume of distribution (Vd) and 
clearance. In one study, a markedly reduced Vd and clearance
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Table 1.1.
Mean pharmacokinetic parameters for intravenous intramuscular morphine in normal volunteers
and
Assay No. Dose Vd Cl.
(jnq) ( 1/kq) ( ml/min/kg)
T 1/2 Reference 
(hr)
HPLC 11
GC
GC
GC
RIA
GC
13
7
6
3*
0 .12/ 2.8 kg
0.15/ 2.9kg
10/ 2.1 70kg
1.2
11.5 3.5
10 3.2
0.25/ 5.0kg
16.2
33.7
27.7 
15.2
2.5
1.0
0.7
3.3
0.1 5.8 21.0 3.3
26.7 2.2
Aitkenhead et al. (1984)
Patwardhan et al.(1981)
Owen et al. (19 8 3) (23-28yrs)
as above (60-69yrs)
Stanski et al.(1982)
Mazoit et al. (1987)
Woolner et al. (1986)
* subjects received i.m. papaveretum.
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Table 1.2.
Mean pharmacokinetic parameters for intravenous andintramuscular morphine in patients
Assav No. Dose(mq) Vd Cl. (1/kq) (ml/min/kg)
T 1/2 (hr)
Reference
ANAESTHETISED PATIENTS
RIA 11 10 - 12.3 1.0 Hand et al. (1987a)
HPLC 4 1.0/kg - 6.7 3.6
Moore et al. (1984a)
GC 8 10-20 6.2 20.5 3.8 Dahlstrdm et al. (1982a)
RIA 10 0.05- 2.0/kg 3.4 23.0 1.7 Murphy and Hug (1981)
RIA 5 1.2 4.9 21.6 2.7 Sandouk et al. (1986)
RIA 10 10 2.2 11.0 2.5 Sear et al. (1989a)
RIA 10 4.1 12.7 4.8 Sear et al. (1989b)
RIA 8 1 - 10.5 1.7 Crotty et al. (1989)
GC 35* 10 - - 3.4 Nordberg et al. (1985)
CANCER PATIENTS
GC 7 4 2.1 9.2 3.1 Sawe St al. (1981)
HPLC 6 4 4.0 28.0 1.7 Sawe et al. (1985)
HPLC 9 15-25 - 17.7 2.7 Gourlay et al. (1986)
RIA 3* 0.2/kg 4.5 15.0 3.5 Sandouk st al. (1984)
* patients received i.m. morphine
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was noted in elderly patients, compared with younger ones 
(Owen et slw 1983). However, the largest Vd observed in the 
studies summarised here was in a group of subjects with a 
mean age of 56 years (Mazoit et ^., 1987). A wide variation 
is also apparent in the values quoted for mean terminal 
elimination half-life (T 1/2), (range 0.7- 3.5 hours). This 
probably reflects the different sampling periods used in each 
study.
Although a number of studies have been performed, 
conclusive data defining the effects of anaesthesia and 
surgery on i.v. morphine handling is still not available, 
although an increased Vd (Dahlstrdm ei, ^ .  , 1982a; Sandouk et 
al. . 1986; Chauvin et al.., 1987) and a decreased plasma
clearance (Moore et ^ . , 1984a; Hand et gT., 1987a) have been 
reported in these patients compared to normal volunteers. A 
within subject study has recorded an increased Vd and 
terminal elimination half-life during major surgery under 
general anaesthesia (Dahlstrdm gt , 1982a) but significant 
differences in these parameters were not observed in a more 
recent study carried out by Sear et âl* (1989a).
No significant differences were observed in the 
parameters obtained when the pharmacokinetics of i.v. 
morphine was investigated in cancer patients (Sawe et al., 
1981; Sawe si al. , 1985; Gourlay ei slw 1986), even though 
the metabolic abnormalities associated with advanced cancer 
(e.g. loss of muscle mass and reduced plasma protein 
concentration), could result in altered disposition.
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Published data investigating morphine pharmacokinetics, 
following i.m. dosing in normal volunteers and patients, has 
generally given rise to values for Vd, clearance and T 1/2 
that are indistinguishable from those obtained in the 
corresponding i.v. studies discussed above. Similarly, no 
significant differences in data were observed when comparing 
normal volunteers with post-operative patients treated in 
this manner.
1.4.3.2. Oral Administration
Oral morphine, usually administered chronically, is the 
treatment of choice for the management of severe cancer pain 
(Hanks, 1989). The availability of new preparations, in 
particular the controlled-release formulation, has required 
the pharmacokinetics of morphine to be more comprehensively 
studied. To this end, a number of groups have investigated 
the way in which a single dose of oral morphine, administered 
either as an elixir or as a controlled-release tablet, is 
handled by both normal volunteers and cancer patients. The 
mean pharmacokinetic data obtained in these studies is shown 
in Table 1.3.
Absorption of morphine from the gastrointestinal tract 
is virtually complete, occurring predominantly in the 
proximal small bowel, with up to 70% of an administered 
radiolabelled dose being recovered in the urine up to 48 
hours (Brunk and Delle, 1974; Twycross ^  al., 1974). Due to 
its basic nature, the ionisation of morphine is suppressed
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Table 1.3.
Mean pharmacokinetic parameters following single doses of 
oral morphine
Assay No. DoseXml
ORAL SOLUTION
GC 7 P
HPLC 6 P
HPLC 9 P
20 -30
20 -25
60
HPLC 15 P 60- 181.5 1.2400
HPLC 23 V 30
HPLC 7 V 10
58.3 1.0
27.7 0.5
Cmax Tmax F
(nmo1/ (hr) (%)11
3.4 38
47
26
Reference
Sawe ei al. (19 81)
Sawe et al. (19 85)
Gourlay et al.(1986)
Sloan ej;. al. (1987 )
Khojasteh et al.(1987)
Moolenaar et al.(1988)
CONTROLLED«RELEASE TABLET
HPLC 11 V 20 39.0 2.4
HPLC 23 V 30 31.6 2.1
HPLC 15 P
HPLC 8 P
60-400
RIA 10 P 20
30
171.3 3.6 (mean)
31.3 1.2
26.7 1.5
18 Vater et al. (1984)
89 (R) Khojasteh et al.(1987)
90 (R) Sloan et aj_ (1987)
Manara ei, al. (1988)
Lew et al. (19 89)
P = cancer/post-operative patient V = normal volunteer
F = absolute bioavailability except:(R) = bioavailability relative to oral solution
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and its absorption is enhanced as the pH rises in this 
region. Further evidence for this is provided by the presence 
of equal amounts of morphine and its glucuronides in the 
urine following both oral and parenteral administration (Sawe 
et al.. 1985). It can be seen that morphine is rather poorly 
bioavailable via the oral route, with a wide range of values 
for absolute bioavailability from 26% to 47%. These values 
predominantly reflect the extensive presystemic metabolism to 
which morphine is subjected. After the administration of an 
oral morphine solution, a range of values for Cmax and Tmax 
have been recorded. In an earlier report, much higher levels 
were found following this treatment (Leslie et aT., 1980). 
These discrepancies are difficult to explain, since specific 
assays were apparently employed in all the studies.
A number of groups have also investigated the 
pharmacokinetics of morphine when administered in the form of 
controlled-release preparations. These tablets are 
manufactured in dose sizes ranging from lOmg to lOOmg. As 
expected, peak plasma concentrations were generally reached 
later than after oral solution administration, although times 
between 1.2 and 3.6 hours have been reported for Tmax. In 
their study, Khojasteh et &1. (1987) compared immediate
release and controlled-release morphine tablets and found a 
significantly higher mean AUC (0-12hr) after the former 
tablets, with a relative bioavailability for the 
controlled-release tablets of 89%. These findings are similar 
to those reported by Hanks et al. (1980) and Sloan el. al.
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(1987), and are also in good agreement with the observations 
of Savarese et al* (1986) and Poulain et ad. (1988) who 
studied cancer patients maintained at steady-state on oral 
morphine. During both these studies comparable values for 
Cmax were observed after both formulations.
The time to reach maximum plasma concentration is 
obviously an important factor governing the usefulness of a 
particular formulation in a given clinical situation. In the 
studies discussed so far, this time has been reasonably 
consistent and predictable. However, a number of factors are 
known to effect the rate of drug absorption, and, 
consequently ^ its efficacy. Recent studies with oral morphine 
have demonstrated that concurrent administration of 
antidepressants increases the bioavailability of oral morphine 
(Ventafridda et &1., 1987). Similarly, a faster rate of onset 
and an increased level of sedation is observed when the 
anti-emetic metoclopramide is administered with oral 
controlled-release morphine (Manara et aj^ . , 1988). It is also 
possible to maintain plasma morphine concentrations at higher 
levels if the oral solution is administered with a high-fat 
meal (Gourlay &t al., 1989).
1.4.3.3. Other Enteral Routes
The extensive presystemic metabolism, which limits the 
bioavailability of morphine administered by conventional oral 
dosing, has led to increasing interest in the use of other 
forms of delivery which avoid first-pass metabolism. To date,
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few studies have reliably investigated the pharmacokinetics 
following such routes. Administration via the sublingual 
route has only been investigated in one study in which 
unreliable results were obtained using a non-specific RIA 
(Pannuti et al.. , 1982). Morphine has been administered by the 
buccal route in the form of immediate release and 
controlled-release tablets. Initial reports indicated that 
administration of morphine by this route gave rise to 
morphine levels equivalent to those obtained after i.m. 
dosing (Bardgett et aul. , 19 83; Bell ei. âi* / 19 85). However, 
subsequent studies have given rise to contrasting results, 
which suggest that -improvement in bioavailability is not 
achieved by this route (Fisher et §1., 1987; 1988; Manara ^  
al.. 1989; Simpson et aiw 1989). Nevertheless, morphine 
absorption via the buccal route has been demonstrated 
(Al-Sayed-Omar et al., 1987), and further study of this form 
of delivery is clearly indicated.
A number of studies have investigated the effectiveness 
of administering morphine by the rectal route, and have 
demonstrated that morphine is apparently well absorbed from 
the rectum, although wide inter-individual variations were 
evident. In their study, Moolenaar et (1988) observed a
similar pattern of absorption for lOmg morphine from either 
an oral solution or a suppository. An increase in 
bioavailability by this route was subsequently demonstrated 
by comparing rectal and oral administration in rats (Katagiri 
et al. , 1988), and rectal and i.v. dosing in patients
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(Jonsson et , 1988). The advantages of rectal
administration over oral dosing requires further study, 
including an assessment of the potentially useful sustained 
release suppository, which has recently become available 
(Hanning et al., 19 88).
Morphine has also been administered systemically by 
other routes, e.g. inhalation of nebulised morphine 
(Chrubasik ^  al., 1988).
1.4.2.4. Spinal administration
Morphine achieves its analgesic effects by interacting 
with opioid receptors in the CNS. Direct administration of 
the drug into the brain compartment, in order to bypass the 
selectively permeable blood-brain barrier, would be expected 
to produce effective analgesia, and perhaps reduce peripheral 
side-effects. For these reasons, in recent years, there has 
been considerable interest in the administration of opiates 
epidurally and intrathecally. There is strong evidence to 
suggest that intrathecal morphine will produce effective and 
long lasting analgesia (Paterson ^  al.. r 1984). In this 
study, the CSF morphine levels were found to be 4000 times 
higher after intrathecal dosing, compared to those achieved 
after i.v. dosing. In addition, following intrathecal dosing, 
the elimination half-life for morphine from the CSF was found 
to be longer than that for diamorphine, presumably explained 
by the differences in lipid solubility. In contrast, after 
extradural injections, a lower CSF:plasma gradient is
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observed with significantly higher levels of morphine found 
in the plasma; it has been proposed that a 5mg extradural 
dose will maintain analgesia for 12-18 hours and, as such, is 
equivalent to a Img dose injected intrathecally (Moore et 
al., 1984c). If a relationship between CSF concentration and
CNS availabilty is supposed, then it is anticipated that 
equivalent or improved analgesia could be achieved by the 
spinal route with much lower doses. There is increasing 
evidence to confirm the efficacy of spinal opiates (Watson et 
al. . 1984), but the relative merits of intrathecal and 
epidural routes, in terms of safety and convenience of 
administration and the resulting toxicity, remain a subject 
of controversy (Cousins, 1987). Whether these routes have any 
significant advantages over oral or parenteral dosing remains 
speculative.
1.4.4. Pharmacokinetics of Morphine Glucuronides
Few of the studies discussed so far have included any 
attempts to measure the quantities of M3G and M6G produced 
after treatment with morphine. This paucity of information 
reflects the absence of suitable methods capable of 
specifically measuring levels of these two metabolites in 
biological fluids. The availability of the HPLC method of 
Svensson et &1. (1982) and the differential RIA technique,
recently proposed by Hand êt (1987a), has enabled some
groups to obtain valuable information concerning the 
metabolic profile following treatment with parenteral and
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enteral morphine.
Originally, M6G was not thought to be of any 
significance as a metabolite of morphine. This conclusion was 
based on the findings of the urinary excretion studies 
carried out by Boerner et al* (1975). The first evidence of 
the quantitative importance of M6G was provided by the study 
of Svensson et al* (1982) who reported a ratio for 
M3G;M6G;morphine of 20:2.5:1 in patients receiving high oral 
doses of morphine (>600mg/day). This group proceeded to 
investigate the metabolism of morphine in a number of 
different situations. In a study investigating 4 patients 
receiving increasing doses of oral morphine (Sawe e^ al., 
1983a), they observed a linear relationship between dose and 
the levels of morphine and glucuronides formed. They also 
demonstrated that the relative concentrations of morphine, 
M3G and M6G were constant in the individual patients, and 
that this relationship was independent of dose or duration of 
treatment. The average molar ratios for M3G:M6G:morphine were 
found to be 34:3.9:1. Their next study provided information 
on metabolite formation following the administration of 
single doses of i.v. or oral morphine (Sawe et âi•/ 1985) 
and, as mentioned earlier, demonstrated a clear correlation 
between in vitro UDPGT activity in the liver and plasma 
M3G:morphine ratios. Following a single oral dose, plasma 
ratios of 24:2.5:1 (M3G:M6G:morphine) found were slightly 
lower than those in steady-state, indicating that these 
metabolites might accumulate during repeated dosing.
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Additional valuable information on this subject has also 
been provided by the work of Hand and colleagues (1987a) 
using their differential RIA technique. In this study, 
following the fate of a lOmg i.v. dose in surgical patients 
over a 3 hour period, a mean Cmax for M3G of 739.7nmol/l was 
found after 1.1 hours, whilst a mean Cmax for M6G of 
71.4nmol/l was observed after 0.7 hours . In another study 
carried out in normal volunteers, they recorded a mean plasma 
AUC (0-3hr) ratio for M6G:morphine of 3:1 (McQuay et al., 
1987) after oral dosing. In a recent study carried out in 
cancer patients at steady-state on oral morphine, much higher 
levels of metabolites, relative to morphine, were found in 
the plasma (molar ratios of 34:5.5:1 for M3G:M6G:morphine), 
(Poulain &t al., 1988). It was suggested that this was due to 
metabolite accumulation in the steady-state patients.
1.4.5. The Effects of Renal and Hepatic Dysfunction on 
Morphine and Metabolite Pharmacokinetics
Mean pharmacokinetic parameters observed in patients 
with renal or hepatic insufficiencies are summarised in Table 
1.4. As outlined earlier, the concensus of opinion now 
indicates that the liver is the primary site of morphine 
metabolism, and that the kidney provides the major excretory 
route for morphine and its metabolites. However, 
controversial results obtained in a number of early studies 
investigating morphine disposition in renal failure patients 
temporarily challenged these theories (McQuay and Moore, 19 84
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Table 1.4.
Mean pharmacokinetic parameters for intravenous and intramuscular morphine in patients with renal or hepatic 
failure
Assav No. Dose Vd Cl. T 1/2 Reference(mg) (1/kq) (ml/ (hr) min/kg)
IMPAIRED RENAL FUNCTION
HPLC 9
HPLC
RIA
GC
RIA
RIA
4*
13
9
0.12/ 1.8 
kg
4 4.4
0 .2/ 2.8 
kg
10 3.0
0.15/ 6.1kg
10 2.4
10.3 3.2
21.1 2.4
17.1 3,1
27.8 1.2
12.2 9.2
9.1 4.8
Aitkenhead et al. (1984)
Sawe and Odar- Cederlof (1987)
Chauvin si al. (1987)
Woolner ei al. (1986)
Wolff et al. (1988) 
Sear at al. (1989b)
IMPAIRED HEPATIC FUNCTION
GC 6
RIA 8
RIA 8
0.15/ 2.3
kg
0.1/ 5.2
kg
14.6 2.2
33.5 1.8
7.8 2.0
Patwardhan et al (1981)
Mazoit et al. (1987)
Crotty si al. (1989)
* patients received i.m. morphine
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Ball et al.,, 1985; Moore et al., 1986). It has long been 
realised that prolonged effects of narcotic analgesics are 
apparent in patients with impaired or absent renal function 
(Don et ai.,, 1975; Bion et al. , 1986). In these studies,
patients appeared to accumulate morphine, and, in one study, 
restoration of renal function was accompanied by a resumption 
of the process of morphine elimination. It was therefore 
concluded that this persistence of narcosis was due to the 
accumulation of free morphine, and questioned the predominant 
role of the liver over the kidney in the metabolism of 
morphine. The same non-specific RIA (Moore et âl*  ^ 1984b) was 
used in all of these studies to determine the levels of 
morphine in these patients. It is now apparent that the assay 
measures combined levels of morphine and M6G, and that the 
observed "persistence" of morphine levels was actually due to 
the unexpected accumulation of M6G that was not being 
efficiently excreted (Hanks and Aherne, 1985; Aherne and 
Littleton, 1986).
Further evidence supporting this explanation was 
subsequently provided by similar studies performed in renal 
failure patients using specific assay techniques. None of the 
patients in these later studies exhibited impaired morphine 
elimination, but accumulation of the glucuronide metabolites 
was evident (Aitkenhead st a%., 1984; Bion et §1,, 1986;
Shelly et al*/ 1986; Woolner et al., 1986; Osborne et al., 
1986; Sawe and Odar-Cederlof, 1987). Specific details were
provided by Sawe and Odar-Cederlof (1987) who calculated the
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mean apparent T 1/2 of M3G in renal failure to range from 
14,4 to 118.8 hours (mean 49.6hr), compared to a mean value 
of 4.0 hours in normal patients. Three recent studies (Wolff 
et al. , 1988, Hasselstrom et al., 1989 and Sear at al.,
19 8 9b) observed impaired elimination of morphine glucuronides 
leading to higher AUCs in renal failure patients. Wolff and 
colleagues (1988) also observed a longer T 1/2 for morphine 
(mean= 9.2 hr), but suggested that this could be due to the 
use of a prolonged observation period, a more sensitive
assay, and older patients than had been used in the other
studies described. It was of interest to note that Woolner 
and colleagues (1986) actually observed more rapid 
elimination of morphine in renal failure. In this study, the 
mean T 1/2 for morphine was significantly shorter in renal 
failure, although there was no difference in the mean values 
calculated for clearance and Vd. The reason for these
differences is unclear.
Despite the predominant role of the liver in the 
metabolism of morphine, relatively few studies have examined 
the pharmacokinetics of morphine in patients suffering from 
hepatic impairment, a condition that may often accompany 
advanced cancer. In the three major studies reported to date 
conflicting results have been obtained (Table 1.4). 
Patwardhan qXl Al. (1981) found no significant differences in 
pharmacokinetic parameters for i.v. morphine in cirrhotic 
patients and normal volunteers. In contrast, Mazoit et al. 
(1987), studying 8 patients with advanced alcoholic liver
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disease, observed a slower total body clearance (33.5 vs. 
21.0 ml/min/kg) and a longer T 1/2 (3.4 vs. 1.9hr) leading to 
an increased plasma AUC in these patients, compared with 
normal subjects. The differences were considered to be due to 
a decrease in hepatic blood flow, reduced hepatic extraction 
or a combination of both factors. In another study, 
prolongation of the mean T 1/2 for morphine in patients with 
septic shock was associated with a significant reduction in 
hepatic blood flow compared to normal controls (MacNab ei 
al. , 1986 ). In their study comparing control and cirrhotic 
patients, Crotty et &1. (1989) observed a 25% reduction in
the hepatic extraction ratio in cirrhosis, but concluded that 
this was the result of impaired hepatic enzyme capacity 
rather than reduced blood flow.
The influence of drugs on morphine metabolism has rarely 
been investigated. High levels of oxazepam were found to 
inhibit the glucuronidation of morphine in vitro (Sawe et 
al./ 1982), although cimetidine, which may alter hepatic 
blood flow or compete for hepatic enzyme metabolism, exerted 
no effects (Mojaverian et al., 1982). The clinical relevance 
of these findings has not been determined.
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1.5. PHARMACODYNAMICS OF MORPHINE
1.5.1. Introduction
A number of attempts have been made to define a 
"therapeutic range" of plasma morphine levels in which 
analgesia can be safely and consistently achieved. However, 
although such a prediction is possible for a number of drugs, 
correlation of the clinical effects of morphine with its 
pharmacokinetics has generally not been possible. A number of 
formidable problems have been identified during the course of 
these investigations. The first problem is to determine in 
which body fluid should morphine be measured. Quantitation of 
morphine in plasma is possible, but this tissue is distant 
from the site of action and, therefore, it may be more 
relevant in the to determine levels in the CSF during 
clinical studies. Other questions raised have been what 
treatment to administer (i.e. single or chronic dosing via 
oral or parenteral routes), what type of pain to monitor 
(i.e. experimental, post-operative, or cancer), as well as 
the difficulties that are associated with pain assessment in 
the clinical situation, particularly in cancer patients 
receiving chronic morphine treatment who eventually become 
tolerant to the effects of the drug.
These factors have undoubtedly limited the success of 
studies designed to find a "minimum effective analgesic 
concentration" of morphine in plasma. However, the final, and 
probably most important, factor to be considered ,in the
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interpretation of data from pharmacodynamic studies is the 
potential contribution of the active metabolites of morphine 
to the clinical effects observed. Circumstantial evidence has 
come from the studies discussed earlier in which persistant 
narcosis has been observed in the absence of morphine in 
patients with renal impairment, and in the different 
oral : parenteral ratios for morphine that are required 
following chronic oral dosing (1:2 to 1:3) and single oral 
dosing (1:6 to 1:8) (Hanks al., 1987).
1.5.2. Clinical Effects of Morphine
The clinical effects of morphine are well recognised and 
are remarkably diverse. The major effects are on the CNS and 
the bowel and include:
(1) Inhibitory action on the CNS accounting for analgesia, 
respiratory depression and somnolence.
(2) Excitatory action on the CNS accounting for miosis, 
vomiting and convulsions.
(3) A stimulant action on peripheral smooth muscle leading to 
constipation, bronchoconstriction, and increased bladder and 
uterine tone.
A number of other peripheral effects have also been 
associated with morphine, including itching, sweating and a 
dry mouth. Some of these pharmacological actions of morphine 
can be directly related to its effects on opioid receptors.
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1.5.3. Opioid Ligands and Receptors
The binding sites, or receptors, for opioids are found 
particularly in synaptosomal fractions of the brain. 
Endogenous opioid-like peptides are abundant in the areas of 
the CNS that are presumed to be related to the perception of 
pain, although they have also been located in cells whose 
functions relate to the motility of the bowel. In all cases, 
these receptors are confined to nervous tissue (Pert and 
Snyder, 1973). Several independant lines of evidence have 
established that there are multiple types of opioid receptor. 
The basis for the current classification originated with 
Martin and colleagues (1976), who postulated the existance of 
three different types of opioid receptors, namely the mu (ju), 
kappa (k), and sigma (a) receptors. Following the 
identification of met- and leu-enkephalins as endogenous 
ligands, the existence of a further receptor type, delta (6), 
in the mouse vas deferens was reported (Lord et §1,, 1977). 
Since this time the existence of another receptor, epsilon 
(e), and subclassifications of the above groups, notably k 
and ]j, have also been proposed, although much of this 
evidence is based on rather unconvincing data derived from 
ligand binding studies (Dougall, 1988).
Since the enkephalins, a number of other endogenous 
opioid compounds have been identified, the most important 
ones being j8-endorphin and dynorphin. The first five amino 
acids of all the endogenous opioid peptides contain the 
structure of either met- of leu-enkephalin. However, their
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gene structures have clearly indicated that they are distinct 
peptides. Morphine is a pure opioid agonist with a 
predominant action at the p receptor. It will also bind to k 
and a receptors, but has low activity at 5 receptors.
The identification of two subtypes of p-receptors by 
Pasternak and colleagues (1980) has had major implications in 
understanding opiate action, particularly their role in pain 
relief. Opiate analgesia is mediated through a complex 
interaction of p-, 5-, and k-opiate receptors. Supraspinally, 
p-receptors seem to be the most important, whereas the 6 and 
k sites are involved at the spinal level. The analgesic 
actions of these various opiate receptor subtypes are 
summarised in Table 1.5. The two major side effects, 
influencing the clinical use of opiates, are respiratory 
depression and inhibition of gastrointestinal tract motility. 
There is evidence to suggest that both effects are mediated 
through p2-receptors (Pasternak, 1988).
The active substance binding to the opioid receptor has, 
in the past, been assumed to be morphine itself. However, 
more recently, a number of jji vivo and in vitro studies have 
provided evidence to suggest that metabolites of morphine may 
be important in producing its effects.
M3G, the major metabolite of morphine, has long been 
regarded as being inactive, with no significant analgesic 
activity after either subcutaneous or intracerebral injection 
in mice (Shimomura et &1., 1971), or in isolated tissue
preparations (Schulz and Goldstein, 1972;
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Table 1.5.
analaesic
Subtyoe
actions
Prototypic Proposed analaesic actions
jul
liaands '
Opiates and most opioid peptides
Supraspinal analgesia: including periaqueductal gray, nucleus raphe magnus, and locus coeruleus.
p2 Morphinesulphate Respiratory depression (also gastrointestinal tract transit)
6 Enkephalins Spinal analgesia
k Ketocyclazocine and dynorphin Spinal analgesia
adapted from Pasternak (19 88).
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Kataoka et al.,1977). À single report has shown M3G to have 
some analgesic activity (Sasajima, 1970), although Schulz and 
Goldstein (1972) suggested that this may have been due to 
prior deglucuronidation. In a later study, Labella et al. 
(1979) showed that, despite its diminished opiate receptor 
potency, M3G exhibited enhanced central excitatory activity 
acting through a naloxone-insensitive receptor, leading to 
hyperaesthesia/hyperalgesia in rats. In a more recent study, 
M3G has been found to be a potent antagonist of morphine 
analgesia (Smith ^  ad., 1990).
Of the remaining metabolites of morphine, M6G, 
normorphine, codeine and morphine ethereal sulphate have all 
been shown to possess analgesic activity. Normorphine and 
codeine have been shown to be several times less potent as 
analgesics than morphine itself (Johannesson and Milthers, 
1962; Jôhannesson and Woods, 1964). Mori et (1972) found
that morphine-3-ethereal sulphate had no analgesic activity 
whereas morphine-6-ethereal sulphate was considerably more 
potent than morphine. Indeed, this conjugate has been shown
to be the most potent of a number of 3- and 6-conjugates of
morphine, both in vivo and iü vitro (Yoshimura a%., 1976; 
Kataoka et al., 1977). However, to date only the 3-ethereal
sulphate has been identified as a minor metabolite of
morphine in man (Yeh et &!., 1977). Of much greater interest 
is M6G, which was found to be 45 times more potent than 
morphine when administered intracerebroventricularly, and 3 
to 4 times as potent when injected subcutaneously in rats
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(Shimomura ^  al., 1971). Several more recent studies have
confirmed these earlier In vivo findings (Pasternak et ad.,
1987; Abbott and Palmour, 1988; Paul et al., 1989; Sullivan 
et al. , 1989) and have also shown that the activity of M6G is 
longer in duration, although there is a wide variation in the 
results obtained.
The interest surrounding the analgesic activity of M6G 
has flourished since it was demonstrated by Sawe ^  al. 
(1983b) that high plasma levels of this metabolite were 
present, particularly after chronic oral dosing with 
morphine. The differences in potency observed for M6G,
morphine and M3G in the In vivo studies has led a number of
groups to investigate the binding of these compounds, using 
established receptor binding studies (Christensen and 
Jorgensen, 1987; Oguri gt al., 1987; Pasternak al., 1987; 
Paul gt nl., 1989). In their experiment, Christensen and 
Jorgensen (19 87) used a homogenate of bovine caudate nucleus, 
which has a high opioid receptor density, and a ratio of p to 
5 binding sites of 1.6. Using this preparation, they observed 
that M6G was 3 times less potent than morphine, and M3G had 
virtually no affinity for the opioid receptor. Oguri et al.
(1987) demonstrated that conjugations at the 6-position on 
the morphine molecule enhanced its binding to 6-receptors but 
diminished its binding to p-receptors, whereas the same 
conjugations at the 3-position resulted in a comprehensive 
reduction in binding. At about the same time, Pasternak and 
co-workers (1987) reported that M6G exhibited a similar
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binding profile to morphine in that both compounds potently 
labelled total p-, pi-, 6- and k receptors with the same 
affinities. Further information has been provided by the 
studies in mouse brain of Paul et âl* (1989) who found that, 
although each compound inhibited pi- and p2- binding with 
similar potencies, morphine demonstrated a higher affinity 
than M6G. This data compared well with that observed in rat 
brain preparations by Thompson ei aJL. (1990), who 
demonstrated that morphine has a higher affinity for the p2- 
receptor than M6G, whereas M6G has the higher affinity for 
the 6- receptor.
Paul and colleagues (1989) were unable to offer a 
satisfactory explanation for the inconsistencies in their in 
vitro and in vivo potency data. Thompson et âl* (1990) 
suggested that if, as is widely believed, the p2-receptor is 
principally involved in mediating the toxicity of morphine, 
the results from their binding studies could account for the 
differences in toxicity previously observed in their 
preliminary clinical studies. In these investigations, they 
reported that M6G caused less respiratory depression and less 
nausea than morphine. They also suggested that the increased 
affinity of M6G for the 6- receptor may, in part, explain its 
increased potency. However these findings are in contrast to 
those of Pelligrano et âi. (1989), who demonstrated that M6G 
was between 5 and 10 times more potent as a ventilatory 
depressant in the dog than morphine, whereas M3G had no such 
activity.
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A number of groups have investigated the mechanisms by 
which substitutions at the 3- and 6- positions on the 
morphine molecule give rise to altered opiate agonist 
activity, and these have been reviewed (Thorpe, 1984). Reden 
et al. (1979 ) and Cheney (1988) both concluded that there is 
a requirement for a hydrophilic group at the 3-position for 
effective receptor binding. Further evidence for this theory 
was provided by Brown et ad. (1985) who showed that 
morphine-3-sulphate demonstrates the same agonist activity as 
morphine (in contrast to the findings of the in vitro binding
studies of Oguri gt , 1987), and that substitution with
larger or less hydrophilic molecules markedly reduced
potency. Similarly, it has been shown that heroin 
(3,6-diacetylmorphine) does not bind to opiate receptors, and 
can only exerts its effects after it has been metabolised to 
morphine via 6-monoacetylmorphine (Inturrisi gt gJL. , 1983).
As indicated in the in vivo and in vitro studies, 
substitution of the 6-hydroxyl group with a more hydrophilic 
group, such as a sulphate or glucuronide conjugate,
consistently results in increased opioid potency. However, 
the mechanism behind this phenomenon is poorly understood. It 
has been suggested that the 6-hydroxyl group hinders binding 
to the receptor and, consequently, its substitution with an 
alternative group results in enhanced binding (Reden et al., 
1979; Thorpe, 1984). However, this theory is not able to 
explain the results of the receptor binding studies discussed 
above, where 6-substitution resulted in decreased affinity
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for theju-receptor, or the data of Gebhart and Spratt (1976) 
who indicated that morphine-6-hemisuccinate was a less potent 
analgesic than morphine itself. Thus, it would appear that 
the increased analgesic potency observed with M6G cannot be 
satisfactorily explained by the evidence that is currently 
available, and, clearly, this is an area that requires 
further investigation.
The passage of M6G into the CNS of animals and the CSF 
in humans following systemic administration has been 
demonstrated by a number of groups (Section 1.4.1). Their 
findings, together with the data discussed in this section, 
provide a further indication that a considerable proportion 
of the analgesic activity observed following morphine 
administration in man is likely to be due to the additional 
presence of M6G, This observation is of particular importance 
in situations in which high levels of M6G would be expected, 
such as during chronic oral dosing and renal failure, and is 
also likely to partly explain the failure of most studies to 
demonstrate a relationship between morphine levels and 
effect.
1.6. AIMS OF THE PRESENT STUDY
This literature review has surveyed the pharmacokinetic 
and other data about morphine and its glucuronide 
metabolites, with the aim of determining other areas of 
interest and aspects which merit further investigation. The 
potential clinical significance of the analgesically active
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M6G has been of prime consideration.
At the start of this project, a reliable method for the 
quantitation of morphine and morphine glucuronides was 
unavailable. The technique of differential RIA offers 
considerable potential for the assay of these compounds in a 
range of biological fluids, but considerable development and 
validation is required before this method can be put into 
routine use. At the same time, the development of a specific 
assay for M6G would be extremely useful, and, attempts to 
prepare a specific antiserum for use in an immunoassay for 
this compound warrant investigation.
Available pharmacokinetic data on morphine after both 
parenteral and oral administration is conflicting, due mainly 
to the use of non-specific assays, and has also been 
complicated by being derived from the study of several 
different types of subject. A re-evaluation of this area, 
using more reliable analytical techniques, is required. These 
studies should include the assessment of normal, healthy 
volunteers, thereby avoiding any possible problems associated 
with disease states or surgery, and additional data on the 
formation of morphine glucuronides (in particular M6G) is 
clearly required. Due to the extensive first-pass metabolism 
of orally administered morphine, attempts to bypass the gut 
may also prove to be of use in certain situations; 
pharmacokinetic study of novel routes of dosing is therefore 
warranted.
The available evidence documenting the pharmacologic
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activity of M6G indicates that this metabolite is an 
important factor in understanding the mode of action
of morphine, and may also be of considerable use as an 
analgesic in its own right. For this potential to be fully 
understood, more information on the disposition of M6G, 
following its systemic administration via conventional routes 
to human subjects, is required so that meaningful 
pharmacokinetic/pharmacodynamic correlations can be
performed.
Finally, further investigation of the distribution of 
morphine and its glucuronides is required. Of particular 
importance is the CNS distribution of these compounds, i.e. 
closer to their site of action, due to the differences in 
potency and lipophilicity that are known to exist between 
them. For this purpose, the analysis of tissue homogenates 
and body fluids using RIA techniques should provide some 
useful data, and the application of a more direct method of 
detection using immunocytochemistry offers exciting 
potential. An assessment of the distribution and elimination 
of these compounds from rat brain and human CSF following a 
range of treatments will be of considerable value in 
assessing the relative advantages of morphine and M6G as 
analgesic agents. At the same time, the effects of 
enterohepatic circulation and plasma protein binding on the 
distribution of these compounds in the clinical situation 
also warrant investigation.
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CHAPTER TWO
MATERIALS AND METHODS
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2.1. CHEMICAL REAGENTS AND EQUIPMENT
2.1.1. Buffer Components and Other Chemicals 
BDH CHEMICALS Ltd.,
Poole, Dorset
Gelatine
di- Sodium hydrogen orthophosphate AnalaR grade 
Potassium dihydrogen orthophosphate 
Thiomersal
Sodium dihydrogen phosphate AnalaR grade 
Sodium dodecyl sulphate Biochemical reagent 
SIGMA CHEMICAL Co. Ltd.,
Poole, Dorset.
Charcoal, activated, untreated powder 250-350 mesh 
lodo-Gen(1,3,4,6-tetrachloro-3,6-diphenylglycouril) 
MAY & BAKER Ltd.,
Dagenham, Essex.
Sodium Chloride AR grade 
PHARMACIA Ltd.,
Milton Keynes, Bucks.
Dextran T-7 0
2.1.2. Drugs and Metabolites 
MACFARLAN SMITH Ltd.,
Edinburgh.
Morphine alkaloid 
Codeine
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Normorphine alkaloid was kindly provided by Dr. G. Frost, The 
Robens Institute, University of Surrey.
Buprenorphine, pethidine and naloxone were obtained from Dr. 
G.W. Hanks, The Royal Marsden Hospital, Sutton, Surrey.
Diamorphine alkaloid 
SIGMA CHEMICAL Co. Ltd.
Morphine-3 ,/3-D-Glucuronide 
SALFORD ÜLTRAFINE CHEMICALS Ltd.,
Enterprise House, Manchester.
Morphine-6 ,j6-D-Glucuronide
2.1.3. Radiolabels 
AMERSHAM INTERNATIONAL pic.,
Amersham, Bucks.
[3H]-Morphine (27Ci/mmol)
[3H]-Dihydromorphine (69.5Ci/mmol)
ICN FLOW
High Wycombe, Bucks.
Na [125]I
2.1.4. Organic Solvents 
BDH CHEMICALS Ltd.,
Methanol AnalaR grade
Acetonitrile HyPerSolve (for far u.v. HPLC)
MAY & BAKER Ltd.,
Chloroform AR grade
2.1.5. Chromatography Materials and Equipment 
VARIAN ASSOCIATES Inc.
Model 5000 Liquid Chromatograph 
Chart recorder
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JONES CHROMATOGRAPHY 
Llanbradach, Wales
15cm Apex 5p Octadecasilyl (C18) HPLC column
ANACHEM
Luton, Beds.
Bond Elut C18 columns (6ml volume)
2.1.6. Glassware and Plastic Consumables 
LUCKHAM Ltd.,
Burgess Hill, Sussex.
LP3 assay tubes 
LP4 assay tubes 
FISONS pic.,
Loughborough, Leics.
LKB Polyethylene scintillation vials
2.1.7. Scintillation Counting Materials and Equipment 
PHARMACIA Ltd.,
Optiphase 'safe' scintillation fluid
LKB 1215/1216 Rackbeta liquid scintillation counters
LKB 12 60 Multigamma 11, gamma counter
2.2. MATERIALS
Glass double-distilled water was used for the 
preparation of assay solutions.
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2.2.1. Assay Buffer
The assay buffer was a 0.05M phosphate buffer, pH 7.4, 
that also contained the following;-
NaCl 6.0 g/1
Gelatine 1.0 g/1
Thiomersal 13.0 mg/1
The buffer was stored at 4°C and was freshly prepared 
each month, or as required.
2.2.2. Standard Solutions
Standard morphine alkaloid (Ipg/ml; 3.30pM) and M6G. 2H,j^ 0 
(Ipg/ml; 2.01pM) working solutions were prepared as follows
(1). Stock standard, Img/ml morphine alkaloid in absolute 
ethanol or Img/ml M6G in distilled water, diluted 1:100 in 
assay buffer to give:
(2). Intermediate standard solution, lO^g/ml in buffer,
diluted 1:10 in assay buffer to give:
(3). Working standard, Ipg/ml in buffer. This standard was 
stored at -20°C in lOOpl aliquots for up to two months. For 
use in each assay it was diluted 1:250 in assay buffer to 
give :
(4). Assay standard, 4ng/ml in buffer. This was prepared 
fresh for each assay.
2.2.3. Radiolabels
Stock solutions of [3H]-dihydromorphine (69.5 Ci/mmol) 
and [ 3H]-^\orphine (27 Ci/mmol) were stored at -20°C. An
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intermediate dilution of each radiolabel (1:100 in absolute 
ethanol) was stored at -20°C and was further diluted for each 
assay to give approximately 2500cpm per assay tube, 
equivalent to 0.025pmol [3H]-dihydromorphine and 0.15 pmol
[3H]-morphine.
[1251]-morphine and [125I]-M6G radiolabels were prepared 
according to the method of Moore and coworkers (1984b). 
lodogen (Ipg in 30jul dichloromethane) was pipetted into an 
Eppendorf tube and the solvent evaporated under nitrogen. For 
the iodination procedure, lOpl of stock buffer (0.5M 
phosphate, pH 7.5) was added to this tube followed by lOpl Na 
[1251] (ImCi) and 2jug morphine alkaloid standard ( lOpl of 
lOOpg/ml solution in methanol). The contents of the tube were 
mixed, with gentle swirling, for 11 minutes at room
temperature. The reaction was terminated by addition of 0.2ml 
working buffer (1:10 dilution of stock). Purification of the 
radiolabel was carried out by means of a C18 Bond-Elut
cartridge. Each cartridge was primed before use with 2 ml of 
methanol followed by 4 ml distilled water. The reaction tube 
contents were transferred to the top of the cartridge along 
with four successive washings of 0.2 ml of working buffer. 
This volume was forced through the cartridge under positive 
pressure and the eluate collected as fraction 1. The
cartridge was then washed with eight 2ml aliquots of
distilled water (fractions 2-9) followed by five 2ml aliquots 
of methanol (fractions 10-14). The passage of 
[1251]-radiolabel and 2pg standard solutions of both morphine
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and M6G through these columns is demonstrated in Fig.2.1. 
These eluates were screened using RIA, and approximately 7 6% 
of added morphine and 93% of added M6G were recovered from 
the columns. Morphine was eluted only in the methanolic 
fractions (10-14), whereas 77% of added M6G was eluted in 
these fractions and 16% was eluted in the earlier wash 
fractions. A lOpl aliquot of each fraction was diluted 1:100 
in working buffer and the radioactivity counted. The 
[1251]-morphine methanol fractions with the highest count 
rates were retained and stored at 4°C. Similarly, the first 
methanol eluate for [125I]-M6G (fraction 10) was retained for 
use and stored at 4°C. These fresh stock solutions were then 
diluted in assay buffer to give approximately 25,000 cpm/tube 
in each assay.
2.2.4. Antisera
Sheep anti-morphine antiserum (batch number HP/S/844 
Ila, 1984), raised following immunisation of a Suffolk Cross 
ewe with an N-succinylnormorphine-BSA conjugate (Morris et 
al. , 1974), had been stored at 4°C following addition of 0.1% 
sodium azide.
Goat anti-morphine antiserum (batch number GGl Vila 
19 73) and rabbit anti-morphine antiserum (batch number GR6) 
were obtained following immunisation of these animals with a 
6-succinylmorphine-BSA conjugate prepared according to the 
method of Simon and coworkers (197L). The goat antiserum was 
kept at 4°C following addition of 0.1% sodium azide. Rabbit
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(a) Morphine and [12611-Morphine
Morphine] nmol/l cpm X 10E+51600 26
1400
20
1200
1000 16
800
600
400
200
6 10 160 a42 12 14
Fraction No.
Morphine [l26i]-Morphlne
(b) M6G and [125i]-M6G
!M6GI nmol/l opmx 10E+51000 60
800 40
600 60
400 20
200
0 6 8 10 162 4 1412
Fraction No.
M6G [126II-M6G
Fig.2.1. Passage of morphine and M6G antigens and [1251]-radiolabelled antigens through a C18 Bond-Elut column.
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antiserum was stored as freeze-dried aliquots at a 1:10 
dilution, which were resuspended in 1ml distilled water as 
required.
2.2.5. Dextran-Coated Charcoal fPCC; 2.5%t
This was required for phase separation of the bound and 
free fractions, and was prepared by mixing a suspension of 
activated charcoal (Norit A) and Dextran T-70. Ig of Dextran 
T-70 and lOg Norit A were mixed in 400ml 0.05M phosphate
buffer (pH 7.4) by stirring overnight at 4°C. The mixture was 
then centrifuged (2500rpm, 4°C, 30 min.) to remove charcoal 
fines. The de-fined pellet was resuspended in a fresh 400ml 
of buffer and always thoroughly stirred before use. This 
suspension was stored at 4“C for up to three months.
2.2.6. Other Reagents
Scintillation fluid used was 'Optiphase Safe', an "all­
purpose liquid scintillation cocktail".
Where possible disposable plastic and glass tubes were
used.
2.3. RIA PROCEDURES
2.3.1. Antiserum Assessment and RIA Protocols
The protocol used for the construction of antiserum 
dilution and displacement curves from which the antiserum 
titre may be calculated is shown in Table 2.1. The assay was
page 80
Table 2.1.
Protocol for antiserum assessment
Total NSB Antiserum
tubes
Displacement
tubes
Diluent eoojji 500pl 400pl 300jul
Radiolabel 100 100 100 100
Antiserum - - 100 100
Standard - “ - 100
Dextran-
coated
charcoal
100 100 100
Aliquot for 500 500 500 500
scintillation
counting
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set up in duplicate, disposable LP3 plastic tubes and assay 
buffer was used to dilute the antiserum and the radiolabel as 
required. Tubes containing diluent, radiolabel and antiserum 
were vortex-mixed and incubated on ice for 1 hour. The 
antibody-bound morphine was then separated from the free 
fraction by incubation with ice-cold dextran-coated charcoal 
for 10 minutes on ice, followed by centrifugation (2500rpm 
for 10 mins at 4“C). When using [3H]-radiolabels, SOOpl of 
the resulting supernatant (bound fraction) wo^ f added to 4.5ml 
of scintillation fluid, vortex-mixed, and the radioactivity 
in the vials was measured by counting each sample for 4 
minutes in a liquid scintillation counter. Duplicate results 
were meaned and calculated as a percentage of the total 
counts (T) following subtraction of counts due to 
non-specific binding (NSB). Percentage bound (B)/T was 
calculated for each point.
The use of solid phase second antibodies as substitutes 
for DCC and for use with iodinated radiolabels, has been 
investigated. For this purpose, donkey anti-sheep-cellulose 
and donkey anti-rabbit-cellulose preparations (Guildhay 
Antisera Ltd.) were used with antiserum GGl Vila and 
antiserum GR6 respectively. However, these reagents offered 
no significant improvements over DCC with respect to assay 
sensitivity and reproducibility, and also proved to be more 
expensive.
When using [1251]-radiolabels, once phase separation had 
been achieved^ the supernatant was aspirated off . the
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remaining charcoal pellet (free fraction) was counted for 100 
seconds using an LKB Wallac Multigamma 1260 12-channel gamma 
counter. Antiserum titre was determined by evaluating the 
dilution of antiserum that bound 50% of the available bound 
radiolabel.
The procedure adopted for the construction of RIA 
standard curves is shown in Table 2.2. Duplicate tubes were 
set up for total, NSB, maximum binding, standard and sample 
determinations. Each sample was assayed at three different 
dilutions. To 400pl of each standard or sample, lOOpl of
diluted antiserum was added, together with lOOpl of diluted 
radiolabel. Maximum binding tubes were prepared by adding 
lOOjjl of radiolabel to a SOOpl aliquot of diluted antiserum. 
Assay conditions were as described above for antiserum titre 
assessment. When using [3H]-radiolabels, NSB was expressed as 
a percentage of total counts and was subtracted from all 
maximum binding, standard and sample counts. Zero (reference) 
and maximum binding of radiolabel were calculated as a 
percentage of total counts (%B/T) and the counts in the 
remaining standards and samples were expressed as a 
percentage of zero binding (%B/Bo). The methods used to
calculate %B/T and %B/Bo when using [1251]-radiolabels were 
modified to take into account that the free fraction was
counted. Data reduction was carried out using a smoothed
spline plot (LKB package) and the results calculated by 
interpolation. For each antiserum, the inter-assay variation 
of seven standard curves assayed on separate days was
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Table 2.2.
Reaaent Total NSB MB Std/Samole
Assay buffer 600pl 500pl - 400pl
Standard - - - 100
Diluted antisera - - 500 100
Diluted label 100 100 100 100
Incubate for 1 hour at 4”C
Dextran-coated charcoal (2.5%) - lOOjul lOOjul lOOpl
Mix and incubate for 10 mins at 4°C, centrifuge at 2500rpm for 10 mins at 4“C
t
Transfer 500pl of supernatant and add 4.5ml scintillant
Count for 4 mins in liquid scintillation counter
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calculated. This data was plotted along with a precision 
profile (Ekins, 1981), prepared by plotting the %c.v. for 
each point of the standard curve. This profile indicates the 
concentration range at which maximum precision may be 
expected.
Theoretical assay sensitivity for each standard curve 
was assessed from the mean of fifteen replicates of the zero 
standard. The sensitivity was defined as the least amount of 
drug that was distinguishable from zero at the 95% confidence 
limit, i.e. 2 S.D.s from mean of zero.
2.3.2. Assessment of Antiserum Avidity and Specificity
If the specific activity of a radiolabel is known, then 
the avidity of the antiserum may be calculated using the 
method of Müller (1980). This method was therefore used for 
avidity calculations in assays which employed
[3H]-radiolabels. However, although a method is available for 
the determination of the specific activities of 
[1251]-radiolabels (Morris et , 1976), it is complicated. 
For this reason, when an iodinated radiolabel was in use, 
indirect determination of avidity was assessed by inspection 
of the relevant antiserum dilution and displacement curves.
Antiserum specificity was assessed by examining the 
extent to which a selection of drugs, with similar structures 
to morphine, and morphine metabolites, interfered in the 
assay. Standard curves, containing aliquots of morphine or a
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structurally related analogue in the buffer volume, were 
constructed and the samples processed as described above. 
Cross-reactivity was determined by comparing the ability of 
each analogue to displace antibody-bound radiolabel. 
Measurable cross-reactivity was calculated using the method 
of Abraham (1969). Taking arbitrarily the cross-reaction of 
morphine or M6G antigen (Ag) with the antiserum to be 100%, 
the percentage cross-reaction of an analogue is calculated at 
50% displacement of the radiolabelled antigen (*Ag) i.e.
% Molar cross-reaction = No. moles Ag required to
of analogue displace 50% of f*Aal 100%
No. moles analogue required 
to displace 50% of (*Ag)
The above method of checking the specificity of an 
antiserum has one important limitation in that it can only be 
applied to those compounds which are known to exist and for 
which a pure standard preparation is available. Therefore, in 
order to ascertain whether or not samples contained any 
unknown cross-reactants, the additional test of generalised 
parallelism was performed by assaying a patient plasma sample 
known to contain high levels of morphine, M3G and/or M6G 
(depending on which compounds the assay was being used to 
measure) at doubling dilutions in assay buffer. Values for 
%B/T obtained for the buffer standard curve and the sample 
dilution curve were compared by plotting them on the same 
axes, and the degree of parallelism between the two curves 
was then assessed.
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2.3.3. Tissue Matrix Effects
In order to assay tissue samples directly, it is 
necessary to determine the extent to which the presence of 
proteins and other matrix constituents effect the 
dose-response curves. For the analysis of plasma this was 
assessed by substituting lOOjul of buffer with lOOpl of neat 
drug-free human plasma in the assay standard curve. The 
resulting standard curves were then compared by plotting %B/T 
for each data point on the same axes. Matrix effects were 
then assessed by recording any displacement in the standard 
curve due to the presence of plasma. For the analysis of 
other human and animal tissues more detailed investigation of 
these effects was carried out, and these are included in the 
individual sections as required.
2.3.4. Analytical Recovery
The accuracy of these RIAs was assessed by determining 
the recovery of morphine, M6G and M3G alone, and also from 
artificial mixtures containing any two of these compounds 
spiked into a pool of normal drug-free human plasma, 
depending on which assay was being investigated. These 
mixtures were prepared in such a way so that the recovery of 
morphine, M6G and/or M3G over concentration ranges which 
might be experienced clinically could be determined. All 
spiked samples were left to equilibrate with the drug for at
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least 2 hours at 4°C before analysis. All samples were 
determined in duplicate at three different dilutions. 
Percentage recovery of morphine and/or metabolites was 
calculated by dividing the measured result by the expected 
result i.e. the result that would be predicted taking into 
account the specificity characteristics of the antiserum 
under investigation.
2.3.5. Assay Quality Control and Validation
Two quality control (Q.C.) samples were processed at the 
beginning and the end of each assay. One sample (low Q.C.) 
was prepared by pooling together a selection of patient 
plasma samples known to contain relatively low levels of 
morphine and metabolites. The second sample was prepared by 
spiking normal, drug-free human plasma with 330nmol/l 
morphine alkaloid, 201nmol/l M6G or 201nmol/l M3G. The 
coefficient of inter-assay variation was calculated for all 
the Q.C. samples assayed in one complete study. Intra-assay 
variability was determined by the measurement of five 
replicates of each Q.C. sample in an assay of 150 tubes in 
length.
Validation of two of these RIAs was carried out by 
comparing results obtained using these methods with those 
obtained using a published HPLC method specific for morphine 
and its metabolites. This involved the analysis of 41 plasma 
samples obtained from normal volunteers who had received lOmg 
morphine sulphate administered via the intravenous, oral or
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sublingual routes, recruited from the Department of Medical 
Oncology at Homerton Hospital. Levels of morphine, M6G and M3G had 
previously been determined using the HPLC method of Joel gt al. 
(1988). The results for morphine and M6G obtained using RIA and 
HPLC were statistically compared by calculating the correlation 
coefficients and regression equations.
2.4. PHARMACOKINETIC ANALYSIS
The pharmacokinetic profiles were calculated using 
"STRIPE", an interactive computer program for the analysis of 
drug pharmacokinetics (Johnston and Woollard, 1983). This 
program uses "least squares" regression analysis of the log 
[concentation] versus time data to derive the best 
exponential fit by "back-stripping" of the curves starting 
with the terminal exponential.
The area under the plasma concentration/time curve (AUC) 
was calculated by the trapezoidal method for the area from To 
- Tn (time of drug administration to last time point). The 
area from To- T <» was estimated by dividing the concentration 
at the last time point (Cn) by the elimination rate constant 
(Kz). The half-life for each exponential, was calculated from 
the formula 0.693/k, where k is the calculated slope of the 
exponential. The apparent volume of distribution (Vd) was 
calculated by dividing the administered dose (D) by the (AUC 
X Kz). Total body clearance (Cl) was calculated by dividing D 
by the AUC. Vd and Cl were only calculated following 
parenteral administration.
page 89
Bioavailability of morphine following oral 
administration (F) was calculated by dividing the AUC 
obtained by the AUC following intravenous administration of 
the same dose expressed as a percentage.
Mean plasma concentrations of morphine and metabolites 
were plotted graphically. When using the differential 
equation to calculate levels of M6G, levels found to be < 10% 
[morphine] were reported as non-detected.
2.5. STATISTICAL ANALYSIS
The statistical methods employed are described in each 
individual section.
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CHAPTER THREE
RADIOIMMUNOASSAYS FOR MORPHINE 
AND MORPHINE GLUCURONIDES
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3.1. GENERAL INTRODUCTION
This chapter describes the development of RIAs for the 
determination of morphine, M6G and M3G in a variety of 
biological fluids. These assays have made use of three 
different anti-morphine antisera that had been produced in 
this laboratory before the start of the present project. 
These antisera had been raised in three animal species, 
following immunisation with two morphine-protein conjugates, 
and displayed a wide range of specificities towards morphine 
and its metabolites. It was decided to make use of these 
specificity differences and investigate the suitability of 
these antisera in RIAs set up to measure the levels of 
morphine and its glucuronide metabolites using a differential 
RIA technique. The principles behind this technique have 
previously been described for RIAs set up to measure 
buprenorphine and its 3-glucuronide metabolite (Hand et &1., 
1986) and, more recently, morphine, M3G and M6G (Hand et al., 
1987a). Essentially, it involves the analysis of a sample 
for levels of a particular drug using an antiserum specific 
for that drug, and subtracting the result obtained from that 
measured when the same sample is analysed using a 
non-specific antiserum that cross-reacts with both the drug 
and one of its metabolites. The difference between the two 
results is taken as an estimate of the level of that _ 
metabolite present in the sample. The following sections 
describe the development of an RIA specific for morphine and 
of assays capable of determining combined levels of either
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morphine and M6G, or morphine and M3G using two non-specific 
antisera.
3.2. DETERMINATION OF MORPHINE IN HUMAN PLASMA BY DIRECT RIA
3.2.1. Introduction
The assay described in this section was developed using 
one of a number of anti-morphine antisera that had been 
raised in a sheep following immunisation with an
N-succinylnormorphine-BSA conjugate. The resulting bleeds had 
been screened for assessment of titre and specificity and 
those with the most suitable characteristics had been
retained for future developmental work. The characterisation 
of one of these antisera, (G/S/7), has already been 
described (Aherne et âi»/ 1983). For the purpose of this 
project, the use of another antiserum that was available in 
larger quantities has been investigated.
Early screening work had been carried out using 
[3H]-dihydromorphine as the radiolabel. During the early 
stages of this project, [3H]-morphine became commercially 
available and both radiolabels have been used for antiserum 
characterisation and assay development. The antiserum was 
found to display similar characteristics with both 
radiolabels and, in the majority of the studies included in 
this thesis, morphine levels have been determined using 
[3H]-morphine. For this reason, the data obtained using this
radiolabel is presented and, where appropriate, comparative
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data obtained using [3H]-dihydromorphine is also included.
3.2.2. Materials
[3H3-dihydromorphine and [3H]-morphine were used as the 
radiolabels.
The antiserum used was sheep anti-morphine antiserum (batch 
number HP/S/844 Ila 1984).
3.2.3. Antiserum Assessment and RIA Protocol
Typical antiserum dilution and displacement curves 
obtained using both tritiated radiolabels are included in 
Fig.3.1. A titre of 1:100 was used throughout the course of 
these studies with both radiolabels. In both cases, addition 
of '0.66pmol morphine standard to the curves
resulted in substantial displacement. When the maximum 
binding values calculated for both radiolabels were compared, 
it was found that a significantly higher percentage of 
[3H3-morphine radiolabel was bound under these conditions. 
Morphine standards used were 0, 0.33, 0.66, 1.32, 2.64, 3.30,
3.96, 5.28, and 6.60nmol/l. Data showing the inter-assay variation of 
seven standard curves obtained using each radiolabel is shown 
in Fig.3.2. Also included are the precision profiles and 
these indicate satisfactory precision across this 
concentration range for both curves.
The theoretical sensitivities for these two assays were 
found to be 0.88nmol/l and 0.90nmol/l using [3H]-morphine and
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Fig.3.1. Antiserum HP/S/844 Ila - Dilution and Displacement curves.
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page 96
[3H]-dihydromorphine radiolabels respectively.
3.2.4. Assessment of Antiserum Avidity and Specificity
Antiserum avidity was calculated from data obtained from 
the standard curves plotted in Fig.3.2 using the method of
Müller (1980). For this calculation, molar concentration of 
the radiolabel and inhibitor, at 50% inhibition of 
radiolabel-antibody binding [It], and molar quantity of 
radiolabel bound in the absence of inhibitor [Tt], were 
required. The average avidity constant, K, of the morphine 
antibody population was then calculated by means of the 
following equation
K =____________ 8__________
3 (It + Tt) - (Tt)
The following values for K were obtained; [3H]-dihydro­
morphine: 8.45 X lOE+10 1/mole, [3H]-morphine: 9.50 X lOE+10
1/mole. These values indicate that the antiserum is of 
sufficient avidity for use in an RIA.
The cross-reactivity of this antiserum with a variety of 
structural analogues is shown in Table 3.1. Measurable 
cross-reactivity was only observed with the parent drug and 
normorphine. The degree of interference from the latter was 
significantly reduced when [3H]-morphine was used as the 
radiolabel.
Parallelism was assessed by analysing a patient plasma 
sample at doubling dilutions from 1:10 to 1:160. The 
resulting sample dilution curve was found to be
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Table 3.1.
Antiserum HP/S/844 lia - % molar cross-reactivities
Opioid r 3H1-M r 3H1-DHM
Morphine 100 100
M6G <0.1 <0.1
M3G <0.1 <0.1
Normorphine 32.1 94.3
Codeine <0.1 <0.1
Diamorphine <0.1 <0.1
Naloxone <0.1 <0.1
Buprenorphine <0.1 <0.1
Pethidine <0.1 <0.1
[3H]-M = [3H]-Morphine 
[3H]-DHM = [3H]-Dihydromorphine
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superimposable upon the buffer standard curve (Fig.3.3), 
providing further evidence that this antiserum is specific 
for morphine and is not susceptible to interference from 
other components that may be present in the plasma samples.
3.2.5. Effect of Plasma on the Standard Curve
The graphs plotted in Fig.3.4 show the result of 
substituting lOOpl of drug-free human plasma into the buffer 
standard curve. It can be seen that the presence of this 
volume of plasma does not cause any significant alteration in 
the shape of the dose-response curve or to the value obtained 
for % binding of the zero standard.
3.2.6. Analytical Recovery
In order to determine the accuracy of this RIA, the 
recovery of morphine spiked into drug-free human plasma in 
the range l-500nmol/l, was determined. The recovery of 
morphine in the presence of increasing concentrations of 
metabolites was also investigated by analysing plasma that 
had been spiked with morphine and either M6G or M3G to give 
morphine;metabolite molar ratios of 1:0 and 1:100 
(l=100nmol/l). The results obtained are shown in Tables 3.2 
and 3.3 and indicate good recovery of morphine at levels 2: 
5nmol/l and negligible interference even from high levels of 
either M6G or M3G.
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Table 3.2.
Recovery of morphine using HP/S7844 Ila RIA 
rMorphine! (nmol/l^ mean % recovery
1 80.7 ± 5.55 101. 0 ± 2.010 105.8 ± 4.250 105.9 ± 10100 119.9 ± 7.5500 104 . 3 ± 3.3
mean ± s.d. (n = 3)
Table 3.3.
Recovery of morphine in presence of M6G or M3G - HP/S/844 Ila morphine assay
Ratio % recovery % recoveryM;metabolite + M6G + M3G
0 1 N.D. N.D.1 0 101.2 ± 4.3 111.3 ± 9.91 0.1 100.5 ± 3.7 —1 0.2 97 . 5 ± 4.0 —1 0.5 93.2 ± 2.5 -1 1 99.9 ± 1.4 94.1 ± 7.71 2 96.5 ± 4.0 -1 5 97.5 ± 6.1 108.3 ± 151 10 98.6 ± 5.2 112.3 ± 131 25 96 . 6 ± 2.3 —1 50 107.0 ± 9.3 104.7 ± 8.81 100 107.5 ± 8.2 134.6 ± 19
mean ± s.d. (n=3)
1= lOOnmol/1
N.D. = none detected
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3.2.7. Assay Quality Control and Validation !
iIntra- and inter-assay variability for this RIA was 
assessed by repeat analysis of two Q.C. samples. This data is 
included in Table 3.4 and indicates satisfactory assay 
reproducibility. (N.B. Different patient plasma pools were 
assayed using the two radiolabels).
Assay validation was achieved by comparing morphine 
results obtained using this RIA with those obtained using a 
published HPLC method. Good agreement between both sets of 
results was found, although the RIA appeared to be giving 
rise to slightly higher levels. The correlation coefficient 
and regression line obtained are shown in Fig.3.5.
3.2.8. Discussion
The characterisation of antiserum HP/S/844 Ila and its 
use in a validated, direct RIA for morphine is described.
This assay has been shown to be robust, reliable and 
reproducible and offers an attractive alternative to the RIAs 
discussed earlier (Chapter One). Initial assessment of this 
antiserum was performed using two different radiolabels.
[3H]-morphine was more efficiently bound by this antiserum, 
probably because its structure more closely resembles that of 
the morphine derivative used as the hapten.
The method of choice for correlation studies is 
ultimately GC/MS. However, such a method is not routinely 
available for morphine and M6G, and the results obtained 
using this RIA have, therefore, been compared with those
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Table 3.4.
Assay performance data - HP/S/844 lia RIA 
USING [3H]-MORPHINE
Intra-assav Result % c.v. n % recovery
Patient pool 40.3 3.8 5Morphine spiked plasma 342.5 4.8 5 104
Inter-assay
Patient pool 37.1 3.4 15Morphine spiked plasma 347.0 5.4 15 105
USING [3H]-DIHYDROMORPHINE
Intra-assay
Patient pool 27.1 4.9 5Morphine spiked plasma 384.4 6.6 5 116
Inter-assav
Patient pool 27.5 10.3 15Morphine spiked plasma 390.7 5.3 15 118
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Fig.3.5. Morphine RIA results. RIA/HPLC correlation of morphine 
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determined using a specific HPLC method that is in routine 
use. An excellent correlation between the two methods was 
obtained although the RIA was found to be giving rise to 
slightly higher levels.
This antiserum exhibited significant cross-reaction with 
normorphine. This problem was to be expected, taking into 
account the position on the hapten molecule at which the 
protein was attached. A similar problem has been observed 
with another antiserum raised to a similar hapten/protein 
conjugate (Findlay et , 1976). This cross-reaction was 
less significant when [3H]-morphine was used as the 
radiolabel. The production of normorphine from morphine is a 
recognised metabolic pathway and was suggested to be of 
importance after chronic oral administration of morphine 
(Brunk and Delle, 1974). However, undetectable levels of 
normorphine were found following such treatment (Sawe et al., 
1983a), or following single doses of oral morphine (Joel 
S.P., personal communication). Therefore, these minor 
discrepancies found between the two sets of results are more 
likely to be due to differences in assay standarisation and 
reproducibility, rather than problems of antiserum
specificity in the RIA.
The use of this antiserum with [1251]-morphine as the 
radiolabel in an attempt to develop a simpler, quicker and 
less expensive assay has also been investigated. The use of 
an iodinated radiolabel enables the free charcoal pellet to 
be counted directly, and, thus, allows the added advantage of
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removing any potential quenching problems which may be 
experienced when counting the bound supernatant fraction of 
highly coloured samples, (this was not found to be a problem 
during the course of these studies). Disappointingly low 
binding of this radiolabel (12-15% maximum bound radiolabel) 
was achieved with this antiserum, possibly due to steric 
hindrance resulting from the introduction of a relatively 
large iodine molecule at a position on the morphine moiety 
which is in close proximity to one of the major antibody 
binding sites.
The success of this direct RIA, compared to other RIAs 
requiring prior extraction of morphine (Grabinski et 
a^.,1983), is due mainly to the use of a specific antibody 
that does not cross-react with compounds having structural 
alterations at 3-phenolic hydroxyl or 6-alcoholic hydroxyl 
positions on the morphine molecule. These specificity 
characteristics have led to measurements obtained with this 
assay being used in combination with measurements using 
non-specific morphine antisera, thus providing information on 
the levels of morphine metabolites present in biological 
samples. This differential RIA will be described in the 
following sections.
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3.3. DETERMINATION OF MORPHINE-6-GLUCURONIDE IN HUMAN PLASMA 
BY DIFFERENTIAL RIA
3.3.1. Introduction
The principles behind the technique of differential RIA 
proposed by Hand et (1987a) involve the use of three
anti-morphine antisera exhibiting varying cross-reactivities 
towards morphine, M3G and M6G. One antiserum was specific 
for morphine and possessed the same specificity 
characteristics as antiserum HP/S/844 Ila (Section 3.2). The 
other two antisera were found to cross-react with morphine 
and one or other of its glucuronide metabolites. It was 
decided to investigate the use of this technique employing 
antisera raised to two morphine-protein conjugates similar 
in structure to those described by Hand and colleagues 
(1987a).
For the purpose of measuring combined levels of morphine 
and M6G, an antiserum that had been raised in a goat to a 
6-substituted morphine-protein conjugate was used. This 
antiserum had previously been screened for titre and 
specificity using [3H]-dihydromorphine as the radiolabel. Its 
use in RIAs for measuring "morphine and codeine 
equivalents" has been described previously (Aherne et al., 
1975). In the present studies the use of iodinated 
radiolabels with these antisera has been investigated. In 
general, [1251] radiolabels have specific activities that are 
40-50 times greater than their tritiated counterparts. This,
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combined with high efficiency gamma counting  ^potentially
allows for the development of a more sensitive, rapid and 
less expensive assay. Morphine has been radioiodinated 
directly to 2-iodomorphine using chloramine-T (Mason &t al., 
1981). More recently, Moore et (1984b) have described the
preparation of [1251]-morphine for use in RIAs, using the 
lodogen method of Salacinski et §1. (1979). The iodogen
method was chosen for use in these studies. This section 
describes the stages involved in the development and
validation of an assay for the measurement of combined levels 
of morphine and M6G. Initially, morphine was used as the 
standard and radiolabel. However, it was subsequently
realised that improved recoveries and a closer agreement with
HPLC results were obtained when M6G standard and radiolabel
were employed, and consequently this assay has been used in 
the majority of the studies performed in this thesis. For 
comparison purposes, the initial characterisation procedures 
using morphine standard and radiolabel have been included 
but, for the sake of brevity, only the details on the
development and validation of the assay using M6G standard 
and radiolabel are described. In addition, it was the
constant aim throughout this project to investigate ways in 
which this particular assay could be improved, and details of 
these efforts are also included.
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3.3.2. Materials
[1251]-morphine and [125I]-M6G, prepared as described in 
Section 2.2.3, were employed as the radiolabels and the 
antiserum used was goat anti-morphine antiserum (batch number 
GGl Vila 1973; Section 2.2.4).
3.3.3. Assessment of Antiserum and RIA Protocol
The ability of this antiserum to bind [1251]- 
radiolabels was investigated. Antiserum dilution curves were 
set up and displacement curves were constructed by including 
an aliquot of 0,402pmol morphine or M6G in the dilution curve. 
Examples of antiserum dilution and displacement curves for 
GGl Vila obtained using both radiolabels are shown in 
Fig.3.6. Dilution curves were repeated for each new batch of 
radiolabel and antiserum titres in the range 1:2300 to 1:2700 
with [1251]-morphine and 1:6500 to 1:11000 with [125I]-M6G 
were used.
M6G standard curves were prepared by spiking normal 
drug-free plasma in the range 0, 0.201, 0.402, 0.804, 1.608, 
2.010, 2.412, 3.216, 4.020nmol/l. The percentage binding was 
calculated for each standard and fitted to a smoothed spline 
function. The results for unknown samples were determined 
automatically by interpolation. The mean data from seven 
separate standard curves, constructed in the range 0- 
6.60nmol/l morphine or 0- 4.02nmol/l M6G are shown in Fig.3.7 
along with precision profiles that show reasonable precision 
across these concentration ranges.
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Theoretical assay sensitivities were calculated to be 
0.56nmol/l when using morphine standard and radiolabel and 
0.27nmol/l when using M6G standard and radiolabel.
3.3.4. Assessment of antiserum avidity and specificity
Indirect assessment of the avidity of this antiserum was 
achieved by comparison of the morphine and M6G antiserum 
displacement curves (Fig.3.6).
The cross-reactivities of GGl Vila with a variety of 
structural analogues is shown in Figs.3.8 and 3.9 with the 
percentage molar cross-reactivities data calculated also 
included in Tables 3.5 and 3.6. When morphine standard and 
radiolabel are used, this antiserum cross-reacts with 
morphine and, to a greater extent, M6G (100% and 314% 
respectively). When M6G standard and radiolabel are used, and 
the cross-reaction with M6G is defined as 100%, then morphine 
apparently cross-reacts to a smaller extent (79%). 
Interference is demonstrated from high levels of diamorphine 
and codeine, but no significant cross-reactivity was found 
with either M3G or normorphine.
For the assessment of parallelism, a clinical sample was 
double-diluted from 1:50 to 1:800 and assayed. The standard 
curve and sample dilution curve obtained using MSG standard 
and radiolabel are both plotted on the same axes in Fig.3.10.
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Fig.3.8. Antiserum GGl Vila - Cross-reactivity with structural analogues using [1251]-morphine and morphine standardisation.
Table 3.5.
Antiserum GGl Vila - % molar cross-reactivities usina r12511-morphine
Ooioid
Morphine 100M6G 314MSG 1.0Normorphine 0.4Codeine 40.0Diamorphine 75.2
Naloxone <0.1Buprenorphine <0.1Pethidine <0.1
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Fig.3.9^ Antiserum GGl Vila - Cross-reactivity with structural analogues using [125IJ-M6G and M6G standardisation.
Table 3.6.
Antiserum GGl Vila - % molar cross-reactivities usina|125I1-M6G
Opioid
M6G 100Morphine 79 .2M3G 2.2Normorphine 1.0Codeine 43.5Diamorphine 67 .3Naloxone <0.1Buprenorphine <0.1Pethidine <0.1
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3.3.5. Effect of Plasma on the Standard Curve
Fig.3,11 presents the result of substituting lOOpl of 
neat drug-free plasma into the assay system employing M6G 
standard and radiolabel. It is evident that the presence of 
plasma has no significant effect on the shape of the
dose-response curve.
3.3.6. Analytical Recovery of Morphine and M6G
As this antiserum was being used to measure combined
levels of morphine and M6G, it was considered necessary to 
assess the recovery of these compounds separately and in
situations where both are present in the same sample.
Despite its apparent low cross-reactivity, M3G is the most 
abundant metabolite of morphine, and, therefore, the recovery 
of M6G, in the presence of increasing levels of M3G, and the 
recovery of M3G alone ha\iQ_also been determined. Five sets of 
recovery standards were prepared by spiking drug-free plasma 
as follows;
(i) 1 - 500nmol/l morphine.
(ii) 1 - 500nmol/l M6G.
(iii) *1:0 - 1:80 morphine:M6G.
(iv) *1:0 - 1:80 M6G:M3G.
(v) 1 - lOpraol/1 M3G.
* molar ratios; l=100nmol/l.
These recovery samples were assayed and the percentage 
recoveries are presented in Tables 3.7- 3.10. Complete
recovery from samples containing morphine and/or M6G was
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Table 3.7.
Recovery of morphine and M6G using differential M6G RIA with 
M6G standardisation.
[Morphine 1 fnmol/I) mean % recovery
1 120.7 ± 18
5 92.7 ± 8.2
10 105.3 ± 7.4
50 97.7 ± 8.3
100 87.3 ± 5.1
500 99.3 ± 6.1
[M6G1 (nmol/l)
1 122.0 ± 8.5
5 119.0 ± 10
10 110.0 ± 4 . 0
50 104 . 3 ± 12
100 97.3 ± 4.0
500 104.7 ± 9.1
mean ± s.d. (n=4)
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Table 3.8.
Recovery of morphine and increasing concentrations of M6G 
using differential M6G RIA with M6G standardisation.
Morphine:M6G ratio Result fnmol/1^ mean % recovery
0 1 104.4 ± 2.4 104
1 0 92 . 8 ± 5 . 9 93
1 0.1 109.0 ± 2.1 99
1 0 . 2 122 . 5 ± 4 . 0 102
1 0.5 148.6 ± 4.7 99
1 1 213.2 ± 18 107
1 2 347.8 ± 2 . 1 116
1 5 642.0 ± 11 107
1 10 1012 ± 85 92
1 25 2695 ± 273 104
1 50 5033 ± 58 99
1 100 10983 ± 66 109
mean ± s.d. (n = 3)
1= lOOnmol/1
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Table 3.9.
Recovery of M6G in the presence of M3G usina differential M6GRIA with M6G standardisation
M6G:M3G ratio Result fnmol/l) % M6G recovery
1:0 96.9 ± 13 1001:1 101.1 ± 9.7 1041:5 114.1 ± 4.4 1181:10 118.3 ± 6.0 1221:20 146.2 ± 8.7 1511:40 164.3 ± 9.1 1691:50 184.0 ± 7.5 1901:100 240.0 ± 6.9 248
mean ± s.d. (n=3)
1= lOOnmol/1
Table 3.10.
M3G recovery and % interference - Differential M6G RIA withM6G standardisation '
Std. fM3Gl fnmol/l) Result fnmol/1) % interference
A 100 1.72 1.7B 500 6.01 1.2C 1000 11.9 1.2D 2500 24.6 1.0E 5000 41.8 0.8F 10000 105 1.0
mean of 3 results
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found using this assay. However, the recovery of M6G was 
distorted when high levels of M3G (>20:1) were also present, 
even though the recovery of M3G alone up to levels of 
lOpmol/1 was negligible. As expected, falsely elevated 
morphine levels were also recorded in the presence of high 
levels of M3G (M3G:M >50:1) (results not shown).
Differential Calculation
Levels of M6G present were calculated using the 
following equation:
[M6G] nmol/l = (GGl Vila result) - (HP/S/844 Ila result)
3.3.7. Assay Quality Control and Validation
Three Q.C. samples were included in each assay. Low Q.C. 
samples were prepared by mixing a number of patient samples 
known to contain low combined levels of morphine and M6G. Two 
spiked plasma samples containing either 330nmol/l morphine 
or 201nmol/l M6G were also prepared and aliquots included in 
each assay. Intra- and inter-assay variations were calculated 
for each Q.C. sample following repeated analyses using the 
assay standardised with M6G (Table 3.11). These results 
indicate reasonable precision and reproducibility in this 
assay.
For the purpose of assay validation, the samples 
obtained for the morphine HPLC/RIA method comparison, 
described in Section 2.3.5 , were also assayed for levels of 
M6G using the differential RIA method using either morphine
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Table 3.11
Assay performance data - Differential M6G RIA with M6G 
standardisation.
Intra-assay Result % c. V . n % recovery
Patient pool 18.3
Morphine spiked plasma 289.8 
M6G spiked plasma 194.1
5.9 
9 .1 
6.0
88
97
Inter-assav
Patient pool 19.1 11.0 10 -
Morphine spiked plasma 303.4 5.4 10 92
M6G spiked plasma 215.4 7.5 10 107
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or M6G standard and radiolabel. These results were compared 
to those determined by HPLC and the correlation coefficients 
and regression equations obtained are shown in Fig.3.12.
These results indicate that there was good agreement 
between these methods. An excellent correlation was obtained 
between HPLC and the RIA standardised using morphine but the 
levels of M6G obtained using this differential RIA were also 
consistently higher. This overestimation was not apparent
when M6G was used as the standard and radiolabel in the RIA.
The graphs plotted in Fig.3.12(c) indicate that the
differences in M6G results obtained by HPLC and RIA are 
proportional to the levels of M3G (as determined by HPLC) 
present in the same clinical samples.
3.3.8. Optimisation of M6Q Differential RIA
3.3.8.1. Introduction
This section describes the attempts that have been made 
to improve the assay previously described in Section 3.3. In 
steroid RIAs, improved assay specificity has been achieved 
by altering the antigen/antibody incubation times used 
(Vining et ai.., 1981). The effects of varying incubation 
times on the
degree of interference from M3G in the 
assay has been assessed.
In an attempt to achieve maximum specificity and
sensitivity, the possibility of using an initial
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chromatographic step, to separate M3G, M6G and morphine, was 
also investigated. Separation of morphine from its 
glucuronide metabolites has been achieved using solvent 
extraction (Grabinski et al., 1983), liquid-solid 
chromatography (Sandouk et a%., 1984; Quinn et âi*/ 1988b) 
and HPLC (Nelson et , 1980). However, in order to separate 
all three compounds a more selective system was required and 
the HPLC method of Svensson et al. (1982) was therefore 
chosen.
3.3.8.2. Effects of Increasing Assay Incubation Time on M6G 
Recovery
3.3.8.2.1. RIA Protocol
Comparative M6G standard curves obtained following 1 and 
24 hour incubation times are shown in Fig 3.13 and indicate 
no significant alterations in the shape of the dose-response 
curve with increased incubation time.
3.3.8.2.2. Analytical Recovery of M6G
Plasma recovery standards (iv) containing M6G with 
increasing concentrations of M3G, prepared as described in 
Section 3,3.^, were analysed using this RIA employing either 
1 or 24 hour incubation periods. These results are shown in 
Fig.3.14. In each case the recovery of M6G from the first 
standard, (i.e. in the absence of any M3G), was taken to 
represent 100% recovery to allow easier comparison. This data
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indicates that decreased interference from M3G was evident 
when the assay was incubated for 24 hours.
3.3.8.3. Separation of M3G and M6G Fractions using HPLC
3.3.8.3.1. Materials
The HPLC system was manufactured by Varian Associates 
Inc. and consisted of a Model 5000 Liquid Chromatograph with 
a UV-5 0 variable wavelength detector and a Model 917 6 chart 
recorder. The HPLC column was a 15cm reverse-phase column 
packed with 5/j Apex ODS material (Jones Chromatography) . The 
mobile phase was prepared using lOmM sodium dihydrogen 
phosphate, ImM sodium dodecyl sulphate and 26% acetonitrile. 
•These were mixed and degassed in a Sonicor ultrasonic bath. 
The pH was adjusted to 2.1 using orthophosphoric acid.
3.3.8.3.2. Procedure
The following conditions were adopted for each run:
Pump flow rate: 1.5ml/min.
U.V. detector: 210nm; range 0.2 Absorbance Units.
Rheodyne valve: lOOpl loop fitted; 200jul injection volume. 
Chart recorder: range lOmV; speed 5mm/min.
50jug aliquots of each standard solution, prepared in 
mobile phase, were injected onto the column. Fractions of 
eluant were collected every 30 seconds, either manually or by 
means of an LKB Redirac automated fraction collector. The 
resulting fractions were scanned at 210nm using an LKB
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ültrospec 4050 spectrophotometer.
3. 3.8.3.3. Results
A typical chromatogram obtained following injection of a 
mixture of all three compounds is shown in Fig.3.15. Using 
the above conditions, retention times for M3G, M6G and 
morphine were 4.8, 6.0 and 10.8 minutes respectively. In 
Fig.3.16, the elution profiles obtained after the injection 
of either MSG or M6G onto the column are shown. It can be 
seen that, although the retention times calculated from the 
chromatograms suggest complete resolution of M3G and M6G 
peaks, satisfactory separation of these two compounds could 
not be achieved by fraction collection using the conditions 
described here.
3.3.9. Discussion
The characterisation of antiserum GGl Vila using 
iodinated radiolabels is described, together with the stages 
involved in validating its use in an RIA to measure combined 
levels of morphine and M6G in plasma samples. The M6G results 
obtained in this way correlated well with those obtained by 
HPLC, but when morphine was used as the standard and 
radiolabel in the RIA the M6G results obtained were 
consistently higher than those measured by HPLC. It is likely 
that these discrepancies were due to the presence of an 
interfering substance in the majority of the samples assayed 
and/or differences in the standardisation procedures used for
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Fig.3.15. Chromatographic separation of M3G, M6G and morphine.
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the two assays. Indeed, this problem was substantially 
improved when M6G was used in the place of morphine in the 
RIA. The reasons for this may be two-fold in that using this 
modified procedure more accurate recovery of M6G in the 
presence of M3G is found, and also standardisation using the 
metabolite rather than the less abundant parent drug may 
enable a more accurate assessment of M6G levels to be carried 
out.
Results from the specificity studies show that, if 
morphine is used as the standard and radiolabel and the molar 
cross-reactivity of this antiserum with morphine is 
arbitrarily defined as 100%, then the % molar
cross-reactivities of M6G and M3G are 314% and 1.0%
respectively. However, the recovery of morphine and/or M6G 
was found to be complete over a wide concentration range 
implying that, although M6G apparently cross-reacts by >100%, 
increased recovery of M6G was not e x p e r i e n c e d c v ^ b
Interference from structurally related compounds, both 
known and unknown, is a well recognised problem with
immunoassays and this antiserum exhibits significant 
cross-reaction with codeine, dihydrocodeine and diamorphine. 
However, co-administrartion of these compounds is rare, and 
although codeine is a recognised metabolite of morphine 
negligible quantities are produced (Yeh, 1974). The
cross-reactivity of this antiserum with M3G is minimal. 
However, the recovery studies indicated that the presence of 
high levels of M3G (M3G:M6G >20:1) can lead to increased
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recovery of M6G, regardless of whether morphine or M6G is 
used to standardise the assay. This interference has been 
recorded with a similar antiserum (Shelly ei. <gJL. , 1988). M3G 
is the major metabolite of morphine and M3G:M6G ratios 
between 6:1 and 10:1 have been reported following oral 
morphine administration (Sawe, 1986). The interference 
demonstrated in the recovery studies is likely to be less of 
a problem in vivo when morphine is also present. 
Nevertheless, the possibility that this method gives rise to 
falsely elevated results for M6G needs to be taken into 
consideration.
Due to the problems discussed above, further attempts to 
to improve the specificity of the M6G standardised 
differential RIA technique were also investigated. When the 
assay incubation time was increased to 24 hours, decreased 
interference from M3G was evident. However, it was 
subsequently revealed that the analytical recovery of 
morphine is also decreased with increasing incubation time 
(results not shown) and, therefore, this modification did not 
offer any immediate practical advantages. Nevertheless, the 
use of longer incubation periods warrants further 
investigation, since interference from either M3G or morphine 
may eventually be completely overcome, thereby allowing 
quantitation of M6G alone. It must be remembered, however, 
that the use of longer incubation periods is effectively 
negating one of the major practical advantages of RIA, i.e. 
speed of operation.
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The use of HPLC to separate fractions of M3G and M6G has 
been tentatively investigated using standard preparations of 
M3G, M6G and morphine. Unfortunately, incomplete resolution 
of the two metabolites was found using the conditions 
described here. It is possible that this overlap of eluting 
fractions was due to the large quantities of standard applied 
overloading the column. The quantities stated were essential 
to enable spectrophotometric monitoring to be carried out. 
More complete separation may be achieved by collecting
smaller fractions, decreasing the acetonitrile concentration 
in the mobile phase, and/or by using a column packed with 
particles of a smaller diameter (e.g. 3p). Successful
resolution of these fractions for immunoreactivity screening 
purposes has been reported by Wahlstrôm et &%. (1988) using 
the same HPLC method, but no details on the exact conditions 
used were included in their report. Easier separation may be 
achieved using a simpler liquid chromatographic procedure, 
such as that successfully employed to separate interfering 
nucleotides prior to analysis by RIA (Piall et ^ . , 1986).
It is also possible to improve the specificity of an 
antiserum by removing cross-reacting antibodies using 
immunoadsorbent purification procedures. The potential 
success of this technique with GGl Vila is, however, in some 
doubt as it is likely that GGl Vila consists of a
heterogeneous population of antibodies, all of which
recognise the same epitopes on the morphine molecule. From 
the cross-reactivity data obtained, significant
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interference was evident with morphine analogues with 
structural alterations at the 3-position, (codeine, 
diamorphine and M3G). The importance of this position as an 
antigenic determinant is questionable. For the same reasons, 
successful production of a monoclonal antibody with a more 
predictable specificity profile using the same conjugate, 
would be unlikely. Additionally, only a small volume of this 
antiserum was available; immunoadsorbent purification 
techniques generally require large volumes of antiserum and 
give rise to purified antisera that need to be used at lower 
titres. These procedures were not investigated further due to 
time constraints and the fact that it was thought unlikely 
that they would give rise to any significant practical 
advantages over the existing assay in its present form.
3.4. DETERMINATION OF MORPHINE-3-GLUCURONIDE IN HUMAN PLASMA 
BY DIFFERENTIAL RIA
3.4.1. Introduction
In their preliminary report into the use of differential 
RIA, Hand âJL* ,( 1987a) described the use of an
anti-morphine antiserum to determine combined levels of 
morphine and M3G. This antiserum had originally been produced 
in this laboratory, following immunisation of a rabbit with a 
6-succinylmorphine-BSA conjugate. Early screening work had 
shown that, although they had been raised to the same 
immunogen, GGl Vila and the rabbit anti-morphine antiserum
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(GR6) possessed markedly different specificity profiles. 
Using [3H]-dihydromorphine as the screening radiolabel, 
Aherne êt. âi» (1975) found that this antiserum exhibited 
significant cross-reactivity with morphine, M3G and codeine, 
but not with M6G. Hand et al. (1987a) subsequently found a 
similar specificity profile using [1251]-morphine as the 
radiolabel. They proposed the use of this antiserum to 
measure levels of M3G using differential RIA. It was decided 
to investigate this technique further. The procedures used 
were essentially the same as those described in Section 3.3, 
with certain modifications for use with this particular 
antiserum.
3.4.2. Materials
Antiserum GR6 and [1251]-morphine radiolabel were used.
3.4.3. Assessment of Antiserum GR6 and RIA Protocol
The ability of this antiserum to bind [1251]-morphine 
radiolabel was assessed, and displacement curves were 
constructed by adding aliquots of morphine standard 
(6.60nmol/l) to a parallel series of antiserum dilution 
curves. Typical dilution and displacement curves are shown in 
Fig.3.17. The antiserum was used at final titres within the 
range 1:2000 to 1:3000. Significant displacement of antiserum
binding was seen in the presence of morphine.
Morphine standard curves were constructed in the range
0-6.60nmol/l. Data from the mean of seven separate standard
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Fig.3.18. Differential M3G RIA - Mean data from 7 separate morphine standard curves.
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curves and the precision profile is plotted in Fig.3.18 and 
shows good precision across this concentration range. 
Theoretical assay sensitivity was calculated to be 
0.16nmol/l.
3.4.4. Assessment of Antiserum Specificity
The cross-reactivity of GR6 with a variety of analogues 
is shown in Fig.3.19 and Table 3.12. Significant 
cross-reaction with morphine analogues, having structural 
alterations at the 3-phenolic hydroxyl position, is 
demonstrated. Negligible cross-reactivity was found with M6G 
and normorphine.
Parallelism was assessed by plotting the buffer standard 
curve and the sample dilution curve, obtained by analysing a 
plasma sample serially diluted from 1:100 to 1:1600, on the 
same graph. This data is shown in Fig.3.20. The sample 
dilution curve is displaced to the left; this is likely to be 
due to one or more components within the sample matrix 
interfering with the antigen/antibody binding mechanism.
3.4.5. Effect of Plasma on the Standard Curve
The addition of lOOjul of normal drug-free human plasma 
to a buffer standard curve resulted in a marked reduction in 
the zero standard binding value, and led to significant 
displacement of the resulting standard curve (Fig.3.21).
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Fig.3.19. Antiserum GR6 - Cross-reactivity with structural analogues.
Table 3.12.
Antiserum GR6 - % molar cross-reactivities 
Opioid
MorphineM3GM6GNormorphineCodeineDiamorphineNaloxoneBuprenorphinePethidine
100 82.1 0.4 0.2 63.9 117 
< 0.1 
< 0.1 <0 .1
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3.4.6. Analytical Recovery of Morphine and M3G
The recovery of morphine and/or MSG from spiked samples 
containing morphine and/or MSG over a wide range of 
concentrations was assessed (Section 2. S. 4-). Recoveries are 
shown in Tables S.IS and S.14, and it can be seen that whilst 
the recovery of morphine , alone is satisfactory, falsely 
elevated results are obtained when samples containing MSG are 
analysed.
Differential Calculation
MSG levels were calculated using the following equation: 
[MSG] nmol/l = (GR6 result) - (HP/S/844 Ila result)
3.4.7. Assay Quality Control
Assay performance was assessed by determining intra- and 
inter-assay precision data for spiked plasma samples 
containing SSOnmol/1 morphine or 201nmol/l MSG, and for the 
patient pool (low Q.C.). Reasonable intra- and inter-assay 
precision was evident with all Q.C. samples, but the recovery 
of MSG from the spiked samples was high, as indicated in 
Table S.15,
3.4.8. Discussion
The use of antiserum GR6 in an RIA to measure levels of 
morphine and MSG has been investigated. Although the presence 
of a neat plasma matrix resulted in a significant inhibition 
of binding, only a small number of plasma samples required
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Table 3.13.
Recovery of morphine and MSG using differential M3G RIA
rMorphine 1 (nmol/l) mean % recovery
1 5 10 50 100 500
FMSG1 fnmol/1)
1 5 10 50 100 500
108.0 ± 6.9122 . 0 ± 17109.0 ± 14110.4 ± 9.994.8 ± 6 . 8105 . 5 ± 7.8
118.1 ± 2.4IIS.S ± 8 . 6115 . S ± S.O123 . S ± 12101. 6 ± 2.S117.8 ± 5.5
mean ± s.d. (n = S)
Table 3.14.
Recovery of morphine and increasing concentrations of MSG using differential MSG RIA.
Morphine;MSG ratio Result (nmol/l) mean % recovery
1:0 112.5 ± 16 1121:1 236.2 ± 26 1181:5 762.6 ± 46 1271:10 1585 ± 169 1441:50 7SS7 ± 870 1441:100 1912S ± S580 189
mean ± s.d. (n = 3) 
1= lOOnmol/1
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Table 3.15.
Assay performance data - Differential MSG RIA
Intra-assav Result % C.V. n % recovery
High patient pool 1129.4 6.9 5
Low patient pool 84.7 5.5 5 -
Morphine spiked plasma S15.8 10.9 5 96
MSG spiked plasma SOS.S 1S.6 5 151
Inter-assay
High patient pool 121S.5 11.0 10 -
Low patient pool 71.2 11.8 10 -
Morphine spiked plasma S12.8 10.1 10 95
MSG spiked plasma 277 . 6 11.8 10 1S8
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analysis with this assay and these needed dilution to fall 
within the range of the standard curve. Initial 
cross-reactivity data had indicated that this antiserum has 
the required specificity profile for use in such a role. 
However, subsequent recovery studies indicated that, although 
the recovery of morphine was complete, when this antiserum 
was used in an RIA to measure combined levels of M3G and 
morphine, falsely elevated levels of M3G were obtained. This 
was found to be more of a problem when high levels of M6G 
were also present (M6G:M3G ratio >5:1; results not shown). 
However, this situation is unlikely to be experienced 
clinically. These results would not have been predicted from 
the cross-reactivity data obtained, which indicated that GR6 
apparently cross-reacts to a lesser extent with M3G than with 
morphine, and the reasons for these findings are unclear.
3.5. DETERMINATION OF MORPHINE AND M6G IN RAT TISSUES
3.5.1. Introduction
The RIAs described previously were developed to allow 
the direct determination of morphine, M6G and M3G in human 
plasma samples. The need to determine levels of these 
compounds in other biological tissues also arose during the 
course of this project. The RIA procedures described earlier 
in this chapter have therefore been modified and further 
validated so that these assays could also be used to measure 
levels of morphine and M6G in samples of rat serum, brain,
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liver and kidney.
3.5.2. Preparation of Rat Tissue Homoaenates
Pre-treatment of samples of rat brain, liver and kidney 
for analysis by RIA was carried out using a similar method to 
that described by Plomp et a_l. (1981).
Adult male Wistar/albino rats (200-300g) were used. 
After treatment, blood was collected by cardiac puncture 
under light ether anaesthesia. The animals were then killed 
by cervical dislocation and the brain, liver and kidneys were 
rapidly excised and kept in ice-cold 0.9% physiological 
saline prior to homogenisation.
Blood collected was allowed to clot at 4°C in sterile 
plain glass tubes. These tubes were then centrifuged at 
2000rpm for 15 mins at 4“C and the serum removed and stored 
at -20“C until analysis.
The other tissues were blotted on tissue paper and wiped 
clear of any surface blood and saline before weighing. Each 
tissue was then homogenised in 4 volumes of 0.9% saline using 
a Polytron homogeniser (type PTIO, Northern Media Supply 
Ltd., Brough, North Humberside U.K.). These homogenates were 
then stored at -20“C until analysis (within two months). Upon 
thawing, a 2ml aliquot of each homogenate was centrifuged 
(33,000g for 20mins; 4°C; Beckman J2-21 centrifuge). Aliquots 
of. the resulting supernatants were then taken for analysis. 
Control tissues obtained from untreated animals, kept under 
the same conditions, were prepared in the same manner.
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3.5.3. Tissue Matrix Effects
It was necessary to investigate the effects of the 
presence of control rat tissues on the NSB and zero standard 
binding values in both assays. This data is summarised in 
Fig.3.22. The addition of 50pl of brain supernatant led to a 
decrease in the zero standard binding for both assays, 
although no change in NSB was observed. The addition of 20pl 
of either kidney or liver supernatants had no effect on zero 
standard binding, but resulted in marked increases in NSB.
3.5.4. RIA Protocol and Preparation of Tissue Standard Curves
Taking into consideration the matrix problems 
experienced above, it was decided to construct standard 
curves containing aliquots of lOOjul rat serum, 50jul brain 
supernatant, 20/j1 kidney supernatant or 20jul liver 
supernatant. For this reason, samples of brain, kidney and 
liver were diluted in control tissue supernatant, and 
analysed at dilutions of 1:2 (brain) or 1:5 (kidney and 
liver) in both assays. The addition of 50pil aliquots of brain 
supernatant and 20pl aliquots of kidney or liver supernatants 
to each standard curve was necessary to correct for the 
presence of these matrices. Parallelism between buffer 
standard curves, containing the required volume of blank 
tissue, and sample dilution curves for all these tissues, for 
both the specific morphine assay and the differential M6G 
assay, are presented in Figs.3.23 and 3.24. In general, these 
curves were superimposable, although slight displacement was
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Fig.3.22. Effects of rat tissue matrices on non-specific binding and binding of zero standard.
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Fig,3.24. Differential M6G RIA parallelism. Assessment of rat tissue
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evident when kidney and liver samples were analysed, possibly 
due to a slight inter-sample variation in homogenate 
composition. Theoretical sensitivities, obtained by analysing 
15 replicates of each tissue blank, were as follows:
Tissue Morphine RIA Differential
M6G RIA
Serum 0.2 3 nmol/l 0.40 nmol/l
Brain 0.28 0.56
Liver 0.40 0.55
Kidney 0 . 30 0,47
3.5.5. Analytical Recovery of Morphine and M6G
The recovery of these compounds, in the range
2-500nmol/l from rat serum and brain tissue and 5-500nmol/l 
from rat kidney and liver tissues, was assessed for both
assays. In general, the recovery of both compounds from all 
tissues was satisfactory, as shown in Tables 3.16- 3.19.
3.5.6. Assay Quality Control
In the absence of any suitable tissue pools at the
beginning of this study, assay quality control was assessed 
by analysing two of the above recovery standards in each
assay, together with a carry-over sample from the previous 
assay.
3.5.7. Discussion
This section describes the steps taken to validate the 
RIAs for morphine and M6G for the analysis of rat tissues.
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Table 3.16.
Recovery of morphine and M6G from rat serum
MORPHINE RIA
rMorphine 1 (nmol/I)
210100500
mean % recovery
88.8 ± 2.683.3 ± 3.0 92.8 ± 15 93.5 ± 8.3
DIFFERENTIAL M6G RIA
rMorphine 1 (nmo1/1) mean % recovery
2 78.0 db 6.110 80 .4 ± 8 . 8100 80 . 6 ± 11500 80.5 ± 13
FM6G1 fnmol/1)
2 90.0 ± 1710 98.8 ± 15100 90.7 ± 17500 88.3 ± 9.1
mean ± s.d; (n = 4)
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Table 3.17.
Recovery of morphine and M6G from rat brain supernatant
MORPHINE RIA
rMorohinel (nmol/l^ mean recovery
10100500
103.7 ± 11
DIFFERENTIAL M6G RIA
fMorphinel (nmol/l) mean recovery
10100500
104.0 ± 14
FM6G1 fnmol/1^
86.610100500 106.2 ± 12
mean ± s.d
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Table 3.18.
Recovery of morphine and M6G from rat liver supernatant
MORPHINE RIA
FMorphinel Fnmol/l^ 
525100500
mean % recovery
9495 10496
± 16 ± 13 ± 7.7 ± 10
DIFFERENTIAL M6G RIA
FMorphinel (nmol/l^
525100500
FM6G1 Fnmol/1)
525100500
mean % recovery
91.2 ± 286.2 ± 1 97.7 ± 4 96.5 ± 8
9 6.5 ± 6,0110.0 ± 4.1111.0 ± 3.2 98.6 ± 13
mean ± s.d. (n = 4)
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Table 3.19.
Recovery of morphine and M6G from rat kidnev supernatant
MORPHINE RIA
FMorphinel Fnmol/l^ 
525100500
mean % recovery
96.0 ± ±8490
213.29.491.0 ± 6.5
DIFFERENTIAL M6G RIA
FMorphinel F nmol/II 
525100500
FM6G1 fnmol/11 
525100500
mean % recovery
98758681
± 15 ± 1.0 ± 7.7 ± 1.7
94.7 ± 1497.2 ± 9.995.7 ± 6.590.2 ± 12
mean ± s.d. (n = 4)
page 152
Suitable correction procedures were required to overcome the 
effects of certain tissues on NSB and zero standard binding. 
It was interesting to note that quenching problems were not 
encountered in the counting of these supernatants, in the RIA 
using [3H]-morphine as the radiolabel (results not shown). 
Using these assay conditions, reproducible recoveries of 
known amounts of morphine and M6G can be obtained at 
concentrations greater than 5nmol/l.
3.6. DETERMINATION OF MORPHINE. M6G AND M3G IN HUMAN 
CEREBROSPINAL FLUID AND BILE
3.6.1. Collection of Clinical Samples
Due to the practical difficulties involved in obtaining 
samples of CSF and bile from opiate-naive cancer patients, 
suitable morphine-free fluid samples were unavailable for use 
as controls. In the absence of appropriate animal 
substitutes, pools were prepared by mixing together a 
selection of patient samples known to contain substantial 
quantities of all three compounds.
3.6.2. Parallelism
Sample dilutions were carried out in assay buffer and 
all samples were analysed directly. Parallelism was assessed 
by analysis of both pools, serially diluted as shown in 
Fig.3.25. These results indicate reasonable parallelism 
between sample and standard curves for these
page 15 3
(a) Morphine RIA
%B/T40
90
20
60 2 3 6 r1 4
Buffer #td. curve 
^ Bile enmple dlln's
[Morphine] nmol/l
 ^ 08F esmple dlln’e
(b) Differential M6G RiA 
%B/TGO
40
30
20
0 41 2 63
Buffer etd. curve 
^ Bile eftiDple dlln'e
Cone, (nmol/l)
^ C8F ««mpie dlln'e
(c) Differential M3G RIA 
%B/T40
30
20
0 61 4 62 3 7
Buffer etd. curve 
 ^ Bile temple dlln'e
Cone, (nmol/l)
^ C8F temple dlln'e
F i g . 3 . 2 5 .  Morphine, M6G and M3G RIAs Assessment of CSF and Bile sample parallelism.
page 154
patient pools.
3.6.3. Analytical Recovery
The recovery of morphine, M6G and/or MSG spiked into 
these pools was determined using all three RIAs (Tables 3.20 
and 3.21). Reasonable recovery of morphine and M6G were 
obtained from both pools.
3.6.4. Assay Quality Control
In the absence of suitable pools, and as these fluids 
were analysed directly using all three RIAs, quality control 
was achieved by the inclusion of the appropriate plasma Q.C. 
samples in each assay.
3.6.5. Discussion
This section describes the validation of the three RIAs 
for morphine, M6G and M3G for use with samples of human CSF 
and bile. The absence of suitable control tissues meant that 
recovery from patient pools was assessed and samples were 
analysed directly. For assays, data for the recovery of
morphine, M6G and M3G, parallelism plots, and assay
performance data resembled those obtained with plasma 
samples. The possibility exists that blank CSF and bile 
matrices may have significant effects on NSB and zero 
standard binding in these assays. This is likely to be less 
of a problem when analysing CSF due to its comparatively low
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Table 3.20.
Recovery of morohine, M6G and M3G from oatient CSF pool
MORPHINE RIA
rMorohinel added Result fnmol/11 mean % recovery
POOL 3.79 ± 0.2+ 5nmol/l 7.92 ± 0.6 90+ 10 11.2 ± 0.5 81+ 50 47.2 ± 2.6 88+ 100 88.4 ± 11 85
DIFFERENTIAL M6G RIA
rMorohinel added Result (nmol/ll mean % recovery
POOL 36.2 ± 1.3+ 5nmol/l 38.8 ± 0.9 94+ 10 43.5 ± 0.7 94+ 50 84.1 ± 5.6 98+ 100 131.8 ± 3.1 97
rM6Gl added
POOL 36.2 ± 1.3+ 5nmol/l 43.5 ± 2.4 106+ 10 50.2 ± 2.9 109+ 50 88.6 ± 1.9 103+ 100 145.0 ± 3.3 106
DIFFERENTIAL M3G RIA
rMorphine 1 added Result (nmol/ll mean % recovery
POOL 162 ± 17+ 5nmol/l 164 ± 2.8 97+ 10 173 ± 16 100+ 50 195 ± 14 92+ 100 260 ± 53 99
rM3Gl added
POOL 162 ± 17+ 5nmol/l 171 ± 27 102+ 10 174 ± 8.5 101+ 50 203 ± 14 96+ 100 328 ± 37 125
mean ± s.d. (n = 3) page 15 6
Table 3.21.
Recovery of morphine. M6G and M3G from patient bile pool
MORPHINE RIA
FMorphinel added Result fnmol/11 mean % recovery
BILE POOL 99.5 ± 2.3+ 20nmol/l 130.0 ± 7.3 112+ 50 146.2 ± 18.1 98+ 250 288.8 ± 22.3 116+ 500 733.8 ± 64.3 122
DIFFERENTIAL M6G RIA
rMorohinel added Result fnmol/11 mean % recovery
BILE POOL 340.5 ± 14.5+ 20nmol/l 361.0 ± 7.4 100+ 50 389.1 ± 20.5 100+ 250 539.1 ± 19.8 91+ 500 960.0 ± 31.9 114
rM6Gl added
BILE POOL 395.0 ± 17.9+ 20nmol/l 414.2 ± 7.6 100+ 50 458.8 ± 24.9 103+ 250 532.5 ± 18.5 83+ 500 857.0 ± 123 96
DIFFERENTIAL M3G ASSAY
FMorphinel added Result (nmol/ll mean % recovery
BILE POOL 2893 ± 432+ 20nmol/l 2953 ± 133 101+ 50 3047 ± 30 104+ 250 3225 ± 106 103+ 500 3788 ± 265 112
FM3G1 added
BILE POOL 2893 ± 432+ 50nmol/l 2960 ± 57 101+ 250 3000 ± 481 95+ 500 3208 ± 311 94+ 1000 4275 ± 318 110
mean ± s.d. (n = 4) page 157
protein concentration, but nevertheless needs to be taken 
into consideration when interpreting results.
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CHAPTER-FOUR
STAGES IN THE PRODUCTION OF A SPECIFIC 
ANTISERUM TO MORPHINE-6-GLUCURONIDE
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4.1 INTRODUCTION
In the search for an assay for M6G that combined the 
qualities of speed of throughput, sensitivity, ease of 
operation and relative cheapness, it was the original 
ambition of this project to develop a method for the 
determination of M6G based on available immunoassay 
technology. This ambition has been partly fulfilled by the 
subsequent development of a differential RIA technique for 
M6G (Chapter Three). However, during the course of these 
earlier studies it became apparent that there were some minor 
specificity problems associated with this assay, and it was 
therefore decided to investigate the possibility of producing 
a specific M6G antiserum. Attempts to synthesise a suitable 
M6G conjugate have taken into account the methods used to 
prepare specific morphine conjugates (Chapter One). At the
same time, it was realised that it was necessary to prepare a
hapten with an amino group available for linkage with the 
carrier protein. This was so that a specific reaction,
coupling hapten amino group to the protein, could be
employed to avoid linking the hapten via the carboxyl group 
on the glucuronide ring. A number of reactions are available 
that will specifically link a protein, via an amino or a 
carboxyl group, to an amino group on the hapten; these were 
reviewed earlier (Chapter One).
In the search for a suitable hapten, it was expected 
that the preparation of an N-substituted M6G hapten would 
involve a complicated synthetic procedure that, even if
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successful, was likely to give rise to a low yield of a
hapten of doubtful purity. Nevertheless, attempts to produce 
two such M6G haptens have been made. Due to the complex
nature of these chemical syntheses, the preparation of these 
M6G haptens has been carried out in specialised laboratories 
equipped with the necessary instrumentation.
Several anti-morphine antisera, with a wide range of 
specificities, have been raised to 2-substituted morphine 
hapten : protein conjugates (Chapter One). One such antiserum 
was reported to be specific for morphine (Hand et al., 
1987a), although no details on the structure of the conjugate 
used were provided.
At the start of this project, commercial supplies of M6G 
were expensive and difficult to obtain. It was decided to 
re-investigate the specificity characteristics of an 
antiserum raised to a 2-substituted morphine : protein 
before preparation of a similar M6G conjugate was begun. In 
addition, a specific morphine antiserum prepared in this way, 
which could be used with [1251]-morphine as the radiolabel, 
might prove to be a quicker alternative to the morphine RIA
described in Section 3.2.
4.2. MATERIALS
Porcine thyroglobulin (Sigma Chemical Co.)
TLC polyester/Silica Gel plates with 254nm Fluorescent 
Indicator (Sigma Chemical Co.)
Silica gel 60-120 mesh
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All chemical reagents used were obtained from Sigma Chemical 
Co. All organic solvents were analytical grade and were 
purchased from BDH Chemicals Ltd., unless otherwise stated. 
All other chemicals were of laboratory grade unless otherwise 
stated.
The materials used in the antiserum assessment and RIA
procedures were as listed in Chapter Two.
The synthesis of [3H]-M6G (66mCi; 10.3Ci/mmol) was
undertaken by Prof. J. Jones of the Department of Chemistry,
University of Surrey. Following tritiation, the dry product
was dissolved in D 0 and its proton and tritium nuclear2
magnetic resonance (NMR) spectra were consistent with M6G 
being labelled with 3H across the 7,8 double bond. This 
preparation of the radiolabel was purified before use in the 
RIA using the procedures previously employed for the 
purification of [125I]-M6G radiolabel (Section 2.2.3).
4.3 PRODUCTION OF ANTI-MORPHINE ANTIBODIES RAISED TO A 
2-CARB0XYPHENYLAZ0M0RPHINE-THYR0QL0BÜLIN CONJUGATE.
4.3.1 Hapten Preparation
The procedures for the preparation of this morphine 
hapten were carried out under the direction of Dr. G. Frost 
(Robens Institute, University of Surrey). The method chosen 
was similar to that used by Spector et, âi- (1973): 
p-aminobenzoic acid (ISlmg, l.lmM) dispersed in 
N-hydrochloric acid (14ml) was cooled to 0-5°C in an
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ice-bath. A solution of sodium nitrite (92mg, 1.3mM) in water 
(4ml) was added dropwise, with stirring, so as to maintain 
the reaction temperature < 5°C. Stirring was continued for 30 
minutes after the final addition and excess nitrite was 
destroyed by the addition of urea.
Morphine base (285mg, l.OraM) was dissolved in methanol (20ml) 
(adjusted to pH 10 with sodium hydroxide). The diazonium salt 
solution was added dropwise, with the addition of aliquots of 
IN aqueous sodium hydroxide to maintain pH 10. Stirring was 
continued for 30 minutes after the final addition, then the 
pH was adjusted to 7.5 by the dropwise addition of acetic 
acid. Isopropanol (300ml) was added and the product was 
allowed to stand overnight. Solid material was filtered off 
(Compound A) and the filtrate evaporated to dryness (Compound 
B). The solid products were dried and weighed:
Compound A 124mg
Compound B 113ma
TOTAL 237mg (approx. 50% yield)
The products were examined by TLC using methanol as the 
developing solvent. Methanol containing 1% 0.88 ammonia
clearly visualized the diazo compound as a red spot, but
methanol alone resulted in a better separation, using ammonia 
vapour as the visualization agent. The bulk compound was
dissolved in water (1ml) and filtered from insolubles. The 
clear filtrate was then acidified with 2N hydrochloric acid 
to precipitate the free carboxylic acid, which was isolated 
by filtration followed by drying in a vacuum desiccator. The
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dried product was dissolved in methanol (400ml), treated with 
Darco C activated carbon (Ig), filtered through kieselguhr 
and the clear orange-yellow liquid was evaporated to a small 
bulk. Following precipitation with diethyl ether (100ml), the 
compound was filtered off and air dried to yield an orange 
powder. TLC (using methanol) showed one major spot resolved 
from two minor spots and two traces.
The reaction scheme for this synthesis is outlined in 
Fig.4.1.
4.3.2 Conjugate Preparation _
This stage involved the linking of the carboxyl groups 
on the substituted morphine hapten molecules to the amino 
groups on the carrier protein, in this case thyroglobulin 
(TG). The method used for this preparation was chosen from 
those listed by Erlanger (1973), and was based upon the 
activated ester synthesis described for use with steroids by 
Gadow Êt al. (1984). Similar reaction schemes have been 
successfully used for the synthesis of peptides (Anderson ^  
âi., 1964).
Solution A: 16,8mg of morphine hapten was dissolved in 0.5ml 
redistilled dimethylformamide in a glass tube. 4.6mg 
N-hydroxysuccinimide was then added to this solution and the 
mixture stirred.
Solution B: While solution A was being prepared, 24.7mg
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N,N'-dicyclohexylcarbodiimide were dissolved in 0.5ml of 
redistilled dimethylformamide.
Solution B was added to Solution A and the mixture left in 
the dark at room temperature for 20 hours.
The quantities used in this procedure were chosen so as 
to give rise to molar ratios of 50:50:150 for 
hapten :N-hydroxysuccinimde:N ,N '-dicyclohexylcarbodiimide.
For the preparation of the hapten:TG conjugate, a molar 
ratio of 200:1 (hapten:TG) was chosen as this is thought to 
be the optimum ratio for use with this protein (Aherne G.W., 
personal communication). 68mg porcine TG were dissolved with 
stirring in 1ml distilled water. To this solution, 0.5ml of 
the hapten solution was added, and the mixture was 
vortex-mixed and left to react in the dark for 24 hours, at 
room temperature. The reaction mixture was then dialysed in 
Visking 8/32" dialysis tubing against distilled water (3 x 
500ml) at 4°C over 48 hours. The contents of the tubing were 
then transferred to a beaker and diluted with distilled water 
to give a final protein concentration of 5mg/ml. 1% sodium 
azide was added as a preservative and the conjugate stored at 
4“C before use.
4.3.3. Immunisation Protocol
Two Suffolk-cross sheep (1652 and 1653) were immunised 
with morphine-TG conjugate. 1ml of conjugate (equivalent to 
5mg protein:hapten) was used, together with BCG (lOOpl of 
standard vaccine) as the primer injection. Half this amount,
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without BCG, was used for subsequent booster immunisations. 
The conjugate was emulsified into 2 volumes of Non-ulcerative 
Freunds Adjuvant (Guildhay Antisera Ltd.) and, after a 
pre-immunisation bleed, the animals were injected into six 
i.m. sites (shoulders, back and loin). The animals were then 
bled 12 days and 9 weeks after injection. The animals were 
boosted twice (9 weeks and 23 weeks post immunisation) and 
further bleeds were taken at frequent intervals until 44 
weeks after immunisation.
4.3.4. Assessment of Antiserum Titre
Initially, antisera from both sheep were screened using 
[3H]-morphine as the radiolabel. Both sheep responded 
quickly, and in a similar fashion. Their response to the 
primary immunisation, and the first and second booster 
immunisations is shown in Fig.4.2. There was a slight 
increase in the immune response of both animals 7 days after 
the first boost. The progress in their response was closely 
monitored, as it is thought that the optimum response is 
obtained if the animals are boosted after the concentration 
of circulating antibodies has just started to fall or have 
reached a plateau (Chapter One). For this reason, the second 
boost was not given to the animals until 23 weeks had elapsed 
since the initial immunisation (l‘V weeks after the first 
boost), following which a huge increase in the immune 
response was observed in both sheep. Titres increased from 
1:30 to 1:400 for antiserum 1652 and from 1:54 to 1:800 for
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Fig.4.2. The immune responses of sheep 1652 and 1653.
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antiserum 1653.
The antisera harvested following the second boost were 
retained for assay development, for which [1251]-morphine was 
used as the radiolabel. During week 24 (post-immunisation) 
three different bleeds were obtained from sheep 1652 and a 
single large bleed was taken from sheep 1653. The bleeds from 
1652 were pooled together for antiserum characterisation. 
Antiserum dilution curves for both antisera are shown in 
Fig.4.3, from which titres of 1:1100 and 1:1800 were 
calculated for antisera 1652 and 1653 respectively.
4.3.5. RIA Procedure
Examples of standard curves obtained using both antisera 
are shown in Fig.4.4. Good displacement was apparent over the 
range of the standard curve.
4.3.6. Assessment of Antisera Specificity
The cross-reactivity of these antisera with a selection 
of structural analogues and metabolites is shown in Fig.4.5. 
Percentage cross-reactivities are shown in Table 4.1 and 
indicate that both antisera exhibit significant 
cross-reaction with codeine, and measurable cross-reaction 
with M3G and diamorphine, whereas the interference from M6G 
and normorphine was negligible. Similar results were obtained 
using [3H]-morphine as the radiolabel.
Due to its more desirable specificity profile, antiserum 
1652 was chosen for further studies, despite its lower titre.
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Fig.4.5. Antisera 1652 and 1653 structural analogues. cross-reactivities
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Table 4.1.
Antisera 1652 Se 1653 - % molar cross-reactivities
Opioid 1652 1653
Morphine 100 100
M6G 2.0 0.8
M3G 7.0 26.0
Normorphine 0.3 4.0
Codeine - 69.0 38.0
Diamorphine 11.0 11.0
Naloxone <0.1 <0.1
Buprenorphine <0.1 <0.1
Pethidine <0.1 <0.1
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4.3.7. Analytical Recovery of Morphine. M3G and M6G
Recovery of morphine was assessed by assaying spiked 
plasma samples containing increasing quantities of M3G or 
M6G, prepared as described in Section 3.3.^, using the assay 
employing antiserum 1652 with [1251]-morphine as the 
radiolabel. These results are presented in Table 4.2 and 
indicate that the recoveries of morphine are rather low and 
these results are dependent upon the additional presence of 
M3G and/or M6G, both of which interfere in the assay at low 
concentrations, leading to substantial overestimation of the 
levels of morphine obtained.-
4.4 PREPARATION OF TWO M0RPHINE~6~GLUCUR0NIDE HAPTENS
4.4.1 Synthesis of N~AminobutylnormorDhine-6"Glucuronide
This work was carried out at the laboratories of Salford
Ultrafine Chemicals under the auspices of Dr. F. Scheinmann.
The hapten was constructed from three intermediates. The
structure of the final product that was used as the hapten is
shown in Fig.4.6(a). The molecular weight of the final
intermediate was checked using a low resolution probe
(electron impact) mass spectrometer. An abundant parent peak
was found corresponding to the molecular weight of
C 'H F NO. (796.27). The final product was checked for the 37 43 3 2 14
presence of the correct number of hydrogen ions (27) using 
NMR.
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Table 4.2.
Recovery of morphine in the presence of M3G or M6G usina 1652 
morphine assav.
Morphine : % recovery + M3G % recovery + M6G
metabolite ratio
1:0 67.1 ± 15 61.2 ± 11
1:1 84.0 ± 12 75.8 ± 5.6
1:5 149 .2 ± 10 84.9 ± 18
1:10 190.4 ± 15 109.5 ± 7.4
1:50 257.1 ib 76 187.1 ± 37
1:100 327.5 ± 96 231.3 ± 44
mean ± s.d; (n=3)
1= lOOnmol/1.
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N-AminobutyInormorphine-6-glucuronide
(a) :n - NH.
(b) CH.I '
""2
' ' / /   N — CHo-/ /
N-p-Aminobenzylmorphine-6-glucuronide
Fig.4.6. The chemical structures of two N-substituted M6G 
haptens.
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4.4.2. Synthesis of N-p-Aminobenzylmorphine-6-Glucuronide
Attempts to prepare this hapten were carried out by Dr. 
G. Frost.
The proposed synthetic scheme was based on that followed 
by Yoshimura et al. (19 68) in their method for the 
preparation of morphine and codeine glucuronides, The 
proposed structure of the final product is shown in 
Fig.4.6(b). The results have so far been extremely 
disappointing in that, although reasonable yields of the 
final intermediate have been prepared, subsequent attempts to 
remove the protecting acetyl groups from the compound have 
proven to be unsuccessful. Indeed, at the end of this project 
a sample of this hapten was still awaited.
4.4.3. Preparation of N-Aminobutylnormorphine-6-Glucuronide- 
Thyroalobulin Conjugate
Unfortunately, due to considerable problems encountered 
during the synthesis, a supply of this hapten only became 
available during the final stages of this project. In an 
attempt to prepare a conjugate quickly and simply, the hapten 
was conjugated to TG (molar ratio 200:1; hapten;ratio) using 
the glutaraldehyde condensation reaction as follows:
lOmg M6G hapten was dissolved in 2.5ml 0.2M borate
buffer pH 8.2 with 20prl 25% glutaraldehyde. This solution was 
stirred for 15 minutes at room temperature. 35mg of TG was 
then added and the mixture stirred overnight at room 
temperature. The resulting conjugate was dialysed with
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distilled water (2 x 500ml) over 48 hours. For immunisation 
purposes, the conjugate was diluted with distilled water to 
give a final protein concentration of 5mg/ml. The 
immunisation protocol was similar to that described earlier 
(Section 4.3.3), but only one rabbit was available (R 29). 
2.5mg of the conjugate (+ BCG) was injected into i.m. sites 
in the back legs and s.c. sites across the neck. Blood was 
taken from the marginal ear vein at intervals following 
immunisation. Serum was collected and stored undiluted at 
4°C, with 0.1% sodium azide as preservative.
4.4.4. Antiserum Characterisation
The early bleeds collected following this immunisation 
have been screened using [3H]-M6G radiolabel (Section 4.2). 
These results are shown in Table 4.3. Antiserum dilution 
curves revealed that bleed number 7 possessed the highest 
titre, and this was used at a dilution of 1:1000. The 
cross-reactivity of this antiserum with M6G and structurally 
related compounds is shown in Fig.4.7. This antiserum did not 
exhibit any measurable cross-reaction with these related 
compounds.
4.5. DISCUSSION
Immunisation of two sheep with a
2-carboxylphenylazomorphine-TG conjugate resulted in the 
successful production of two anti-morphine antisera with 
similar characteristics. The results of the cross-reactivity
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Table 4.3.
Screening of bleeds from rabbit R29. immunised with N-aminobutvlnormorDhine-6-alucuronide-thvroalobulin conjugate
Bleed No. Weeks Dost- iimnunisation
% Binding of F3H1-M6G 
f%B/T)
1 0 * 02 2 2.43 3 33.54 4 47.85 6 51.46 14 # 53. 67 15 53 . 0
* primed with^Smg conjugate (+BCG)# boosted with Img conjugate
%B/B0120
100
80
GO
40
20
1000001000010001000.1 Cone, (nmol/l)
M3Q M6Q Normorphine Codeine Morphine
Fig.4.7. Anti-M6G antiserum structural analogues.
cross-reactivities with
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and recovery studies using one of these antisera were rather 
disappointing. The recovery of morphine alone using this 
assay was incomplete, and was also influenced by the presence 
of glucuronide metabolites, despite their apparent low 
cross-reactivities. These findings further emphasise the need 
to include metabolite recovery assessments, in addition to 
cross-reactivity studies, if a complete investigation of 
suitable candidate antisera for drug RIAs is required. 
Similar interference problems have been reported by other 
workers using analogous conjugates (Chapter One). However, 
the inter-animal specificity variations, reported by Gatlin 
(1977), following the immunisation of two rabbits with a 
2-diazomorphine-BSA conjugate, were not experienced in these 
studies.
The assay in its present form does not offer a serious 
challenge to the direct morphine RIA described in Section
3.2. For this reason, further investigation of these antisera 
was not carried out, and assay validation procedures have not 
been performed. Nevertheless, the production of antibodies to 
this particular conjugate has provided some useful data, and 
subsequently influenced the choice of structures used for 
the preparation of the two M6G haptens.
Attempts that have been made to prepare a suitable M6G 
hapten have proven to be rather disappointing. The use of 
methods previously employed to prepare morphine haptens to 
attach side-chains to the M6G molecule have had limited 
success. The experimental work undertaken has been very
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time-consuming, and at the end of the project only one hapten 
had been successfully synthesised; this only became available 
during the final three months. The structure of this hapten 
was originally chosen with the expectation that it would be 
directly coupled to a protein using N-(m-maleimidobenzoyloxy)- 
succinimide. For this reason a 4-carbon spacer was attached 
during the synthesis, as this has been shown to give rise to 
better quality anti-morphine antisera. (Robinson, 1975). The 
use of the glutaraldehyde reaction introduces an additional 
5-carbon bridge between the hapten and the protein. The 
presence of this longer spacer group may have detrimental 
effects on the quality of any resulting antisera. 
Nevertheless, sufficient quantities of this hapten have been 
synthesised to allow the preparation of a number of different 
conjugates. The use of alternative bifunctional reagents in 
this process warrants further investigation.
The conclusions that may be drawn from these practical 
studies are that the chemical manipulation of compounds 
containing glucuronide moieties is a very demanding process. 
It is possible that the attachment of a side-chain at the 
2-position on the M6G molecule may prove to be an easier 
synthesis to perform. However, the pilot studies using 
morphine as the model compound have demonstrated the 
potential interference that may be experienced from compounds 
with alterations at the 3-position on the morphine molecule. 
This is probably due to the masking of this position by the 
side-chain and carrier protein attached at the 2-position
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rendering it inactive as an antigenic determinant. Similar 
problems would be expected with an M6G conjugate prepared in 
the same manner.
Although, to date, only one animal has been immunised, 
the use of the N-aminobutylnormorphine-6-glucuronide hapten 
has led to the successful production of an antiserum with the 
desired specificity characteristics for M6G. Further 
validation and characterisation of this antiserum is 
required. In the meantime, this report remains the only 
description of the production of antibodies to M6G and offers 
an exciting potential in the development of a specific, 
sensitive assay for M6G.
page 181
CHAPTER FIVE
PHARMACOKINETIC STUDIES WITH MORPHINE 
IN HEALTHY VOLUNTEERS
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5.1 INTRODUCTION
A number of studies have examined the pharmacokinetics 
of morphine after intravenous or oral administration (Chapter 
One). A few of these studies have attempted to relate the 
data obtained to the clinical effects observed. However, 
these attempts have met with limited success, and, so far, 
unsatisfactory correlations between blood levels and 
analgesic response have been demonstrated (Dahlstrom al.,
1982a).
The analgesic activity of morphine's two glucuronide 
metabolites in animals is well documented (Shimomura et al., 
1971; Paul &t a%., 1989). Until recently, the evidence for
analgesic activity of M6G in man has been circumstantial 
(Brunk and Delle, 1974), but Osborne and his co-workers have 
since demonstrated this directly (Osborne et r 1988).
Despite these observations, no reliable information 
concerning the formation, distribution and elimination of M6G 
and M3G is available, due primarily to the absence of 
suitable analytical methods ■ capable of quantitating the
parent drug and metabolites simultaneously. Improved 
techniques have recently become available, and their use in 
studies where levels of morphine, M3G and M6G have been 
measured have indicated that, although M3G is by far the most
abundant metabolite, M6G does occur in significant
quantities, particularly after oral administration of 
morphine in man (Svensson et ^ . , 1982; Sawe st al./ 1983b;
1985). To date, these studies are few in number and have been
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performed predominantly by collecting random samples from 
small numbers of cancer patients or surgical patients. In 
their studies, Sawe and co-workers (1983b) found plasma AUC 
ratios for M6G:morphine in the region of 3:1 following 
chronic oral administration to cancer patients. Similar data 
has been reported more recently after acute oral dosing in 
normal volunteers (McQuay ^  al., 1987). Data following
parenteral administration is less well defined, although it 
would appear that the production of M6G may be reduced by 
this route (Hand et al., 1987a).
At present the first-' choice route of morphine 
administration in chronic pain is the oral route, and two 
such formulations are available: aqueous morphine sulphate 
solution (MSS) and a controlled-release tablet based on the 
Continus system (MST Continus, Napp Laboratories, Cambridge, 
U.K.). Recently, there has been renewed interest in the 
administration of morphine by buccal or sublingual routes 
which may be of particular value to patients who are unable 
to swallow. A controlled-release buccal formulation, again 
based on the Continus system, has been produced but data on 
its bioavailabilty or efficacy is unavailable. It is likely 
that by avoiding the enteral route these preparations will 
give rise to altered proportions of drug and metabolites in 
plasma, and different clinical responses may, therefore, be 
expected.
The object of this study was, therefore, to investigate 
the pharmacokinetics of morphine and M6G in healthy
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volunteers following single doses of morphine given by 4 
different routes; intravenous, oral aqueous morphine sulphate 
solution, controlled-release oral morphine sulphate tablet 
and controlled-release buccal morphine sulphate tablet. 
Firstly, the behaviour of morphine was assessed after 
different routes of administration, and the bioavailability 
of the different preparations was calculated. Secondly, 
preliminary data on the influence of the route of 
administration on the production of M6G has also been 
obtained.
5.2 SUBJECTS AND METHODS
Six healthy volunteer subjects (four female, two male) 
were selected, with a mean age of 31 years (range 26-40). One 
regular smoker was included in these subjects. All were 
screened for normal hepatic and renal function by routine 
blood biochemistry. The study had the approval of the Ethics 
Committee of the Royal Marsden Hospital, and written informed 
consent was obtained from each subject. The doses 
administered were constrained by the availability of lOmg 
controlled-release tablets and the limitation of not giving 
higher doses to normal volunteers.
Each volunteer was studied on four occasions, at least 
one week apart. Subjects were fasted from midnight on the day 
of the study. At 8a.m., a forearm intravenous cannula was 
placed in situ and a pre-dose blood sample was taken. 
Caffeine containing drinks and alcohol were forbidden during
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the course of the study, but normal activities, eating and 
drinking were resumed after the initial 2 hours, which had 
been spent supine and fasting.
The morphine sulphate preparations and doses studied 
were as follows:
(1) Bolus intravenous morphine, 5mg
(2) Oral solution, lOmg
(3) controlled-release oral tablet (MST-Continus), lOmg
(4) controlled-release buccal tablet, lOmg
On each occasion, a different morphine sulphate
preparation was given and the order of administration used 
was (2), (4), (3), (1). The oral solution was freshly
prepared, prior to administration, in the form of an aqueuos 
solution with no added preservative. The buccal tablet was 
obtained from Napp Laboratories Ltd., Cambridge, U.K., and 
was at an early stage in its development, and not available 
commercially.
The oral formulations were swallowed with 100ml of tap
water and the bolus intravenous injections were administered
over 2 minutes. Buccal tablets were placed between the upper 
lip and gum above the incisor tooth.
Following administration of morphine, venous blood 
samples were collected after 15, 30, 45, 60 minutes, 2, 2.5,
3, 3.5, 4, 5, 6, 8, 10 and 12 hours for the oral and buccal
formulations, and after 2, 5, 10, 15, 30, 45, and 60 minutes,
1.5, 2, 2.5, 3, 4, 6, 8 and 12 hours for the intravenous
injection. Blood was collected into a lithium-heparin'tube
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(Sterilin Ltd., Hounslow, Middlesex) and spun immediately at 
3500 rpm for 10 minutes. Plasma was separated and stored at 
-20°C prior to analysis. The acceptability of the buccal 
tablet was also assessed by each subject.
Assay method
Measurement of morphine was performed using the specific 
morphine RIA employing [3H]-dihydromorphine as the 
radiolabel, as described in Section 3,2. Levels of M6G were 
determined by means of the differential RIA technique, using 
[1251]-morphine radiolabel, described in Section 3.3.
5.3 PHARMACOKINETIC AND STATISTICAL ANALYSES
Individual pharmacokinetic data for morphine were 
calculated using an interactive computer program (STRIPE), 
details of which are provided in Section 2.4. Values obtained 
after the subjects had received the intravenous dose were 
normalised to a lOmg dose of morphine sulphate to permit 
comparison between different studies. The AUCs (O-oo) for 
morphine and M6G were calculated for each set of data. The 
extrapolation to infinity resulted in an increase, compared 
with the AUC (0-12hr) of less than 10% for morphine and up to 
30% for M6G, reflecting the difference in elimination phases 
for these two compounds.
The determination of pharmacokinetic parameters (other 
than AUC) for M6G in the presence of the parent drug using a 
curve stripping program such as STRIPE is not to be
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recommended. This is because STRIPE does not take into 
account the continued production of M6G from morphine during 
the sampling period, and is therefore inaccurate in 
estimating any parameters dependant upon the rate of change 
in M6G concentration. To help overcome this problem, 
elimination half-lives were calculated for M6G using the 
SIMP program (Johnston, 1985), based on a two-compartment 
model for morphine and a single compartment for M6G. A 
weighting of the reciprocal of the concentration was used to 
obtain the best fit between measured concentrations and the 
pharmacokinetic model. These analyses were performed by Dr. 
P. Hoskin at St. Bartholomew's Hospital.
5.4 RESULTS
Graphs showing the mean plasma levels (±SEM) of morphine 
and M6G after the four routes of administration are presented 
in Figs.5.1 to 5.4. The individual pharmacokinetic parameters 
for morphine and M6G, and the data for % absolute 
bioavailability of the oral and buccal formulations 
calculated for each subject, are shown in Tables 5.1 to 5.5.
5.4.1. Intravenous Morphine
Mean plasma profiles for morphine and M6G following i.v. 
administration of morphine are shown in Fig.5.1. Morphine 
disposition was best fitted to a two-compartment model in the 
majority of patients, and the mean terminal elimination 
half-life was 1.8 ± 0.2 hours.
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(a) Morphine levels - I.V. (b) M6G levels -  I.V.
Cono. (nrnol/l)1000
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10
0.1 4 6 100 2 8
Cono. (nmol/l)40
00
20
0 2 4 B 10 146 12
Time (hours) Time (hours)
(c) Morphine and M6G levels - I.V.
Cono, (nmol/l)1000
100
10
0.1 40 2 106 8 1412
Time (hours) 
■Morfrfilna —♦-MSQ
Fig.5.1. Plasma profiles for morphine and M6G in volunteers after 5mg i.v, morphine, (a) mean morphine results (± SEM, n=6), (b) mean M6Gresults (± SEM, n=6), (c) meanmorphine and M6G results (n=6).
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Table 5.1.
Pharmacokinetic parameters for morphine after intravenous
administration
Subiect T 1/2 Clearance Volume of
I.D. distribution
(hr) (ml/min/ko) (l/ko)
1 3.0 13.9 7.8
2 1.4 - 16.1 2.7
3 2 . G 21.0 7.0
4 1.6 40.4 4.1
5 1.5 29.3 4.7
6 1.5 22.2 5.7
MEAN 1. 8 23.8 5.3
(± SEM) (0.2) (4.0) (0.7)
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(a) Morphine levels - Oral (b) M6G levels - Oral
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(c) Morphine and M6G levels - Oral
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F i g . 5 . 2 .  Plasma profiles for morphine and M6G in volunteers after lOmg oral morphine solution. (a) mean morphine results (± SEM, n=6),(b) mean M6G results (± SEM, n=6),(c) mean morphine and M6G results (n=6),
Time (hours)
— [Morphine] — IM8Q]
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(a) Morphine levels - MST (b) M6G levels - MST
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10
0^
Tims (hours)
Cono. (nmol/l)70
60
00
40
00
20
Time (hours)
(c) Morphine and M6G levels - MST
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F i g . 5.3. Plasma profiles for morphine and M6G in volunteers after 
lOmg controlled-release oral morphine tablets (MST-Continus), (a) mean morphine results (± SEM, n=6),(b) mean M6G results (± SEM, n=6),(c) mean morphine and M6G results (n=6).
— IMorphlna] •1 M 6 Q ]
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(a) Morphine levels - Buccal (b) M6G levels - Buccal
Cono. (nmol/l)
Time (hours)
Cono. (nmol/l)GO
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(c) Morphine and M6G levels - Buccal
Cono, (nmol/l)00
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20
10 12 144 80 2 6
F i g . 5.4. Plasma profiles for 
morphine and M6G in volunteers after lOmg controlled-release buccal tablets, (a) mean morphine results (± SEM, n=6), (b) mean M6G results (± SEM, n=6), (c) mean morphine and M6G results (n=6).
Time (hours)
—  [Morphine} — IM6Q]
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Table 5.2.
Cmax and T max values for morohine
Cmax fnmol/l)
Subiect lY Oral Buccal MSTsolution
1 1039.5 53.5 4.62 20.52 910. 8 12.9 6.60 5.943 1036.2 54.1 8.25 14.94 1894.2 41.9 9.90 10 . 65 904.2 21.5 12.2 12.96 950.4 25.7 7.59 7.92
MEAN 1122.7 35.0 8.25 12 .2SEM 156.1 7.09 1.09 2.11
-
Tmax (hours)
1 0.03 0.25 >12 0.252 0.03 1. 00 4.0 3.53 0.03 0.50 6.0 1.04 0.03 0.75 6.0 2 . 05 0.03 0.75 2.5 3.06 0.03 0.75 6 . 0 5.0
MEDIAN 0.03 0.75 6.0 2.5
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Table 5.3.
Cmax and T max values for M6G 
Cmax (nmol/l)
Subiect lY Oral Buccal MSTsolution
1 40.4 123.8 41.2 59 .92 35.0 120.4 49.6 61.53 33.8 101.3 48.2 42.04 172.3 106.7 32.8 83.65 39.2 133.1 63.1 95.36 25 . 9 67.7 36.2 85.0
MEAN 57.8 108.8 45.2 71.2SEM 23.0 9.5 4.5 8.2
-
Tmax (hours)
1 1.0 0.75 >12.0 2 . 02 1.5 2 . 0 4.0 2.03 0.5 1.0 6 . 0 2 . 04 0.03 1.0 10.0 2 . 05 0.75 1.0 6 . 0 1.06 0 . 75 1.0 6.0 2.5
MEDIAN 0.75 1.0 6 . 0 2.0
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Table 5.4.
AUC and absolute bioavailability for morphine
Subiect lY Oral Buccal MSTsolution
1 338.6 153.4 59.7* 105.32 352.1 39.3 41.6 38.03 280.8 82.2 62.0 65 .34 353.1 75 . 9 86.1* 77.95 246.5 47.2 66.0 69.06 248.2 41.2 49.8 48.2
MEAN 303.2 73.3 54.8 67.3SEM 20.7 17 .5 5.6 16.2
Bioavailabilitv (%)
1 45.3 10.6# 31.12 11.2 11. 8 10.73 29.2 22.1 23.24 21.5 20.5% 22.05 19.2 26.7 28.16 16.7 20.1 19.4
MEAN 23.8 22.4SEM 4.9 fci.'L. 2.9
* Values derived using elimination rate after i.v, administration and are not included in calculation of means,
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Table 5.5.
AUC for M6G and M6G;morphine ratios 
AUC fO-w) (nmol/l/hr)
Subiect IV Oral Buccal MSTsolution
1 422.9 624.5 458.1* 415.12 381.5 372.2 277 .4 401. 03 343.5 300.7 290.0 304.94 496.7 496.7 605.0* 385.35 282.6 440.0 538.9 510.56 288 . 8 264.5 291,5 445.2
MEAN 369 .2 420.1 349.3 410.4SEM 40.6 55.5 63.1 27.7
Molar ratios; (M6G:Morohine)
1 1.25 4.07 7.67* 3.942 1.08 9.47 6.67 10.53 0.97 3. 66 4. 68 4.674 1.41 6.54 7.03% 4.955 1.15 9.32 8.16 7.406 1.16 6.42 7.01 9.24
MEAN 1.17# 6.58 6.t& 6.7 8SEM 0.06 1.01 \.4S 1.10
# Difference is significant compared with oral, MST andbuccal routes, p < 0.001 C^tK.\rtcA ^
* Values derived using elimination rate after i.v.administration and are not included in calculation of themeans.
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Morphine was detectable in all subjects up to 6 hours 
after dosing, and in one subject low levels were still 
detectable after 12 hours. The mean morphine AUC (O-oo) was 
303.2 ±20.7 nmol/l/hr (Table 5.4) and mean values for total
body clearance and volume of distribution were 23.8 ± 4.0
ml/min/kg and 5.3 ± 0.7 1/kg respectively (Table 5.1).
The rate of formation of M6G from morphine was very 
rapid. M6G was detectable in one subject after 5 minutes, and 
in all but one subject after 15 minutes. After 30 minutes, 
the mean plasma levels of M6G exceeded those of morphine, and 
remained higher until the end of the 12 hour sampling period, 
after which time the levels were approaching the limit of 
detection of the assay (« lnmol/1).
Peak M6G levels (Cmax) were achieved 1.00 ± 0.42 hours 
after administration. Mean molar ratios of plasma AUCs for 
M6G:morphine were calculated to be 1.17 ±(o.06):l (Table 5.5). 
In general, M6G persisted in the plasma longer than morphine, 
with levels in most subjects still detectable after 10 hours. 
Using the SIMP program, the mean elimination half-life of M6G 
was 2.2 ± 0.4 hours, which was not significantly longer than 
the half-life for morphine (1.8 ± 0.2 hr); (p>0.1; paired
Student's t-test).
5.4.2. Oral Morphine (Elixir and Controlled-Release Tablet)
Mean plasma profiles for morphine and M6G following oral 
administration are shown in Fig.5.2 (elixir) and Fig.5.3 
(controlled-re lease tablet). The pharmacokinetics of
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morphine observed after oral administration were markedly 
different from those seen after parenteral dosing. As 
expected, there was a delay in the time taken for morphine 
levels to appear in the plasma, particularly following the 
controlled-release formulation. The quantities of morphine 
found following both routes were much lower than those 
observed after parenteral administration (Table 5.2). 
Nevertheless, morphine was rapidly absorbed following 
administration of the oral solution (Tmax 0.75hr; range
0.25-lhr), although a trend towards reduced Cmax and longer 
Tmax for morphine was noticed for the controlled-release 
tablet, reflecting the slower delivery of morphine from this 
preparation. Low levels of morphine were still detectable at 
12 hours after both these routes. There were no differences 
between the absolute bioavailabilities of morphine from the 
two oral preparations (Oral 23.8 ± 4.9% and MST 22.4 ± 2.9%) 
(Table 5.4).
Similar quantities of M6G occurred in the plasma after 
the two oral preparations, and were not significantly 
different from the amounts found after intravenous dosing 
(p=0.7; one- way analysis of variance) (Table 5.5). Peak 
concentrations of M6G were considerably higher after 
administration of the oral solution than after the other 
three routes. The time taken for the metabolite to appear 
varied slightly between volunteers, but M6G was detectable in 
most subjects 15 minutes after dosing with either oral 
solution or MST, a similar lag time to that observed after
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i.v. administration (Table 5.3). Tmax values for M6G were 
similar to those recorded for the parent drug, with a delay 
seen following the controlled-release tablet. In addition, 
the mean Tmax observed following administration of the oral 
solution was comparable to that recorded following i.v. 
dosing (mean Tmax oral 1.1 ± 0.18 and i.v. 1.0 ± 0.17 hours) 
(Table 5.2). Low levels of M6G were still detectable at the 
last time point following both formulations, although the 
levels were higher than those persisting 12 hours after an 
equivalent dose of morphine given intravenously. Relatively 
more metabolite was produced after oral administration than 
i.v. administration (mean molar ratios of AUC (O-oo) 
M6G:morphine were 6.6:1, 6.8:1 and 1.2:1 after oral, MST and 
i.v. routes respectively) (Table 5.5).
5.4.3. Controlled-Release Buccal Morphine
Mean plasma profiles for morphine and M6G following this 
route of administration are shown in Fig.5.4. The 
controlled-release buccal morphine tablets gave rise to 
considerably lower levels of morphine than i.v.
administration. The time taken for the appearance of 
detectable levels of morphine to appear in the plasma ranged 
from 0.5 to 2.5 hours (Table 5.2). A similar trend to that 
seen following MST tablets was observed, in that a reduced 
Cmax was recorded together with an increase in Tmax compared 
to oral dosing. Indeed, although comparable Cmax values were 
obtained following both controlled-release preparations (MST
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and buccal), the time taken for this concentration to be 
achieved was significantly longer. Greater inter-subject 
variation was observed following buccal administration. 
Indeed, two subjects failed to reach an elimination phase at 
12 hours, and estimates for the AUCs in these subjects were 
made using the elimination half-lifes calculated following 
i.v. injection. These results were not included in the 
calculation of the mean values for this parameter. Morphine 
AUCs after this formulation were similar to those calculated 
after the two oral routes, and there were no differences in 
the absolute bioavailabilities for the three preparations 
(Table 5.4).
Cmax values for M6G following this route were 
considerably lower, and were observed later, than after the 
other routes investigated (Table 5.3). However, the mean 
values for M6G AUC (0-w) and for AUC M6G:morphine ratios 
resembled those found after oral administration (Table 5.5).
5.5. DISCUSSION
The pharmacokinetic parameters after i.v. administration 
in these healthy volunteers show good agreement with those 
reported from other recent studies in normal volunteers (Owen 
êt âiw 1983; Aitkenhead et ai., 1984; Persson et âiw 1986; 
Mazoit ai*/ 1987)). Comparison with earlier studies
carried out in anaesthetised or post-operative surgical 
(Murphy and Hug, 1981; Dahlstrom êt ai*/ 1982; Moore Qt al., 
1984b; Sandouk et ai*/ 1986; Hand &t âi*/ 1987a) or cancer
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patients (Sâwe et al., 1981; Gourlay et âi*/ 1986), reveals 
that the mean plasma clearance of the normal subjects in the 
present study exceeds that found in these patients. However, 
other studies have revealed no such differences in the rate 
of plasma clearance (Sawe st ai*/ 1985; Sear et al., 1989a). 
The volume of distribution, however, is within the same range 
in all these studies.
After i.v. injection, M6G was found to be present in 
large quantities with the AUC (0-co) for M6G greater than that 
for the parent drug. In a recent study of anaesthetised and 
awake surgical patients. Sear et âi*/ (1989a) observed
smaller quantities of M6G compared to morphine in both sets 
of patients. In contrast, Sawe and coworkers (1987) reported 
a plasma profile for M6G similar to those observed in the 
present study in a single unanaesthetised patient. Comparison 
of the assay methods used revealed that Sear and colleagues 
(1989a) used RIA techniques similar to those employed in the 
present study, whereas Sawe's group (1987) used an HPLC
method based on that described by Svensson and colleagues
(1982). The use of different assay methodologies could offer 
an explanation for these contradictory findings. The
half-life calculated for M6G in the present study was similar 
to the value of 115 minutes derived for the elimination of
total conjugated morphine in the dog after i.v. morphine
dosing (Hug et âi*/ 1981), but was significantly longer than 
that calculated for elimination of M3G following its i.v. 
administration to dogs (Garrett and Jackson, 1979).
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After administration of the oral morphine solution, the 
mean morphine AUC (0-<») ( 73. 3nmol/l/hr ± 17.5) was similar to 
that observed in two other normal volunteer studies for which 
this data \s available (Khojasteh et ai,, 1987; Moolenaar gt 
al., 1988). Existing data for the bioavailability of an oral
elixir, relative to i.v. morphine in healthy volunteers, is 
unreliable. A number of studies have been carried out in 
cancer patients, and these have generally reported mean 
values for absolute bioavailability between 2 6 and 47% (Sawe 
et al., 1981; 1985; Gourlay Qt âi*/ 1986), slightly higher
than the value obtained in the present study (23.8% ± 4.9%). 
These figures reflect the contribution of the first pass 
effect, limiting the availability of morphine to the systemic 
circulation. Another study has reported a bioavailability of 
100% for an oral solution in patients, but the RIA method 
employed is now recognised to cross-react extensively with 
M6G, giving rise to falsely elevated results (Aherne and 
Littleton, 1986).
The absolute bioavailability for morphine of 
controlled-release morphine sulphate (MST-Continus) was found 
to be 22.4 ± 2.9%, and, as such, was not significantly
different from that after oral aqueous solution, in keeping 
with a number of studies (Hanks âfe âl */ 1980; Savarese ât.
âl*/ 1986; Homesley et âi*/ 1986; Sloan et âi*/ 1987;
Khojasteh ât âi*/ 1987; Poulain et âi*/ 1988). These studies 
reported the relative bioavailability of MST, compared with 
aqueous solution, to be between 85 and 94%. This figure is
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also similar to that reported by Vater and his colleagues 
(1984), who investigated the i.v. pharmacokinetics of 
morphine in a group of healthy volunteers, and in a 
subsequent study compared this data with plasma 
concentrations after MST administered to the same subjects.
During the course of the present study, preliminary 
results from a similar volunteer study were reported, in 
which the bioavailability of morphine in 8 subjects, aged 30 
years or less was compared with 9 subjects, aged 68-90 years 
(Baillie âi. âi*/ 1987). Morphine concentrations were measured 
using a specific RIA. Mean -absolute bioavailability for the 
oral solution was 20.1% for the young subjects and 29.3% for 
the elderly. MST bioavailability was 22.9% for the young and 
28.7% for the elderly. These differences between preparations 
were not significant, and the data from the group of young
patients compares well with the data presented here.
After oral dosing, M6G was found to be present in 
similar quantities to those found after i.v. morphine. The 
mean M6G:morphine AUC ( O - o o )  molar ratios were 6.6:1 and 6.8:1
for oral solution and MST respectively. Both values were
considerably higher than the 3:1 ratio observed in cancer 
patients (Sawe et âi*/ 1985) and normal subjects (McQuay 
âi* f 1987). Indeed, this ratio is similar to that found in 
cancer patients after chronic oral administration (Poulain et 
âi* / 1988). The cause of the apparent differences between
these studies cannot be completely determined on the basis of 
the available evidence, but may be due to the use of
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different assay techniques and the examination of 
stable-state rather than single-dose pharmacokinetics. At 
this point it is worth emphasising that the present study was 
carried out in the early stages of this project, and M6G 
levels were determined using the differential RIA technique 
in which morphine was employed as the assay standard and 
radiolabel, which was subsequently found to occasionally 
measure higher levels.
Following administration of the buccal tablet, it was 
hoped to determine whether morphine bioavailability is 
significantly altered by -attempts to bypass the small 
intestine. As expected, the major effect of this route of 
administration was to delay the absorption of morphine and, 
thus, attenuate the peak plasma conentrations of both 
morphine and M6G, compared to oral administration. However, 
although the controlled-release buccal tablet resulted in a 
slightly lower AUC for morphine and M6G, compared to the oral 
preparations, no significant differences in absolute 
bioavailability were observed. In two subjects, the AUC is 
derived because they did not reach an elimination phase after 
12 hours. These results should, therefore, be interpreted 
with caution. Indeed, the Tmax was considerably later than 
following the oral controlled-release preparation, and in 
subject 1 was still not reached after 12 hours.
The appearance of M6G in the plasma, following buccal 
dosing, was remarkably similar to that observed after oral 
dosing, as was the molar ratio for AUC (0-co) for M6G:morphine
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(6.9:1). These figures were unexpected, bearing in mind that 
buccal administration should avoid the first pass effect. 
Buccal absorption of morphine in aqueous solution has been 
demonstrated in normal volunteers (Al-Sayed-Omar ât al.. 
1987). Problems associated with differing rates of 
dissolution have been reported for one buccal formulation 
(Fisher ât al., 1987). Subject acceptability of this
preparation was poor, due, principally, to the release of the 
characteristically bitter taste of morphine for considerable 
periods, and to local discomfort. The above findings for 
bioavailability and metabolite production suggest that a 
significant proportion of the buccal morphine was absorbed in 
the conventional fashion, after having been swallowed. Since 
no measures were taken to prevent swallowing, this 
possibility needs to be taken into consideration when 
interpreting these results. The results obtained in the 
present study are completely different to those observed in a 
previous study (Bell et al., 1985), despite using the same 
tablets. Bell and colleagues (1985) reported a large increase 
in bioavailability by this route. In another study, Bardgett 
and coworkers (1983) reported an increase in Cmax and AUC 
(0-8hr) for morphine with buccal tablets, when compared to 
i.m. administration. The findings of a number of more recent 
studies (Fisher et âi-/ 1987; 1988; Manara et al., 1989;
Simpson et âi*/ 1989) lend support to the data obtained here. 
The discrepancies found between these studies may be due to a 
number of different factors, notably the use of different
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formulations and the wide inter-individual variations 
observed. The process of wetting the tablets before 
administration was found to have little effect on the levels 
of morphine obtained (Shelly si &!., 1989a), despite earlier 
suggestions to the contrary (Fisher Qt al., 1988). In their 
study, Manara and colleagues (1989) also measured levels of 
metabolites after this route, and found similar data for M6G 
to that recorded in the present study. They offered a similar 
explanation for their findings; their patients recorded a 
high incidence of bitter taste suggesting that the tablets 
had dissolved in saliva and had been swallowed. Whilst it 
would seem that this is the most likely explanation for the 
reduced bioavailability and increased metabolite levels 
measured after this route, the presence of a glucuronidation 
capacity in the buccal mucosa of various species has been 
demonstrated (Hartiala et al., 19 64). The contribution of 
this process to these findings needs to be taken into
consideration.
From the findings of the present study, it would appear 
that buccal administration of morphine offers no obvious
advantages over existing enteral preparations. Nevertheless, 
the pharmacokinetic data obtained suggest that the buccal 
route would offer an acceptable alternative route of 
administration in situations where oral dosing is not 
possible. Improved buccal delivery of other opioid
analgesics using bitterless pro-drugs has been reported
(Hussain et ai*/ 1988). Studies investigating the feasibility
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of delivering morphine in this form would be of interest.
The above findings highlight some of the problems 
involved in interpreting morphine efficacy data from clinical 
studies, after different routes of morphine administration. 
The presence of two factors (quantity of morphine and M6G) 
need to be considered, but, to date, the agents controlling 
the production of morphine glucuronides are not well defined. 
Available information suggests that although both M3G and M6G 
are produced by hepatocytes, intestinal mucosal cells do not 
produce M6G (Koster et al., 1985b). The glucuronidation
capacity of intestinal cells varies along the small 
intestine, being maximal in the duodenum and least in the 
colon (Koster et al., 1985a). If the glucuronidation capacity 
differs between the buccal and small intestine mucosa, then 
differences in the quantity of M6G appearing after these 
routes may be observed.
During the final stages in the preparation of this 
thesis, data from a similar, but more comprehensive, study 
investigating morphine pharmacokinetics in normal volunteers 
became available (Osborne et al., 1990). This group observed 
the behaviour of morphine, M6G and M3G following 
administration of morphine by i.v., oral, buccal and 
sublingual routes. The analytical method used for the 
determination of these compounds was HPLC (Joel et al., 
1989). The pharmacokinetic parameters reported in their study 
are in close agreement with those presented in this chapter 
and, therefore, lend considerable support to the conclusions
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that have been made. It was of particular interest to find 
good agreement between the ratios for AUC (O-oo) of 
M6G;morphine found after various routes of administration, 
bearing in mind the different assay procedures used.
In conclusion, this study has revealed the changes in 
morphine and M6G pharmacokinetics which occur after i.v., 
oral and buccal administration in the same normal volunteers. 
Relatively large quantities of M6G are produced, particularly 
after oral dosing, and these findings confirm the potential 
contribution of this metabolite to the analgesia experienced 
after treatment with morphine, both enterally and 
intravenously. This contribution is likely to be of 
particular importance after chronic oral dosing, but a 
significant proportion of the clinical effects observed after 
a single i.v. or oral dose of morphine, are probably
attributable to M6G. Wide and unpredictable inter-subject
variability of morphine and metabolite behaviour has also 
been demonstrated, particularly following oral dosing. These 
findings may partly explain the poor correlation observed 
between dose and response for this drug. Indeed, this
inter-individual variability in morphine disposition, 
particularly with regard to the rate and degree of production 
of M6G, indicates that clinical use of morphine will continue 
to be assessed in terms of observed clinical response, rather 
than on simpler predictors derived from pharmacokinetic data.
The data obtained in this study has formed the basis of 
a recent publication (Hoskin et âi*/ 1989a, see Appendix
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III). The results in this paper were reported in mass units 
to enable direct comparisons with previous clinical studies 
to be carried out.
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CHAPTER-SIX
PHARMACOKINETIC STUDIES WITH MORPHINE-6-QLUCURONIPE 
IN HEALTHY VOLUNTEERS AND CANCER PATIENTS
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6.1. INTRODUCTION
Evidence for the pharmacological activity of M6G has 
accumulated slowly, and has involved the use of both in vitro 
and in vivo studies to demonstrate its morphine-like 
properties. In all of these investigations, M6G has been 
found to be more potent than the parent drug itself.
The pharmacological activity of this metabolite 
originally appeared to be nothing more than a curiosity, 
since early pharmacokinetic work concluded that it comprised 
less than 1% of the metabolites of morphine in man (Boerner 
et al., 1975). However, - Svensson and coworkers (1982)
demonstrated that M6G occurred in large quantities in humans 
after chronic oral doses of morphine. The studies reported in 
this thesis, and by Osborne et (1990), have expanded the
observations of Sëwe et al. (1983b; 1985) and Hand &t al. 
(1987a), indicating that M6G is an abundant metabolite, not 
only after oral treatment but also after other enteral routes 
and i.v. dosing. Indeed, after a single oral dose, M6G 
appears to be present in quantities which exceed those of 
morphine by a factor ranging from 7:1 to 11:1. The abundance 
of this metabolite, combined with its narcotic activity, 
strongly suggests that it could be responsible, in part, for 
the clinical effects seen after morphine treatment. 
Circumstantial evidence in support of this has been provided 
by the observation that narcotic effects may persist in renal 
failure patients in the absence of measurable quantities of 
morphine, but in the presence of M6G (Osborne et, al., 19 86).
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The actions of M6G in man were recently defined in a 
study by Osborne and colleagues (1988). Their report provided 
data from a Phase I trial conducted in 6 cancer patients 
investigating the analgesic properties and cardio-respiratory 
effects of treatment with lmg/7 0kg of M6G administered 
intravenously. Their results indicated substantial analgesia 
in the majority of these patients, lasting up to 7 hours. At 
the same time, clinical toxicity was not observed at this 
dose, indicating that higher dose levels were feasible. In 
the same study, limited pharmacokinetic data was obtained in 
2 patients, and these results emphasised the need to consider 
the importance of renal function when dealing with this 
compound.
In order to investigate further the potential of this 
metabolite as an analgesic in its own right, more detailed 
pharmacokinetic data is required following its systemic 
administration to humans. To this end, this study has been 
designed to obtain information on the disposition of i.v. or 
oral M6G in healthy volunteers, and to investigate the 
pharmacokinetics of increasing doses of i.v. M6G in cancer 
patients.
6.2. SUBJECTS AND METHODS
M6G was specially synthesised for use in these studies 
by Dr. F, Scheinmann of Salford Ultrafine Chemicals Ltd., 
Salford, U.K., and was prepared as an isotonic solution in 
saline at a concentration of Img/ml. Doses of M6G were chosen
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on the basis of the findings of Osborne and colleagues 
(1988). The drug was administered intravenously as a 5 minute 
infusion into a peripheral vein in a total volume of 5ml of 
normal saline. Oral administration was achieved by swallowing 
a Img/ml solution of M6G, followed by 100ml of water. '
These studies had the approval of the Ethics committee 
of St. Bartholomew's Hospital, and written informed consent 
was obtained from each subject.
STUDY I
This experiment examined the pharmacokinetics of a 
single intravenous injection of lmg/7 0kg M6G to 6 healthy 
volunteers recruited from the medical staff at Homerton 
Hospital.
STUDY II
This experiment examined the pharmacokinetics of a 
single intravenous dose of 1, 2 or 4mg/70kg M6G in adult
cancer patients.
12 patients treated in the Department of Medical 
Oncology, Homerton Hospital were studied. These patients were 
under the care of Dr. P. Thompson and Dr. M. Slevin. They 
were subsequently divided into 3 groups, each of 4 patients. 
Members of each group received doses of 1, 2 or 4mg/70kg M6G. 
Details of these patients are summarised in Table 6.1.
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Table 6.1,
Patient details - i.v. M6G study.
Patient Age S ex Weiaht Dose Dose
I.D. (kg) fma/70ka^ (mg)
LB 55 F 56.0 1,0 0.80
RP 78 M 59.0 1.0 0.84
DJ 68 M 70.0 1.0 1.00
ST 56 M - 87.0 1.0 1.24
EW 38 F 50.0 2 .0 1.50
JB 29 F 65.0 2.0 1.95
JH 25 F 36.5 2.0 1.00
AH 74 M 51.0 2.0 1.45
CB 48 F 79.0 4.0 4.50
TM 69 M 78.0 4.0 4.40
PK 66 M 54.0 4.0 3.10
GT 65 M 55.0 4.0 3.14
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STUDY III
This experiment investigated the plasma disposition of a 
single oral dose of 2mg/70kg M6G in 9 healthy volunteers 
recruited as in Study I. Subjects were fasted overnight prior 
to the study and were not allowed food or drink for a period 
of 4 hours following drug administration. Serial blood 
samples were collected from all the subjects in each group 
for 12 hours after dosing. Blood was centrifuged at 3500rpm 
for 10 minutes and the plasma was stored at -20“C prior to 
analysis.
Assay method
Measurement of plasma morphine and M6G was performed 
using the RIAs described for this purpose in Chapter Three, 
using [3H]-morphine and [125I]-M6G as the radiolabels.
6.3. PHARMACOKINETIC ANALYSIS
Individual data for half-life, AUC (0-w), total 
clearance and volume of distribution were calculated using 
STRIPE.
6.4. RESULTS 
STUDY I
Mean plasma levels after administration of lmg/7 0kg M6G
i.v. to volunteers are plotted semi-logarithmically in 
Fig.6.1. Peak concentrations were observed at the first time
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Fig.6.1. Plasma levels of M6G following administration of lmg/70kg M6G i.v. to volunteers. All points on graph are group mean ± SEM, n=6.
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Table 6.2.
lma/70ka: i.v. M6G to healthv volunteers
Subiect Dose Cmax T 1/2 Cl. Vd AUC (O-oo)
I.D. (mg) (nmol/l) _(hr). (ml/min/ (l/kg) (nmol/l/h)
kgl
A 2.43 384.0 1.77 0.64 0.10 453.0
B 1.71 279 .2 1.48 0.54 0.07 376.9
C 2.29 402.0 1.71 0.50 0.07 546.7
D 1.73 424.0 1. 88 0.49 0.08 414.5
E 2.35 374.0 1.85 0.78 0.12 355.7
F 1.63 308.0 1.51 0.53 0.07 363.1
mean 2 .02 361.9 1.70 0.58 0.09 418.3
(± SEM) (0.15) (23.0) (0.07) (0.02) (0.01) (29.7)
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point (5 minutes). Low levels of M6G were measured in all 
subjects after 12 hours. Mean pharmacokinetic parameters 
calculated following this treatment are shown in Table 6.2. 
M6G disposition was best fitted to a two-compartment model, 
and the mean terminal elimination half-life in these subjects 
was 1.7 hours. The mean values for M6G clearance (40.6 ± 3.2 
ml/min) and volume of distribution (6.00 ± 0.63 1) were
consistent throughout the whole group. Morphine was 
undetectable in all samples taken from these subjects.
STUDY II
Mean plasma data obtained following the administration 
of increasing doses of i.v. M6G to patients is presented in 
Fig.6.2 and Table 6.3. As in Study I, M6G levels reached a 
peak after 5 minutes and proceeded to decline in a
bi-exponential fashion. The half-lives of the terminal phases 
in these patients^ were slightly, but not significantly,
longer than those observed in the healthy volunteers. Mean 
values for clearance, volume of distribution and AUC (0-w) 
were also marginally higher in these patients, although the 
inter-individual variation was considerably larger. A 
significant linear correlation was observed between
administered dose and AUC (0-m), (r=0.993). As in the
previous two experiments, morphine was undetected in the
plasma samples collected.
page 219
(a) 1mg/70kg 
M6G conc. (nmol/l)
(b) 2mg/70kg
1000
100
6 8 10 14120 2 4
M6G conc. (nmol/l)1000
100
6 1080 12 142 4
Time (hours) Time (hours)
(c) 4mg/70kg (c) All groups
M6G conc. (nmol/l)10000
1000
100
0 6 8 10 142 124
Time (hours)
10000p
1000
100
0 6 82 104 12 14
Time (hours)
• img/70kg — 2mg/70ko 4itig/70kg
Fig.6.2. Plasma levels for M6G following administration of Img, 2rag or 4mg/70kg i.v. M6G to patients, (a) mean results after lmg/70kg (± SEM, n=4), (b) mean concentrations after2mg/70kg (± SEM, n=4), (c) mean results after 4mg/70kg (±SEM, n=4), (d) mean results for all groups (n=4).
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Table 6.3.
JT -LClOlllCl k^ii.a.J.iUO.01and 4ma/70ka i.V. M6G to oatients
Patient Dose Cmax T 1/2 Cl. AUC (0-m)I.D. (mo) (nmo1/1) (hr) (ml/min/ (1/kg), (nmol/l/h'
M X
lmg/70kg PATIENTS
LB 0.80 379 .3 2.36 0.68 0.14 561.7RP 0.84 547.0 2 .58 0.71 0 .16 566.0DJ 1.00 352.0 2.36 1.26 0.26 380.3ST 1.24 593.0 2 .11 0.93 0.17 640.5
mean 0.97 467.8 2.35 0.90 0.18 537 .1
(± SEM) (0.10) (60.0) (0.10) (0.13) (0.03) (55.3)
2mg/70kg PATIENTS
EW 1.50 608 . 0 1.68 0.88 0.13 814.8JB 1.95 924.5 2.57 1.13 0.25 829.2JH 1.00 255.0 2.31 1.11 0.22 431.8AH 1.45 680.0 4.01 0.38 0.13 1842.1
mean 1.47 616.9 2.64 0.88 0.18 979 .5
(± SEM) (0.19) (138.3) (0.49) (0.17) (0.03) (301.9)
4mg/70kg PATIENTS
CB 4.50 1195 2.44 1.09 0.23 1979.7TM 4.40 1198 4.03 0.97 0.34 2174.0PK 3.10 956 3,84 0.81 0.27 1835.2GT 3.14 1086 3.10 0.69 0.18 2180.4
mean 3.78 1108.8 3 . 35 0.89 0.25 2042.3
(± SEM) (0.38) (57.2) (0.36) (0.09) (0.03) (83.3)
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STUDY III
The mean plasma profile following the administration of 
2mg/70kg M6G to healthy volunteers is shown in Fig.6.3. 
Pharmacokinetic data for each subject are included in Table
6.4. Mean values for Cmax and AUC (0-12hr) were reasonably 
consistent throughout the group. M6G was quickly absorbed, 
with low levels observed in the plasma after 15 minutes. In 
the majority of subjects, an initial absorption peak was 
observed between 1.5 and 2 hours after dosing. These levels 
then declined slightly for the next 2 hours, after which a 
sharp rise was observed,^ leading to a secondary peak 
occurring between 8 and 10 hours in most subjects. In 
general, the levels of M6G measured at these later time 
points exceeded those found at Tmax (absorption), and this 
explains the wide range in values recorded for Tmax. In six 
of these subjects, 24 hour plasma samples were also obtained, 
and low levels of M6G were still apparent after this time 
(7.41 ± 1.24 nmol/l; range 3,58-12.5 nmol/l). Morphine was 
undetectable at all times after this treatment.
6.5. DISCUSSION
As mentioned earlier, very few studies have investigated 
the disposition of the glucuronidated metabolites of morphine 
and most have been concerned with the disposition of its 
major metabolite, M3G, in animals (Garrett apd Jackson, 1979; 
Olsen Êt f 1988; Olsen &1., 1989).
The results of the present study indicate that, after
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Fig.6.3. Plasma levels of M6G following administration of 2mg/70kg oral M6G solution to volunteers. All points on graph are group mean ± SEM, n=9.
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Table 6.4.
2ma/70ka oral M6G to healthv volunteers
Subiect Dose Cmax Tmax AUC (0-12hr)
I.D. (mg) rnmol/l) fhr) inmol/l/hr)
RO 2.5 14.7 1.5 93.8
PT 1.6 26 . 6 10 153.7
SJ 2.4 16.8 8 148.5
MC 1.9 27.7 10 112 . 8
AD 2.0 24.0 8 174.2
DS 1.9 16.1 0.75 136.4
AB 1.9 13.7 12 123.4
RG 2.5 22.8 6 122.2
DT 2.3 14.2 10 107.7
JW 2.3 19.1 8 146.2
mean 2.1 19.6 7.4 131.9
(± SEM) (0.10) (1.67) (1.51) (7.70)
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the administration of i.v. M6G to volunteers and patients, 
the metabolite rapidly declines in a bi-exponential manner. 
The correlation observed between dose and AUC (0-#) in the 
patient studies implies that M6G obeys dose-independent 
kinetics. In general, the pharmacokinetic data obtained for 
M6G in the present study is ■ in good agreement with
that described for M3G in previous studies. Data has been 
obtained for M6G disposition in humans after morphine 
administration to healthy volunteers in Chapter Five. Similar 
values for the terminal elimination half-life of M6G were 
recorded in the present study, although in patients a large 
individual variation in this parameter was evident. The 
present kinetic data is also comparable to that obtained in a 
single patient with normal renal function dosed with lmg/70kg 
i.v. M6G (Osborne et al.. , 1988). Comparison of the data
obtained in the volunteers and patients in this study 
revealed slightly higher values for the kinetic parameters 
calculated in patients. These discrepancies probably reflect 
the close depend&nce that M6G elimination has on renal
function as, although these patients had no apparent major
renal insufficiencies, a wide range in values for plasma 
creatinine was found (42-113 pmol/l). At the same time, it 
was rather surprising to note higher values for both 
clearance and half-life in the patients, and the only 
possible explanation for these findings is the wide
inter-patient variations experienced.
When this data is compared to that obtained in Chapter
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Five, following i.v. administration of morphine to healthy 
volunteers, a number of interesting comparisons can be made. 
The rates at which morphine and M6G are eliminated, after 
their respective systemic administration, appear to be rather 
similar, despite their physicochemical differences. The
figures for clearance and volume of distribution were as 
expected, with the higher values for morphine probably 
reflecting its high hepatic extraction ratio, and its
increased plasma protein binding (see Chapter Eight of this 
thesis). Similar differences in these parameters were
observed following systemic, administration of morphine and
M3G to dogs (Garrett and Jackson, 1979). In the same study, 
they concluded that renal excretion is the sole route of 
systemic glucuronide elimination. The present data supports 
their findings, since the clearance of M6G did not appear to 
be do se-'dependent in the patients in this study. The same 
group also observed that, following the systemic 
administration of M3G, there was not the prolonged terminal 
phase for the administered glucuronide that appeared when 
morphine was injected. They concluded that this was because 
only the hepatically conjugated morphine is partitioned into 
bile in the liver and subject to enterohepatic cycling. No 
significantly prolonged terminal phase was apparent for M6G 
after i.v. morphine in the volunteers studied in Chapter 
Five, although results obtained later in this thesis (Chapter 
Eight) are highly suggestive of an enterohepatic circulation 
for morphine. The absence of any secondary M6G peaks in the
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present study indirectly supports the conclusion that the 
systemically administered glucuronides do not undergo biliary 
excretion and subsequent enterohepatic circulation.
When M6G was administered as an oral solution, a 
reasonably consistent pattern of absorption was apparent in 
all the subjects studied. Peak levels of M6G were reached in 
most subjects after 2 hours, which was considerably longer 
than the equivalent Tmax for absorption of the oral morphine 
solution (45 minutes) observed in Chapter Five. By comparison 
of the mean AUCs (adjusted for dose) following i.v. and oral 
M6G in the range of patients and volunteers studied here, a 
mean bioavailability for the oral M6G solution of 13.6% ±
0.7 6 (mean ± SEM; n=4) is obtained. This is considerably 
lower than that reported in volunteers for the oral morphine 
solution studied in Chapter Five (23.8% ± 3.4; mean ± SEM; 
n=6). It has been well established that morphine (pKa= 8.0) 
is almost completely absorbed from the gastrointestinal 
tract, though it is . almost completely ionised at the 
physiological pH (6.5) of the small intestine (Tan et al., 
1989). Due to its amphoteric nature, M6G is also likely to be 
ionised to some degree along the whole length of the 
gastrointestinal tract. It has been suggested that ion 
permeation through the intestinal membrane is a feasible 
mechanism for the absorption of ionised compounds (Lanman et 
ad., 1971). The differences in absorption rate and, to a 
certain extent, bioavailability between morphine and M6G from 
these oral solutions, therefore, are more likely to reflect
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their differences in lipid solubility (Schanker, 1959). 
Unfortunately, urinary excretion data is unavailable from 
these two studies and comparison on the relative efficiencies 
of the oral absorption of these two compounds is not 
possible.
In the absence of urinary excretion data for these 
subjects, the metabolic fate of systemically administered M6G 
can only be partly defined. Morphine was undetected in the 
plasma, indicating that significant systemic de- 
glucuronidation of i.v. or oral M6G does not occur. Further 
evidence for this was provided by analysing plasma samples, 
from two of the volunteers who received i.v. M6G, for the
presence of M3G using HPLC (Joel ^  al•  ^ 1988). M3G was not
detected in any of these samples (Joel S.P., personal 
communication). These findings are in agreement with those of 
Osborne and colleagues (1988) in patients, and Garrett and 
Jackson (1979) in dogs, but are contrary to observations in 
rats, where morphine and M3G were found in the urine after 
i.v. M6G treatment (Ida et âiw 1975). Similar discrepancies 
have also been noted in earlier studies investigating the 
disposition of phenyl glucuronide compounds; Garton and
Williams (1949) did not observe any hydrolysis of i.v. 
phenylglucuronide, whereas Kamata and colleagues (1967) 
reported that a small portion of i.v.
p-nitrophenylglucuronide was hydrolysed by the action of 
^-glucuronidase in the bladder.
Of particular interest was the appearance of delayed
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secondary M6G peaks in all subjects 8-10 hours after
ingestion of the oral M6G solution. It is unlikely that this 
is due to enterohepatic circulation. It is possible that 
these peaks were simply due to a significantly delayed 
absorption of M6G. An alternative explanation is that M6G, 
being very polar, travels the gastrointestinal tract 
undergoing the limited absorption observed in these subjects, 
until it reaches the large intestine. In the caecum,
bacterial action may split the glucuronide linkage to 
liberate morphine, which may be absorbed by the colon. A 
similar process has been described for sulphasalzine, another 
polar compound, following oral administration (Houston and
Wood, 19 80). However, the absence of measurable morphine and
the presence of M6G in these later samples suggests that, if 
this process does occur, then this free morphine is 
reglucuronidated during and/or after absorption by the caecum 
and colon. This process may occur to some extent all the way 
along the small intestine. Roster al» (1985a) reported 
that glucuronidation capacity was evident along the entire 
length of the rat intestine, but that it was less in the 
large intestine, where the activity of the /3-glucuronidases 
was the greatest. It would therefore be of interest to 
analyse any late plasma samples for the additional presence 
of M3G likely to be formed if re-glucuronidation is occurring 
in this way. It is apparent that the factors governing the 
fate of orally administered M6G need further investigation.
The role of the liver in excreting systemically
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administered M6G has not been studied. In addition, the 
transformation of M6G to morphine-3,6-diglucuronide has not 
been investigated due principally to the lack of an assay 
system capable of detecting and quantitating small amounts of 
this polar metabolite. Nevertheless, this metabolite has been 
characterised in the urine of addicts receiving morphine (Yeh 
et al. , 1977) and, bearing in mind the large quantities of
M3G formed after morphine administration, the likely presence 
of this metabolite after M6G treatment needs to be realised. 
Attempts to synthesise the raw metabolite have so far proven 
unsuccessful (Scheinmann, F._, personal communication), and 
its cross-reactivity with the antisera used in these studies 
has, therefore, not been assessed. The potential problem of 
interference from high levels of M3G with antiserum GGl Vila 
was noted earlier in this thesis (Chapter Three), and the 
possibilty that morphine-3,6-diglucuronide may cause similar 
problems cannot be dismissed. These observations need to be 
taken into consideration when interpreting the results from 
any future studies in which these assays are employed.
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CHAPTER .5EVEN
THE DISTRIBUTION OF MORPHINE AND MORPHINE-6- 
GLUCURONIDE IN RAT TISSUES
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7.1. INTRODUCTION
The distribution of a drug throughout the body is
governed by the affinities it has for various constituents of
the tissues, including aqueous solubility, lipid solubility, 
binding to extracellular substances, and intracellular uptake 
and storage. For ionised drugs, the distribution between
compartments, separated by a lipid-permeable membrane,
depends on the pKa of the drug and the pH values of the 
aqueous phases in the compartments. The rate of reaching 
equilibrium distributions between drug in the blood and in a 
tissue depends largely on the rate of blood flow through the 
tissue. This flow rate is rapid for lung, brain, liver and 
kidney but less rapid for resting muscle and adipose tissue.
The very nature of the pharmacological effects elicited 
by morphine and its surrogates indicates a highly selective 
action at specific receptor sites, but, nonetheless, these 
compounds are organic bases and, therefore, share many 
features governing biological disposition, which are 
characteristic for basic compounds. Most organic bases, after 
being absorbed, rapidly leave the blood and localise in high 
concentrations in organs, such as the lung, spleen, liver and 
kidneys. Indeed, these organs generally exhibit drug 
concentrations considerably in excess of those present in the 
blood within a few minutes after drug absorption has taken 
place. Brain, skeletal muscle and other tissues also have 
this ability to concentrate organic bases, but to a much 
lesser extent.
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The plasma is the physiological medium of exchange 
between the drug and the tissue. If the physico-chemical 
properties of morphine are considered, it would be predicted 
that this compound is unlikely to pass across the selectively 
permeable blood-brain barrier into the CNS with ease (Mayer 
et al.. 1959). Nevertheless, to directly affect CNS cells, 
the pharmacokinetics of a drug must be such that appreciable 
quantities appear in the extracellular environment of these 
cells.
An understanding of the basis of drug interactions 
requires, among other things, a consideration of the role of 
pharmacologically active metabolites in the dose-response and 
time-action characteristics of a drug. Although the 
literature on this topic is extensive for morphine, there is 
little information available on its metabolites. A small 
number of studies have tentatively investigated the 
distribution of the metabolites of morphine within certain 
tissues, but limited useful information has been forthcoming. 
The metabolic fate and tissue distribution of M3G and M6G in 
rats has been investigated using radiolabelled techniques and 
TLC (Yoshimura âlw 1973; Ida et al., 1975). More
detailed pharmacokinetic data was obtained following i.v. 
administration of radiolabelled M3G in the dog (Garrett and 
Jackson, 1979). Recently, the placental permeability of 
morphine and M3G has been investigated in animals by a number 
of groups who all demonstrated restricted permeability for 
the larger, more polar metabolite (Olsen âi., 1988; 1989;
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Gerdin êt il*/ 1990). These studies remain the only direct 
investigations into the distribution of these metabolites in
animal tissues.
Although the measurement of drug concentrations in
tissue homogenates provides much useful information, in order 
to investigate drug distribution within a certain target 
tissue other techniques, such as autoradiography and 
immunocytochemistry, can yield some useful information. 
Autoradiographical localisation of morphine and morphine-like 
analgesics within the CNS has been observed (Appelgren and 
Terenius, 1973), and other groups have employed 
gamma-scintigraphy for the -same purpose (Tafani et al., 
1989). Since the technique of immunocytochemistry was 
introduced (Coons si &1., 1941), it has been successfully 
used to visualise a number of compounds within certain 
tissues, including anti-cancer drugs (Henneberry et al., 
1987). Morphine has also been localised using this technique 
by employing an immunofluorescent label (Morley and Gee,
In view of the analgesic activity of M6G, further 
information on the metabolic fate of both morphine and M6G is 
required. It was the primary aim of this study to investigate 
the tissue distribution of morphine and M6G after the 
separate administration of both compounds. This chapter 
describes the attempts that have been made to achieve , by 
using sensitive RIAs and immunocytochemical techniques to 
follow distribution in rats.
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The doses employed were pharmacological, and allowed 
comparison with other studies. In addition, it was necessary 
to take into consideration the sensitivity of the analytical 
methods being employed, and the cost of the raw metabolite.
7.2. MATERIALS AND METHODS
Adult male Wistar/albino rats (200-300g) were used. They 
were maintained in a temperature controlled environment 
(25°C) with a regular day-night cycle, and were allowed free 
access to standard rat food and water. Morphine, in the form 
of its sulphate, was used throughout these studies, and was 
obtained from St. Luke's Hospital Pharmacy, Guildford, 
Surrey. Morphine-6-jS,D-glucuronide was synthesised by Salford 
Ultrafine Chemicals (Salford, U.K.).
Drugs were administered in solution with 0.9% saline to 
rats as a single i.p. dose in the middle of the abdomen.
Doses of the drugs given refer to the salts.
Rat tissue homogenates were prepared for analysis of 
morphine and M6G using RIAs modified for use with these 
tissues (Section 3.S).
7.2.1. Dosing Procedures
Twelve groups of rats (n= 4-7) were injected i.p.
(200-300^1) with Img/kg body weight of morphine or M6G. At 
various time intervals (5, 15, 30, 60, 120, 300min) after
dosing the rats were bled by cardiac puncture under light 
ether anaesthesia, before being sacrificed by cervical
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dislocation. Brain, kidney and liver samples were removed from 
each animal and homogenates were immediately prepared for 
analysis. The same tissues from one rat in each group were 
removed, rinsed in 0.9% saline, and retained for 
immunocytochemical analysis.
Control animals were treated by injection of 0.9% saline
i.p. instead of the drug. Two control animals were included 
in each group. The tissues from one animal were taken for 
analysis of morphine and M6G content and the tissues from the 
other animal were retained for immunocytochemical analysis.
7.2.2. Data Analysis
Concentrations of morphine and M6G expressed as nmol/l 
(serum) or nmol/g (brain, kidney and liver). For the purposes 
of pharmacokinetic analysis, only the time points between 0 
and 2 hours after dosing were included in the calculation of 
AUCs and half-lives. The morphine and M6G concentration 
profiles were calculated for all the tissues analysed; areas 
under the serum concentration/time curves (0-2hr) and 
elimination half-lives were determined using STRIPE (Section
2.4). Cmax and Tmax were also recorded. Data is presented as 
mean ± SEM for each group.
7.2.3. Immunocytochemical Analysis
The tissues that were collected for immunocytochemical 
staining were fixed in 10% neutral buffered formalin for a 
period of at least 1 week. Cross sections of forebrain,
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hindbrain, liver and kidney were cut and embedded in paraffin 
wax. A number of slides were prepared from sections 5pm 
thick, cut from each tissue block. The routine 
immunocytochemical materials and procedures employed are 
included in Appendix I. Using these methods, the sections 
were successively incubated with anti-morphine antiserum 
(first antibody), horseradish peroxidase (HRPO)-labelled 
second antibody, and peroxidase substrate (diaminobenzidine). 
Second antibody dilutions used were the same as those chosen 
in earlier studies investigating the distribution of 
anti-cancer drugs (Henneberry H.P., personal communication). 
The following antibody dilutions were investigated; (i) Sheep 
anti-morphine antiserum (HP/S/844 Ila; Section 3.2) used at 
titres ranging from 1:50 to 1:5000 with HRPO-labelled donkey 
anti-sheep second antibody, used at a dilution of 1:300. 
ii) Goat anti-morphine antiserum (GGl Vila; Section 3.3) used 
at titres ranging from 1:500 to 1:5000, with HRPO-labelled 
donkey anti-goat second antibody, used at a dilution of 
1:200.
In order to demonstrate the specificity of 
immunostaining, the same sections were incubated with a 
non-immune serum from the same species replacing the first 
antibody. Tissues from drug-treated and control animals were 
processed simultaneously.
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7.3. RESULTS
Levels of morphine and M6G were determined in all the 
tissues collected 5 hours after dosing. However, these were 
not included in the pharmacokinetic calculations due to the 
low levels measured and the long time interval between 
sampling points, making data interpretation difficult.
The results in Table 7.1 show that, following i.p. 
administration, morphine was rapidly absorbed into the 
systemic circulation, reaching a peak concentration in the 
serum after 5 minutes and then rapidly disappearing over the 
next 2 hours. A semi-logarithmic plot showing the
disappearance of morphine was composed of at least two 
exponential terms (Fig 7.1(a)), with half-lives of 0.13 hours 
(5-15min) and 0.51 hours (15-120min). The mean AUC (0-2hr)
was 175.lnmol/1/hr. Low levels of M6G were apparent in the 
serum of these rats 15 minutes after dosing, and these slowly 
declined over the remaining time period.
Distribution of morphine into the brains of these 
animals appeared to follow a similar pattern to that observed 
in serum (Table 7.1 and Fig.7.1(b)). Maximal levels were
found after 5 minutes, and these declined fairly rapidly over 
the next 2 hours. This disappearance curve could be fitted to 
at least two compartments, with half-lives of 0.08 hours 
(5-15min) and 0.97 hours (15-120min), The mean AUC (0-2hr)
was calculated to be 66.5nmol/l/hr, giving a mean morphine 
AUC (0-2hr) ratio of brain;serum of 0.4. In Fig.7.1(c) the 
ratio of brain to plasma concentration is plotted as a
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Table 7.1.
Distribution of morphine and M6G in rat tissues following a 
single administration of Ima/ka morphine i.p.
Time Serum
fhr) (nmol/1)
Brain
( nmol/o')
Liver
(nmol/g)
Kidney
(nmol/g)
MORPHINE LEVELS
0.08 338 (97.7) 144 (17.5) 3128 (271) 1515 (229)
0.25 199 (14.8) 55.6 (12.3) 770 (21.3) 2700 (319)
0.5 92 . 3 (15.2) 22.2 (0.7) 645 (40.4) 1460 (149)
1.0 43.5 (7.0) 19.3 (1.7) 124 (11.7) 391 (46.7)
2 . 0 11.9 (1.4) 7.91 (1.9) 31.8 (9.3) 75.7 (19.0)
5 . 0 9.64 (1.8) 6.14 (4.4) 135 (33.4) 44 . 0 (12.9)
M6G LEVELS
0.08 N.D. N.D. N.D. N.D.
0.25 45.5 (3.0) N.D. N.D. N.D.
0.5 35.3 (6.5) 20.7 (3.8) N.D. N.D.
1.0 33.9 (4.5) 6.29 (2.9) N.D. N.D.
2.0 5.34 (1.9) N.D. N.D. N.D.
5.0 11.2 (2.0) N.D. N.D. 28.7 (7.9)
mean (± SEM); n = 4-6 rats
page 239
(a) Serum (b) Brain
Morphine] nmol/l1000
T 1/2 ■ 0.l3hr (alpha)
0.51hr (beta)
AUC (0-2hr) • 176.1 nmol/l/hr
100
10
2 Z60 0.6 1.61
Morphine] nmoi/g tissue
T 1/2 - O.OShr (alpha)
0.67hr (beta)
AUC (0-2hr) - 68.6 nmol/l/hr
100
0 0.6 1.6 2.621
Time (hours) Time (hours)
(c) Braimserum morphine
0.7
0.6
0.6
0.4
0.6
0.2
0.1
0 20.6 2.61.61
Fig.7.1. Disappearance of morphine from rat serum and brain tissue after a single i.p. dose of Img/kg morphine, (a) mean serum results (± SEM, n^4-7), (b) mean brain results (± SEM, n=4-7), (c) mean brain:serum ratios (n=4-7).
Time (hours)
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function of time. This figure is seen to fluctuate between
0.4 and 0.2 over the first hour, and then rise to 0.7 after
2 hours. Low levels of M6G were detectable in all the brains 
collected after 30 minutes, and in 3 out of 6 brains 1 hour 
after dosing, beyond which time M6G was undetectable in all
brains analysed. The persistence of low nanomolar quantities 
of morphine in the serum and brain, and M6G in the serum, 5
hours after dosing was evident in most of the animals
studied.
Following morphine dosing, morphine was also found to be 
rapidly absorbed by the liver and kidney at concentrations 
considerably in excess of those present in serum and brain 
(Table 7.1). Peak levels of morphine appeared in the liver 5 
minutes after injection, and these rapidly declined over the 
remaining 2 hours. Considerable quantities of morphine were 
also present in the kidney after 5 minutes, beyond which time 
the levels exceeded those found in the liver, with peak 
concentrations observed after 30 minutes. These levels 
declined rapidly, although the rate at which this
disappearance occurred appeared to be slower than that 
observed in the liver. In general, M6G was undetectable in
samples of either liver or kidney obtained. However, low
levels were detected in the samples of kidney taken
5 hours after dosing in all but one of the animals studied.
Following the administration of Img/kg M6G i.p., rapid 
absorption from the injection site, followed by distribution 
to the various tissues, was observed (Table 7.2). Peak serum
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Table 7.2.
Distribution of M6G and morphine in rat tissues following a 
single administration of Ima/ka M6G i.p.
Time Serum Brain Liver Kidney
(hr) (nmol/l) (nmol/g) (nmol/g) (nmol/g)
M6G :LEVELS
0 . 08 4532 (508) 474 (24.6) 643 (212) 1848 (459)
0.25 2128 (147) 350 (54.8) 4516 (441) 7581 (484)
0.5 1174 (103) 242 (62.2) 4228 (371) 2194 (712)
1.0 304 (33.7) 74.1 (9.2) 1784 (498) 1499 (331)
2 . 0 91.9 (19.5) 37.5 (12.7) 350 (139) 713 (242)
5.0 6.06 (0.7) 12.4 (0.6) 47.2 (3.7) 56.3 (18.2)
MORPHINE LEVELS
0 . 08 N.D. N.D. 150 (40.5) 15.8 (3.1)
0 .25 N.D. N.D. 473 (48.2) 68.8 (3.4)
0.5 N.D. N.D. 262 (71.6) 77.6 (8.9)
1. 0 N.D. N.D. 99.0 (22.6) 40,7 (2.9)
2.0 N.D. N.D. 45.5 (14.1) 34.9 (6.8)
5.0 N.D. N.D. 19.2 (3.6) 88.0 (6.3)
mean (± SEM); n = 4-6 rats
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levels were found after 5 minutes. These levels quickly 
declined, this disappearance being composed of at least two 
exponential terms with half-lives of 0.17 hours (5-60min) and
0.58 hours (l-2hr) (Fig.7.2(a)). The mean AUC (0-2hr) was
found to be 1950.3nmol/l/hr.
Distribution of M6G into the brains of these animals 
took place rapidly, with peak concentrations occurring after 
5 minutes. M6G quickly disappeared from the brain over the 
first hour, then more slowly over the next hour. At least two 
compartments could be fitted to this disappearance curve. 
These were found to have half-lives of 0.33 hours (5-30min) 
and 1.02 hours (30-120min) (Fig 7.2(b)). The mean AUC (0-2hr) 
was found to be 319.lnmol/1/hr, giving rise to a mean 
morphine AUC (0-2hr) ratio for brain:serum of 0.2.
Brain:serum concentration ratios are plotted against time in 
Fig 7.2(c) and are seen to rise slowly from 0.1 to 0.4 over 
the 2 hour study period. Morphine was undetectable in the 
brains collected from these animals. As with the rats dosed 
with morphine, low levels of M6G were present in the sera and 
brains of rats collected 5 hours after dosing.
M6G was quickly taken up by both the liver and the 
kidney, and remained present in these tissues at all times at 
concentrations that were significantly higher than those 
measured in the serum and brain (Table 7.2). Peak levels of 
M6G observed after 15 minutes in the liver declined
slowly over the first hour and then fell more rapidly over 
the next hour.
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(a) Serum (b) Brain
!M6Gl nmol/l10000
T 1/2 ■ 0.17hr (alpha)
0.6dhr (beta)
AUC (0-2hr) ■ 1850.3 nmol/l/hr
1000
0 0.6 1 1.6 2 2.6
;M6G1 nmol/g tissue1000
T 1/2 ■ 0.33hr (alpha)
1.02hr (beta)
AUC (0-2hr) ■ 310.1 nmol/l/hr
100
0 0.6 1.61 2 2.6
Time (hours) Time (hours)
(c) Brain:serum M6G
0.6
0.4
0.3
0.2
0.1
0 0.8 1 1.6 2 2.6
Fig,7 .2 . Disappearance of M6G from rat serum and brain tissue after a single i.p. dose of Img/kg M6G, (a) mean serum results (± SEM, n=4-7), (b) mean brain results (± SEM, n=4-7), (c) mean brain:serum ratios(n=4-7).
Time (hours)
page 244
The levels found in the kidney were considerably higher 
than those measured in the liver with peak concentrations 
found after 15 minutes. These levels declined slowly over the 
first hour, but then fell more rapidly.
Significant levels of morphine were also found in the 
liver and kidney of animals treated with M6G, low levels 
being detected in both tissues 5 minutes after dosing (Table 
7.1). Peak morphine concentrations were measured after 15 
minutes in the liver and these levels rapidly declined over 
the remaining time period. Greater amounts of morphine were 
detected in the liver than,in the kidney over the 2 hour 
time period. A mean peak concentration of morphine was 
apparent in the kidney after 30 minutes, and these levels 
were seen to decline quickly over the next 1.5 hours. 
Substantial levels of M6G and morphine remained in the liver 
and kidney samples collected after 5 hours, indeed the levels 
of morphine in the kidney were higher than those observed in 
the initial peak 30 minutes after dosing.
When the same tissues from control rats in each group 
were analysed, all the results obtained were below the limits 
of detection for morphine and M6G in each tissue (Section
3.5.4).
Unfortunately, time constraints allowed only the brains 
collected from these animals to be analysed by 
immunocytochemistry. The results obtained were rather 
disappointing; positive immunostaining was not observed in 
any of the tissues analysed with either of the anti-morphine
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antibodies.
7.4. DISCUSSION
These preliminary studies in the rat were initiated to 
investigate the distribution of morphine and M6G into various 
tissues over a 5 hour period, following the administration of 
both compounds.
A number of the studies described earlier (Chapter One) 
were particularly concerned with the passage and distribution 
of morphine into the CNS. To date, the most reliable of these 
studies has been conducted by Dahlstrom and Paalzow (1975b), 
who investigated the pharmacokinetics of morphine in the 
serum and brain of rats that had been dosed intravenously 
with 2.5mg/kg morphine. In their study, GLC was used as the 
analytical method, and the brain concentrations obtained were 
corrected for the amount of morphine remaining in the blood 
vessels of the brain. This data correction was not found to 
be common practice in other experiments and allowances were 
not made for this problem in the present study. Thus, 
although efforts were made to remove any surplus blood from 
the tissues after collection, contamination of the resulting 
homogenates with residual blood is a possibility that needs 
to be taken into consideration. Indeed, this procedure is to 
be recommended and a simpler method involving the comparison 
of tissue haemoglobin content is also available (Tasker and 
Nakatsu, 1986). It is also possible that the method used to 
achieve anaesthesia may influence the metabolite profile
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following morphine administration, as has been demonstrated 
in surgical patients (Shelly et al., 1988). At present, no 
investigations have been carried out into the effects of 
ether anaesthesia on the disposition of morphine.
In the present study, morphine administered to rats i.p. 
was rapidly absorbed into the systemic circulation and 
distributed to the tissues. Maximal levels were found in both 
serum and brain after 5 minutes, with significantly lower 
quantities appearing in the brain. These findings are similar 
to those observed after intravenous dosing in rats (Paalzow 
and Paalzow, 1971; Plomp et _al.. 1981), although in another
study in rats, peak levels were not observed in the brain 
until after 15-20 minutes (Dahlstrom and Paalzow, 1975b). 
Serum and brain levels obtained here are lower than those 
reported at equivalent time points in other studies in which 
morphine had been administered i.p. to rats (Jôhannesson and 
Woods, 1964; Ko and Dai, 1989). However, similar values for 
the ratio of brain:serum morphine were evident, and the 
variations in concentration observed probably reflect the 
differences in absorption rate from the site of dosing, the 
use of different morphine formulations, inconsistent timing 
of sample collection, and the use of various analytical 
methods.
A similar pattern of elimination was observed from both 
serum and brain compartments. Elimination from the brain was 
found to be the slower process, probably reflecting the 
relative difficulty that morphine experiences in passing
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across the blood-brain barrier. Similar elimination patterns 
have been observed over the first 2 hours by a number of 
other groups investigating the kinetics of i.v. and s.c. 
morphine in rats and dogs (Paalzow and Paalzow, 1971; 
Dahlstrom and Paalzow, 1975b; Hipps si si*/ 1976; Finck st
al., 1977; Mullis et al., 1979; Nishitateno si r 1979;
Bolander si , 1983). Recent data obtained for serum
elimination half-lives in rabbits also exhibit a similar 
pattern (Katagiri et al., 1988). Long terminal elimination
half-lives were observed in both tissues by Hipps and 
colleagues (1976) and Mullis- and colleagues (1979), but not 
from the brain by Dahlstrom and Paalzow (1975b). In their 
comprehensive study investigating the pharmacokinetics of
i.v. morphine in the dog, Garrett and Jackson (197 9)
suggested that this slow terminal phase was due to either 
enterohepatic metabolite recirculation, gastrointestinal 
hydrolysis and hepatic first-pass reconjugation, or the 
existance of a "deep" compartment for morphine, or a 
combination of both factors. In their study, Plomp et
al. (1981) described a similar disappearance of morphine from 
serum, but, in direct contrast to the present findings, they 
observed a terminal elimination phase from the brain that was 
quicker than the initial rate. In a number of the
experiments reported here, values for terminal elimination 
half-lives have been calculated using only 2 or 3 late time 
points for which considerable inter-animal variation is 
evident. This needs to be taken into consideration when
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commenting on the significance of these results.
The pattern observed for the braimserum morphine ratios 
calculated in this study was generally consistent with those 
obtained by Dahlstrom and Paalzow (1975b) and Plomp ei al. 
(1981). However, lower individual ratios were reported by 
Dahlstrom and Paalzow (1975b), possibly reflecting the 
correction made in their study for residual blood present in 
the brain, although the consistency of the measurements at 
the earlier time points of the present study suggests that 
this is unlikely to be the only explanation.
As expected, following i.p. administration, morphine was 
selectively concentrated in the liver and kidney. Morphine 
arrives quickly at the liver and appears to pass through as a 
surge peak 5 minutes after dosing and then rapidly disappear. 
The increased levels observed after 5 hours were not apparent 
in any other tissue analysed, and may possibly be due to 
contamination with residual blood. Morphine was also readily 
concentrated in the kidney although peak levels were not seen 
until 30 minutes after dosing. Other studies investigating 
hepatic and renal distribution of morphine are relatively few 
in number. Miller and Elliott (1955) found that 1 hour after 
a s.c. dose of labelled morphine the renal: hepatic ; cerebral 
radioactivity ratios were about 80:25:1. This compared well 
with the data from a similar study conducted by Mullis et al. 
(1979), and with the ratios calculated by Yoshimura ei al. 
(1973), 45 minutes after i.p. administration. Comparable 
ratios (66:29:1) were obtained earlier in this study (after
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30min) with a ratio of 20:6:1 found after 1 hour. These 
differences are likely to be due to variations in the dosing 
regimens and analytical methods used.
The appearance of M6G in the serum of all rats 15
minutes after dosing with morphine indicates that, although
it is not a major metabolite, significant quantities are
produced following this route of administration. These levels
slowly declined but were still detectable at the end of the
study period (after 5 hours). Low, but significant, levels of
M6G were also detectable in all the brains collected 30
minutes and 1 hour after dosing. Both Siminoff and Saunders
(1958) and McDougal et al,. (1981) failed to detect morphine
glucuronide in the brains of rats, dosed s.c. with up to
25mg/kg morphine, using spectrophotometric and RIA detection
techniques respectively. However, Raffa et (1982)
indirectly detected significant levels of morphine 'Hs-c
glucuronide ingrats treated with 80mg/kg s.c., using HPLC with 
electrochemical detection. In the present study, it was 
rather surprising that M6G was undetectable (< 10% morphine 
levels) in the liver or kidney when measurable quantities had 
been found in the serum and brain of these animals. These 
findings reflect the problem of using differential RIA to 
quantitate low levels of M6G in the presence of large amounts 
of parent drug.
Following the administration of a Img/kg dose of M6G 
i.p. to rats, this compound was rapidly absorbed and 
distributed to serum and brain tissue at a similar rate to
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that observed for morphine, with peak levels occurring in 
both tissues at the first time point (5min). Similar patterns 
were also apparent for its elimination from these two tissues 
over the next 2 hours. These findings are in good agreement 
with the data obtained after i.v. administration of M3G to 
dogs (Garrett and Jackson, 1979). Rapid disappearance from 
serum has also been demonstrated following oral 
administration &or other glucuronidated compounds (Garton and 
Williams, 1949). M6G was found in all the tissues studied in 
higher amounts than morphine after i.p. administration. These 
contrasting results may be partly explained by differences in 
the metabolism of the two compounds, and may also reflect the 
fact that these doses were not prepared as solutions of free 
base. When concentrations in the serum and brain 
compartments were compared, M6G brain:serum ratios calculated 
following M6G administration were lower than the equivalent 
ratios for morphine found following morphine treatment. These 
ratios increased at a similar rate over the following 2 
hours. In their experiment, Yoshimura ^  al. (1973) reported 
a lower value for this ratio 45 minutes after M6G 
administration. Nevertheless, both studies arrived at the 
same conclusion, namely that substantially less M6G enters 
the brain from the systemic circulation, compared to 
morphine, reflecting the relative difficulties these two 
compounds experience in passing across the blood-brain 
barrier. These findings are likely to explain the differences 
experienced in the analgesic activities of the two compounds,
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* also due to differences in Vd for the two compounds»
following systemic and intracerebroventricular administration 
(Shimomura ât âi*/ 1971). However, the data in the present 
study indicated that M6G was taken up by, and eliminated 
from, the brain at similar rates to those observed for 
morphine itself. It was of interest to note that following 
M6G administration morphine was not detected in the serum and 
brain of these animals; this data is in agreement with that 
of Yoshimura et al. (1973) who observed that M6G penetrates 
the blood-brain barrier and does not undergo extensive 
deglucuronidation within the CNS.
As expected, M6G was also rapidly accumulated by the 
liver and kidney, the quantities being comparable to those 
found for morphine. M6G was abundant in both tissues over the 
entire study period, with peak levels occurring after 15 
minutes. The rapid surge to the liver, experienced after 
absorption of morphine, was not apparent after M6G 
administration, possibly reflecting a slower rate of 
absorption of M6G from the abdominal cavity.
It was rather surprising to find significant quantities 
of morphine present in the organs of excretion taken from the 
animals treated with M6G, in view of their apparent absence 
from the other tissues analysed. A study by Ida et §1. (1975) 
demonstrated the presence of M6G, morphine, M3G and 
normorphine in rat urine after s.c and i.v. administration of 
M6G, and suggested that the presence of these compounds was 
the result of M6G having been initially excreted in the bile. 
The hydrolysis of 0-glucuronides in vivo has been
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demonstrated (Kamata st âiw 1967) with the /3-glucuronidase 
activity located in the bladder. In view of the limited 
quantity of information available on this topic, the present 
findings remain unexplained.
Attempts were made during the course of this study to 
mimic chronic oral treatment in rats by administration of 
morphine or M6G in drinking water over a period of two weeks 
(Ko and Dai, 1989). However these efforts were not successful 
due to irregular consumption by the rats, and also proved to 
be rather expensive in terms of the quantity of metabolite 
required and were, therefore, not repeated. Similarly, the 
effects of repeated i.p. dosing with either morphine or M6G 
were also tentatively investigated. For this purpose, two 
groups of rats were dosed with either morphine or M6G once a 
day for five consecutive days as described by Nagamatsu st 
al. (1983). Morphine and M6G were not detected in the tissues 
collected from these animals (results not shown), but the 
effectiveness of this treatment is questionable.
The results obtained in this study have provided some 
useful information on the distribution and elimination of 
morphine and M6G in rats. When discussing these results, it 
is important to remember that the amount of drug that 
distributes to the tissues is dependent upon several 
unpredictable variables; one of the most important of these 
is the extent to which the circulating drug is bound to 
plasma protein, as only the free drug will be available to 
these tissues (Oldendorf et al., 1972).
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The outcome of the immunocytochemical studies was rather 
disappointing, and information on the localisation of these 
compounds within rat tissues was not obtained, despite 
attempts to improve the sensitivity of the method by varying 
the concentrations of the first and second antibodies used. 
It is possible that the sensitivity of this method may be 
improved by the use of a more easily detectable 
immunocytochemical label, such as silver enhanced immunogold 
(Holgate et al., 1983), which may also be viewed using
electron microscopy, or by the use of the biotin/streptavidin 
alkaline phosphatase system_.(Wilchek and Bayer, 1983). These 
possibilities require investigation with all available 
anti-morphine antisera in order to fully assess the exciting 
potential of this technique.
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CHAPTER EIGHT
STUDIES INTO THE DISTRIBUTION OF MORPHINE 
AND MORPHINE-6-GLUCURONIDE IN MAN
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8.1. GENERAL INTRODUCTION
The results obtained in Chapter Seven provide^ useful 
information on the tissue distribution of morphine and M6G in 
rats. These experiments were facilitated by the availability 
of RIAs suitable for the analysis of these matrices. However, 
extrapolation of data from animals to man is a process that 
is not without its problems, and it was the aim of the 
present study to obtain similar data in the clinical setting. 
For this purpose, a number of studies have been carried out 
involving the collection of a range of biological fluids from 
advanced cancer patients. These samples have been analysed 
for the presence of morphine and its metabolites by means of 
the RIAs specially validated for use with these tissues 
(Chapter Three).
8.2. DISTRIBUTION OF MORPHINE AND M0RPHINE-6-GLUCUR0NIDE INTO 
HUMAN CEREBROSPINAL FLUID
8.2.1. Introduction
The analgesic action of opioid drugs is considered to be 
a result of their binding to specific opioid receptors in the 
CNS. Recently it has been postulated that much of the 
activity of morphine may, in fact, be due to the analgesic 
action of one of its metabolites, M6G. For this to be the 
case, the passage of M6G into the CNS is obviously an 
essential prerequisite. The glucuronide metabolites of 
morphine are polar, water soluble compounds which would not
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be expected to pass readily across the blood-brain barrier. 
Nevertheless, the data presented and discussed in Chapter 
Seven has provided evidence that this passage does indeed 
take place following systemic administration of morphine and 
M6G in rats. Whilst direct examination of CNS tissue is not 
possible in man, cerebrospinal fluid (CSF), which is in 
intimate contact with the spinal cord and brain stem, can be
obtained. There is no appreciable barrier to aqueous
diffusion between CSF and the extracellular fluid of brain 
tissue, since the membrane lining the cerebral ventricles is 
permeable to hydrophilic substances of high molecular weight. 
Indeed, the concentration of drug in the brain tissues may be 
considerably higher than in CSF or plasma because of uptake 
into neuronal lipids, or binding to neuronal proteins.
In the study described in this section, four groups of 
patients were recruited and treated with either morphine or 
M6G as required. The initial experiment was designed to
investigate the presence of morphine, M3G and M6G in the CSF 
of patients receiving chronic oral morphine. Subsequent 
experiments were carried out to investigate the time course 
of CSF disposition of morphine and M6G, following the 
administration of i.v. or oral morphine, or i.v. M6G as
single doses to cancer patients. The numbers of patients 
recruited into these groups were small, and two different 
clinical centres were approached for collaboration in these 
trials. The limited number of patients available reflects the 
difficulties involved in obtaining CSF samples from advanced
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cancer patients.
8.2.2. Patients and Methods
The patients in Groups 1 and 3 were recruited at the 
Department of Radiotherapy and Oncology of the Royal Marsden 
Hospital and at the Institut Gustave Roussy, Villejuif 
respectively, and were under the care of Dr P.J. Hoskin, Dr. 
G.W. Hanks and Dr. P. Poulain.
The patients in Groups 2 and 4 were recruited at the 
Department of Medical Oncology at Homerton Hospital, and were 
under the care of Dr. P. Thompson and Dr. M. Slevin.
Drug administration and sample collection were carried 
out under the direction of the above named clinicians, and 
patients did not experience untoward effects from the 
treatment. In all the patients studied, CSF was obtained 
either at the time of diagnostic myelography or after the 
insertion of an indwelling intrathecal catheter. All patients 
gave written consent after a full explanation of the aims of 
the study, and approval was obtained from the local ethical 
committee at each centre.
CSF samples were collected into a plain plastic 
container and stored at -20“C prior to analysis. Care was 
taken not to contaminate these samples with blood on 
collection. At the same time, peripheral venous blood samples 
were collected into a plastic heparin tube and centrifuged at 
3500rpm for 10 minutes. The plasma was separated and stored 
at -20°C. Random samples of plasma and CSF were obtained at
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the time of lumbar puncture from the patients in Group 1. 
Serial paired plasma and CSF samples were obtained from each 
patient in Groups 2-4 over a 12 hour period following drug 
administration. These patients were all opiate-naive before 
the start of the trial.
Samples from all patients were analysed for morphine and 
M6G by RIA. Samples obtained from the patients in Group 1 
were also analysed for the presence of M3G using differential 
RIA.
GROUP 1: Six cancer patients who were receiving chronic oral 
therapy (between 40-260mg/24hr) with morphine or diamorphine. 
GROUP 2: Three cancer patients were treated with a 5mg/70kg
dose of morphine, administered as an i.v. bolus injection. 
GROUP 3; Two cancer patients were given 20mg aqueous morphine 
sulphate by mouth.
GROUP 4: Three advanced cancer patients were given a 2mg/7 0kg 
dose of M6G intravenously as a single bolus injection.
The details of all the patients recruited are summarised 
in Table 8.1.
8.2.3. Results
The patients in Group 1 had been taking the same dose of 
oral opioid for at least 8 days, and these results, 
therefore, represent steady-state concentrations in chronic 
use. One patient was treated with oral diamorphine, but this 
would be expected to be rapidly deacetylated to morphine.
page 259
Table 8.1.
Patient Details - CSF Pharmacokinetic studies.
Patient S ex Drua/ Dose Duration of
I.D. route present dose
la 63 F Oral M 100mg/24hr 8 days
Ib 58 M Oral M 260mg/24hr 6 months
le 26 F Oral M 20mg/24hr 3 months
Id 52 F Oral M 300mg/24hr 8 days
le 67 F Oral DM 60mg/24hr 6 months
If 71 M Oral M 40mg/24hr 4 weeks
2a 34 F IV M 6. 3mg -
2b 37 M IV M 5. 8mg -
2c ? F IV M 5.0mg/7 0kg -
3a 51 F Oral M 20mg -
3b 45 M Oral M 20mg -
4a 42 F IV M6G 1. 7mg -
4b 27 F IV M6G 2. Omg -
4c 34 F IV M6G 2. 2mg -
M = Morphine
DM = Diamorphine
M6G = Morphine-6-glucuronide
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These results are therefore comparable to those in patients 
receiving morphine. The mean molar ratios of morphine:M3G;M6G 
in these tissues are shown in Table 8.2(a), and the mean 
molar ratios for CSF;plasma for all three compounds are 
included in Table 8.2(b). Considerable inter-individual 
variation was evident, particularly in the levels of these 
compounds in the CSF. Unfortunately, insufficient CSF sample 
was available from patient la to allow repeat morphine 
analysis; the values quoted for the metabolites represent 
levels of [metabolite + morphine] and have not been included 
in the calculation of the means.
Plasma/CSF profiles for morphine following i.v. morphine 
administration to patients in Group 2 are plotted 
semi-logarithmically in Fig.8.1, and the mean pharmacokinetic 
data is summarised in Table 8.3. Wide inter-individual 
variation was apparent in the CSF results, particularly at 
the earlier time points. As expected, levels of morphine 
peaked in the plasma at the first time point and then rapidly 
declined over the next 6 hours in a bi-exponential manner 
with a mean terminal half-life of 1.5 hours. In the CSF, low 
levels of morphine were detectable in the first sample 
collected from each patient.
The average time required to achieve mean peak morphine 
concentrations in the CSF was 2.8 hours, and after this time 
the levels declined with a mean terminal half-life of 3.3 
hours. However, this terminal half-life was not significantly 
longer than that observed in plasma (p=0.1; paired Student's
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Table 8.2.
Plasma and CSF morphine ;metabolite molar ratios following 
chronic oral dosing (Group
Patient I .D. M3G M6G Morphine
laPlasma 49.6 7.2 1CSF No data No data No data
lbPlasma 21.8 6.4 1CSF 3.8 0.9 1
IcPlasma 56 6.5 1CSF 2.2 0 . 6 1
IdPlasma 6.3 0.9 1CSF 9.5 1.3 1
lePlasma 9.5 1.6 1CSF 15.2 0.7 1
IfPlasma 33.1 8.0 1CSF 15.9 2.2 1
Plasma 29.4 5.1 1(n = 6) (8.4) (1.2)
CSF 9.3 1.1 1(n = 5) (2.8) (0.3)
mean (± SEM)
(h) CSF ; Plasma molar ratios fGrouo IK
Patient X.D. M3G M6G Mornhine
la 0.16 0.13 No datalb 0.10 0.36 2.44Ic 0.31 0.13 2.71Id 0.82 0.95 0.59le 0.15 0.20 0.13If 0.48 0.83 1.74
mean 0.34 0.43 1.52(± SEM) (0.11) (0.15) (0.50)
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(a) Patient 2a (b) Patient 2b
Morphine] nmol/l1000
100
0.10 6 8 102 A 12 14
Time (hours) 
Plasma CSP
Morphine] nmol/l1000
100
0.10 2 6 84 10 12 14
Time (hours) 
Plasma CSF
(c) Patient 2c (c) Mean data
Morphine] nmol/l1000 F
100
0.10 6 82 104 12 14
Time (hours) 
Plasma CSF
Morphine] nmoi/i1000
100
0.10 1 2 8 4 6 6 7
Time (hours)
Plasma —^  CSF
Fig.8.1. Plasma/CSF morphine profiles followingadministration of a single dose of 5mg/70kg morphine i.v, to patients, (a) Patient la, (b) Patient lb, (c) Patient Ic, (d) mean data (n=3).
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Table 8.3.
Plasma/CSF pharmacokinetic data following administration of
Patient Cmax Tmax T 1/2 AUC fO-oo)I.D. (nmol/l) (hr) (hr) (nmol/I/hr)
PATIENT 2a
PLASMAMorphineM6G
219 .7 62.0
0.08 1.0 1.34
149.7244.2
CSFMorphineM6G 13.6 1.0 None detected 3.47
88.9
PATIENT 2b
PLASMAMorphineM6G 148.5 65 .9 0.080.75 1.59 97.2226.9
CSFMorphineM6G 14.6 3.5 None detected 4.30 107.5
PATIENT 2c
PLASMAMorphineM6G 123.053.4 0.081.5 1.71 81.4198.8
CSFMorphineM6G 8.37 4.0 None detected 2.01 107.7
PLASMAMorphine 163.7(28.9) 0.08 1.55(0.11) 109.4(20,6)
M6G
CSFMorphine
60.4(3.69)
12.2(1.93)
1.08
(0.22)
2.83(0.93) 3.26(0.67)
223.2(13.2)
101.4(6.23)
M6G None detected
mean (± SEM); n = 3
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t-test). A mean CSF:plasma ratio for morphine AUC (O-oo) of 
0.9:1 was found. Significant levels of plasma M6G were formed 
after i.v. morphine dosing, and comparison of AUC (0-co) for 
morphine and M6G revealed a mean molar ratio (M6G;morphine) 
of 2.0:1. M6G was detectable in the plasma of all three 
patients after 10 minutes with mean peak levels occurring 
after about 1 hour, after which time the levels steadily 
declined (Fig.8.2). Following this route of administration, 
M6G was not detected in the CSF of these patients.
Following the administration of single doses of 20mg 
oral morphine, a wide variation in CSF morphine and M6G 
levels was found between the two patients studied (Group 3). 
Mean plasma/CSF profiles for both morphine and M6G following 
this treatment are shown in Figs.8.3 and 8.4, and the 
pharmacokinetic data is listed in Table 8,4. Peak plasma 
concentrations of morphine and M6G were achieved in both
patients after 1 hour and 2 hour respectively. Low levels of
both compounds were detectable in the CSF of patient 1 after 
30 minutes, and after 1 hour in patient 2. Peak CSF 
concentrations of morphine and M6G were reached much later
(4 and 6 hours in patient 3a; 8 hours in patient 3b).
Comparison of the AUC (0-12hr) gave ratios of 
morphine:M6G in plasma of 1:9 and 1:11 in patients 1 and 2 
respectively. These ratios were substantially lower in the 
CSF (1:6 in patient 1 and 1:2 in patient 2). CSF:plasma 
ratios for morphine and M6G were found to be 0.7 and 0.4 in 
patient 1, and 0.5 and 0.1 in patient 2.
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[M6G] nmol/l70
60
60 No M6G detected in CSF 
of these patients
40
30
20
10
0 2 4 6 8 10 12 14
Time (hours)
Fig.8.2. Plasma levels of M6G following administration of a single dose of 5mg/7 0kg morphine i.v. to patients. All points on graph are group mean ± SEM, n=3.
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(a) Patient 3a (b) Patient 3b
!MorphineI nmol/l100
0.1 106 8 12 140 2 4
Time (hours) 
Plasma — CSF
Morphine] nmol/l100
0.1 6 8 12 140 102 4
Time (hours)
Plasma CSF
(c) Mean data
60
40
20
8 100 6 12 142 4
Time (hours)
Plasma —^  CSF
F i g .8.3. Plasma/CSF morphine profiles following administration of a single dose of 2 0mg oral morphine to patients, (a) Patient 3a, (b)Patient 3b, (c) mean data (n=2).
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(a) Patient 3a (b) Patient 3b
M6Q] nmol/l1000
100
1080 84 12 142
M6G1 nmol/l1000
100
0.10 6 8 102 4 12 14
Time (hours) Time (hours)
Plasma CSF Plasma — CSF
(c) Mean data
!M6Q1 nmol/l800
260
200
160
100
60
0 6 8 102 4 12 14
Fig.8.4. Plasma/CSF M6G profilesfollowing administration of a single dose of 20mg oral morphine topatients, (a) Patient 3a, (b)Patient 3b, (c) mean data (n=2).
Time (hours)
Plasma CSF
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Table 8.4.
Plasma/CSF pharmacokinetics following single doses of 20mg
oral morphine (GrouD 3)
Cmax Tmax AUC fO-12hr)(nmol/l) (hr) fnmol/l/hr)
PATIENT 3a
PLASMAMorphine 60.0 1.0 127.6M6G 248.7 2.0 1157.9
CSFMorphine 12.4 4.0 84.5M6G 63.3 6.0 509 .5
PATIENT 3b
PLASMAMorphine 47.0 - 1.0 119.7M6G 305.0 2.0 1339
CSFMorphine 5.2 8.0 63.6M6G 18.9 8.0 151.7
PLASMAMorphine 53.5 1.0 123.6(6.5) (3.9)M6G 276 . 8 2.0 1248.4(28.1) (90.5)
CSFMorphine 8.8 6.0 74.2(3.6) (2.0) (10.2)M6G 41.2 7.0 330.6(22.3) (1.0) (178.9)
mean (± SEM); n = 2
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Mean M6G plasma/CSF profiles for patients in Group 4, 
who received a single dose of 2mg/70kg of M6G as an i.v. 
bolus, are shown in Fig.8.5. The kinetic data is summarised 
in Table 8.5. After dosing, peak plasma levels were apparent 
in all three patients by 10 min, after which time they 
rapidly declined. This disappearance was composed of two 
exponential components with a mean terminal half-life of 1.9 
hours, M6G was detectable in the CSF from all patients at the 
first time points, and average peak levels were achieved 
after 2.5 hours. These levels declined with a mean terminal 
half-life of 4.5 hours, which was not significantly longer 
than that observed in plasma (1.9hr) (p=0.06; paired
Student's t-test). CSF:plasma ratios were calculated for each 
patient by comparison of AUCs ( O - o o ) ,  and the mean value (± 
SEM) was 0.1 (± 0.03):1. Morphine was not detected in plasma 
or CSF from all patients in this group.
8.2.4. Discussion
By confirming the presence of significant quantities of 
morphine and M6G in the CNS after systemic administration of 
morphine and M6G in humans, the data obtained in the present 
study complements the results obtained in rats.
Considerable individual variation, in patients receiving 
oral morphine in chronic doses, was seen in the 
concentrations of morphine, M3G and M6G, particularly in the 
CSF. In two patients, CSF morphine levels were substantially 
lower than plasma. In three other patients they were much
page 270
(a) Patient 4a (b) Patient 4b
!M6Ql nmol/l1000
100
10
0 6 1082 4 12 14
Time (hours) 
Plasma —^  CSF
!M6Gl nmol/l1000
100
0.10 6 82 4 10 12 14
Time (hours)
Plasma CSF
(c) Patient 4c (c) Mean data
!M6Q1 nmol/l1000
100
0 2 8 8 104 12 14
Time (hours) 
Plasma — CSF
M6GI nmol/l)1000
100
0 2 6 84 10 12 14
Time (hours)
Plasma —^  CSF
Fig.8.5. Plasma/CSF M6G profiles following administration of a single dose of 2mg/70kg M6G i.v. to patients, (a) Patient 4a, (b) Patient 4b, (c) Patient 4c, (d) mean data (n~3).
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Table 8.5.
sinale doses of 2ma/70ko• M6G intravenously fGrouD 4)
Patient Cmax Tmax T 1/2 AUC ( O - o o )I.D. (nmo1/1) .(hrj. -Chrj. (nmol/I/hr)
PATIENT 4a
PLASMAM6G 520.0 0.8 1.78 550.1
CSFM6G 4.3 2.5 4.55 40.9
PATIENT 4b
PLASMAM6G 599.0 0.08 2.30 548.0
CSFM6G 8.2 3.0 3.63 46.3
PATIENT 4c
PLASMAM6G 729 .5 0.17 1.64 937.2
CSFM6G 24.5 2.0 5.34 170.0
PLASMAM6G
CSFM6G
616.2(61.1)
12.3(6.19)
0.11(0.03)
2.5(0.29)
1.91(0.20)
4.51(0.49)
678.4(129.4)
85.7(42.2)
mean (± SEM); n = 3
N.B. NO MORPHINE DETECTED IN ANY SAMPLES
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higher. This is a reflection of the variations in dose and, 
perhaps, time of sampling, as well as individual differences 
in morphine handling. For the two glucuronides, CSF 
concentrations V&re in all cases lower than the corresponding 
plasma concentrations, which is in keeping with their more 
polar characteristics. Again, wide individual variation 
between patients apparent. High CSF;plasma ratios for
morphine do not necessarily seem to correlate with similarly 
high ratios for the glucuronides, but greater concordance is 
seen in the ratios for M3G and M6G. This may indicate 
different transport mechanisms for morphine compared to its 
metabolites. In other studies carried out in cancer patients 
receiving chronic oral morphine, CSF M3G levels were reported 
to be approximately 7.5% of plasma M3G (Sawe, 1986); similar 
data has been reported more recently for CSF M6G levels 
(Hasselstrom st âi•a 1989). In their study, Venn ^  al. 
(1989) reported even lower CSF concentrations after chronic 
oral morphine, with levels of the glucuronides found to be 
100-2 00 times lower than the corresponding plasma 
concentrations, although details on the dose administered or 
the sample collection times we.r</ not provided. These figures 
are all considerably lower than the values obtained for M3G 
and M6G in the present study (34% and 43% respectively), 
these discrepancies probably being due to differences in 
dose, sampling time, and assay methodologies. Th^ data also 
indicates that M6G is more available to the CSF than M3G, 
which is in agreement with the recent findings of Bigler et
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al. (1990). This is likely to be due to the slight polarity 
differences between these two compounds.
The ratios calculated for morphine:M3G;M6G in the plasma 
and CSF are consistent. A mean plasma ratio of 1:29:5 is 
similar to data from another study, in which patients were 
receiving chronic oral morphine (Poulain ei âl*/ 1988). The 
morphine:M6G ratio was surprisingly lower than that found 
after single oral dosing in volunteers reported in Chapter 
Five. Significantly lower concentrations of metabolites were 
found in the CSF, the mean ratio being 1:9:1 for 
morphine:M3G:M6G, reflecting the poor entry of the two 
metabolites into the CSF.
In general, the plasma pharmacokinetic data observed 
following i.v. or oral administration of single doses of 
morphine to cancer patients (Groups 2 and 3) was comparable 
to the data obtained in healthy volunteers (Chapter Five), 
although higher ratios for M6G:morphine were obtained in the 
present studies. Following both treatments, morphine was 
rapidly detected in the CSF, although maximal levels were not 
achieved until 2.5 hours after i.v. dosing and 6 hours after 
oral dosing. Mean morphine levels in the CSF exceeded those 
in the plasma, 2 hours after i.v. dosing and 4 hours after 
oral dosing. After i.v. dosing, the average terminal 
half-life of elimination from the CSF compartment (3.3hr) 
was not significantly longer than that observed from plasma 
(1.5hr) (p=0. 1; paired Student's t-test), and there was 
considerable inter-individual variation in CSF kinetics.
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similar findings for elimination kinetics have been observed 
in other experiments using animal models (Finck et , 1977; 
Nishitateno et al., 1979; Todd et al., 1982), and comparable 
patterns were observed in the experiments carried out in rats 
in Chapter Seven. In their study, Nordberg êi âl» (1985) 
found a mean CSF:plasma morphine ratio of 0.9:1 in surgical 
patients receiving i.m. dosing. This figure is similar to 
that obtained after i.v. dosing in the present study, but 
higher than that found after oral dosing. They also observed 
that CSF concentrations rarely exceeded the corresponding 
plasma levels over a 6 hour period, and, therefore, concluded 
that elimination from these two compartments took place at 
similar rates over this time period. The same group had 
previously found a mean terminal elimination half-life from 
CSF of approximately 3 hours over a 20 hour period after 
intrathecal morphine (Nordberg âi*/ 1984), which was
slightly longer than that found recently in similar studies 
by lonescu &1. (1988) (2.3 hours over a 24 hour period) 
and Bigler ei al., (1990) (2.1 hour over a 5 hour period). 
The CSF half-life reported in the present study is within the 
wide range found after intrathecal morphine by Moore et al. 
(1984c), and is more in keeping with that described by Hanna 
et al. (19 90) (3.7 hours over a 24 hour period).
Following the administration of i.v. morphine, M6G was 
not detected (i.e. < 10% morphine levels) in the CSF, whereas 
significant concentrations were observed after oral dosing, 
with a ratio of morphine:M6G AUCs (0-12hr) of 1:4.4. Peak
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levels of M6G were achieved in the CSF after a mean Tmax that 
was slightly longer than that observed for morphine. 
CSF:plasma M6G ratios were substantially lower than those 
calculated for morphine.
After acute oral administration of morphine, CSF:plasma 
ratios for morphine and M6G were in keeping with the 
brain:serum ratios in rats, but the figure for morphine was 
lower than that calculated after i.v. dosing. Terminal 
elimination half-lives were not calculated after this route 
of administration. However, the elimination phase curves from 
the plasma and CSF compartments are seen to intersect rather 
than decline in parallel, indicating a slightly longer 
residence of morphine and M6G in the CSF compartment, 
although these differences are unlikely to be significant.
After single doses of oral morphine to post-operative 
patients. Hand et al. (1987b) found the ratio of mean values 
for morphine:M3G:M6G in the CSF to be 1:1.1:0.2. However, in 
their study single sample estimations were made 9 0 minutes 
after one oral dose. These results are, therefore, difficult 
to interpret and are not directly comparable with the results 
of the present study. From their data they suggested that M6G 
may account for 85% of the analgesic activity of morphine, 
based on the relative intracerebroventricular potencies found 
in rats (Shimomura et al., 1971). When a similar calculation 
is performed using the data from the present study, an even 
greater analgesic contribution by M6G is derived, with M6G 
accounting for over 99% of the total analgesic activity. This
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calculation is, however, based on a number of assumptions 
which may be erroneous; such as the relative potency between 
morphine and M6G is the same in man as that derived by 
experimental pain methods in a single study in rats, and CSF 
concentrations are an accurate predictor of quantities of 
drug actually binding to opioid receptors in the CNS.
From the data obtained in these single dose studies with 
morphine, it would seem possible that the quantity of M6G 
entering the CSF is more dependant on the relative amounts of 
M6G and morphine in the plasma, rather than on plasma 
concentrations of M6G alone.-This is likely to be the case if 
the two compounds are competing for the same transport system 
across the blood-brain barrier. This theory may also help to 
explain why comparatively less morphine enters the CSF from 
the plasma after oral dosing than after i.v. dosing. However, 
this theory suggests a different transport mechanism to that 
proposed earlier, based on the CSF:plasma ratio data obtained 
after chronic oral dosing (Group 1). Further investigation of 
this topic is required.
Following the administration of single i.v. doses of M6G 
to patients in Group 4, similar plasma pharmacokinetic 
profiles to those described for the patients in Chapter Six 
were observed. As in this earlier study, morphine was not 
detected in any of the samples analysed. M6G quickly entered 
the CSF and similar Tmax values to those found for morphine 
in the patients receiving i.v. morphine were observed (Group 
2). The elimination patterns of morphine and M6G from the
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plasma and CSF compartments were also comparable. M6G 
disappeared from the CSF at a slightly slower rate than 
morphine, but these differences were not significant (p=0.2; 
unpaired Student's t-test). Previous studies have shown that 
opioids with low lipophilicity tend to persist in CSF 
(Sjostrom et al., 1987a; 1987b). Furthermore, an inverse
correlation between potency and lipophilicity has been
demonstrated for opioids applied directly to rat spinal cord 
(McQuay &1., 1989; Sullivan si. al., 1989). However, the
vast differences in terminal half-lives for morphine and M6G 
reported by Hanna and colleagues (1990) following intrathecal 
administration were not observed. Similar patterns were 
observed in rat brain tissues in Chapter Seven.
It was of interest to note the absence of significant 
quantities of morphine or M6G in the CSF following i.v.
administration of these compounds. Low levels of M6G have 
been detected in the brains of rats treated with i.p.
morphine (Chapter Seven) and intracerebroventricular morphine 
(Hanks and Wand, 1989), In addition, endogenous morphine has 
been detected in fentomolar quantities in human CSF (mainly 
in its conjugated form) by Cardinale ^  al» (1987), and 
glucuronidation of morphine has recently been demonstrated in 
post-mortem brain tissue (Wahlstrom et âl*a 1988), although 
the rate at which this occurred was very low compared to that 
in the liver. The findings in this study imply that there is 
no interference from endogenous morphine or M6G, and 
significant metabolism within the brain tissue does not
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occur. Thus, the metabolite concentrations observed in the 
CSF following oral dosing most probably reflect hepatic 
biotransformation of free morphine in the plasma.
In conclusion, these studies have demonstrated the 
presence of significant quantities of morphine and M6G in the 
CSF of patients receiving chronic or acutedoses of morphine, 
as well as the passage of M6G across the blood-&Sf^ barrier 
following its parenteral administration. In all the patients 
studied, peak concentrations of these compounds were achieved 
several hours after dosing, and disappeared from the CSF at a 
slower rate than from plasma,, with M6G taking slightly longer 
to egress than morphine. However, vast differences in the 
terminal elimination half-lives of morphine and M6G, giving 
rise to significant M6G accumulation within the CSF, were not 
apparent. These findings are supported by the fact that 
higher relative concentrations of metabolite were not found 
in the patients receiving chronic oral morphine therapy 
compared to those who were administered a single dose. These 
findings have important implications when considering the 
relative toxicities of morphine and M6G. It would appear that 
single oral doses are relatively ineffective because of the 
poor bioavailability for unconjugated morphine and the delay 
in achieving adequate concentrations of morphine and M6G 
within the CNS. In addition, the wide inter-individual dose 
requirements experienced probably reflect variations in the 
kinetics of morphine and its metabolites observed in the 
present study.
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The analgesic activity of M6G has been demonstrated 
directly in cancer patients (Osborne et , 19 88).
Intrathecal M6G has been shown to be 13-fold more potent than 
intrathecal morphine in the rat (Sullivan e^ âiw 1989), and 
also has greater analgesic activity in man (Hanna ^  al., 
1990). On the basis of this data, and that obtained in the 
present study, it seems likely that M6G makes a significant 
contribution to the analgesic efficacy and duration of action 
of morphine itself. However, the extent to which M6G 
contributes to the increased potency of repeated doses of 
oral morphine remains undetermined.
The data obtained in this section has formed the basis 
of two recent publications (Hoskin et al., 1989b; Poulain et 
al. , 1990; see Appendix III).
8.3. STUDIES INVESTIGATING ENTEROHEPATIC CIRCULATION OF 
MORPHINE IN MAN
8.3.1. Introduction
A large number of drugs are inactivated by glucuronide 
or sulphate conjugation in the liver; these conjugates may be 
excreted in the bile and hence into the gastrointestinal 
tract. Hydrolysis of conjugates may subsequently occur, due 
to the action of bacterial enzymes derived from the gut flora 
in the small or large bowels, and the liberated free drug may 
be reabsorbed. This process is believed to contribute to the 
therapeutic effect of some drugs.
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The first published evidence for the existence of an 
enterohepatic circulation cycle for morphine was provided by 
Walsh and Lavine (1975). In their experiments, biliary 
excretion was shown to account for approximately half of a 
subcutaneously administered dose of morphine in rats, with 
predominantly morphine glucuronide being excreted into the 
duodenum. In the same study, extensive enterohepatic 
circulation, involving deglucuronidation and reabsorption of 
free morphine in the large bowel, was also demonstrated. In a 
later experiment investigating the first-pass effect of 
morphine in rats, Iwamoto . and Klaassen (1977) found a 
secondary morphine peak in plasma 4 hours after the initial 
peak had been seen after oral administration, and proposed 
that this was due to enterohepatic circulation. Evidence for 
the existence of this cycle for morphine after both oral and 
i.v. dosing has been provided by the work of Dahlstrdm and 
Paalzow (1978) in rats, and of Garrett and Jackson (1979) and 
Jacqz and colleagues (1986) in dogs. Similar secondary 
morphine peaks have been observed in human volunteers (Leslie 
et âiw 1980), and in cancer patients treated with a 
controlled-release preparation of morphine and an oral 
morphine solution (Poulain et al., 1988). It has been 
suggested that such peaks are due to enterohepatic 
circulation of morphine occurring in man which is likely to 
be of importance in maintaining plasma levels during chronic 
oral administration (Hanks sJl , 1987). However, delayed
peaks were not apparent in the volunteers treated with
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morphine in Chapter Five, or in the study reported by 
Osborne and colleagues (1990), although the detection of 
these peaks can depend on the exact timing of the samples 
collected.
Direct evidence for the biliary excretion of morphine 
and its metabolites in man is limited. Since the presence of 
an enterohepatic circulation for morphine and its active 
metabolites would be of importance, particularly when 
considering its duration of action during chronic oral 
dosing, this study was designed to examine the extent to 
which morphine and morphine.glucuronides are excreted in the 
bile.
The small number of patients recruited into this study 
reflects the difficulties involved in finding cancer patients 
in whom the biliary system is readily accessible, and from 
whom samples can be obtained with minimum disruption.
8.3.2. Patients and Methods
Patients were undergoing treatment at the Royal Marsden 
Hospital, and were under the care of Dr. P. Hoskin and Dr. 
G.W. Hanks. Two of these patients had been on oral morphine 
for several months and a third had received repeated doses of 
subcutaneous diamorphine. Bile samples were obtained from all 
three patients, and a random steady-state plasma sample was 
also taken from two patients at the time of bile sampling. In 
the same two patients it was also possible to measure the 
total 24 hour volume of bile produced. The details of these
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patients are summarised in Table 8.6. Plasma and bile samples 
were analysed for the presence of morphine, M3G and M6G using 
differential RIA.
Table 8.6.
Bile study - patient details
Patient Age 
I.D.
48
32
68
Sex Source 
of bile
M T-tube
F Gastrostomy
F Post mortem
Morphine Route 
dose
(mg/24hrs)
140 Oral
570 Oral
192 S.C.*
* Patient 3 received diamorphine.
8.3.3. Results
The concentrations of morphine, M3G and M6G in the 
samples collected from all three patients are shown in Table 
8.7. The total 24 hour biliary excretion of these three 
compounds was calculated, together with the bile:plasma 
ratios in the two patients for whom this was possible; these 
results are also included.
8.3.4. Discussion
Significant quantities of morphine and its two major 
metabolites were detected in bile from patients receiving 
chronic oral dosing with morphine (or diamorphine).
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Table 8.7.
( a ) uoncenr.2 from cancer
:auion or patients
morpnine, riJVr aiiu rn on repeated doses of oral
uj-j.e aiiumorphine.
Patient Sample Morphine M3G M6GI.D. {pmol/1) (pmo1/1) (pmol/1)
1 Bile 0.35 1.70 0.35Plasma 0.17 3.03 0.30
2 Bile 5.71 27.7 29.5Plasma 1.16 20.5 5.43
3 Bile 9 . 67 1.33 3.86Plasma No sample available
Patient Sample Morphine M3G M6GI.D.
1 Bile 1 4.9 1.0Plasma 1 18.0 1.8
2 Bile 1 4.9 0.5Plasma 1 17.6 4.7
3 Bile 1 0.14 0.40Plasma No sample obtained
(c) 24 hour Biliary excretion of morphine and its metabolites 
Patient 24hr bile Biliary excretion (umol/24hr) *I.D. vol. (ml) Morphine M3G M6G
1 200 70.0 340.1 69.52 1700 9705 47155 50233 24hr volume not available
* assuming stable bile concentrations
(d) Bile/Plasma ratios for morphine and its metabolites 
Patient I.D. Morphine Bile:Plasma ratio M3G
2.1 0.64.9 1.3No plasma sample available
M6G
1.20.5
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In the two patients from whom plasma samples were also 
obtained, relative amounts of morphine and its metabolites 
were remarkably consistent, although the ratios in plasma 
were lower than those found in a group of patients receiving 
similar treatment recruited in an earlier study (Section 
8.2). Morphine was present in the bile in greater amounts 
than its metabolites, and the absolute values for morphine 
concentration in bile vtJOjre also considerably higher than in 
plasma.
The levels in the bile from patient 3 do not follow the 
same pattern as the results from the other two patients, with 
lower metabolite levels and higher morphine levels (assuming 
some relation between dose and bile concentration exists). 
These discrepancies could be explained by the fact that this 
was a post-mortem sample taken approximately 18 hours after 
death, during which time deglucuronidation of the two 
metabolites may have taken place. Data on the stability of 
M3G and M6G at mortuary temperature is unavailable, although 
they appear to be stable in plasma at -20“C (Joel S.P., 
personal communication).
In the two patients in whom 24 hour biliary volumes were 
measured, the actual amounts of morphine and metabolites 
excreted over this period have been calculated, assuming a 
stable concentration in bile. When this data is converted 
into mass units, the presence of 225jug total morphine 
equivalents is seen in patient 1 and 2 8.9mg in patient 2 over 
24 hours. These figures represent 0.16% and 5.4% of the doses
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administered to patients 1 and 2 respectively. The kinetics 
of morphine and morphine glucuronides in bile are unknown, 
and these levels were measured in single samples rather than 
in aliquots from a pooled collection. This needs to be taken 
into consideration when interpreting the data, and the 
derived 24 hour excretions may be misleading.
In conclusion, this study has demonstrated that bile is 
a definite excretory route for morphine, M3G and M6G. Once in 
the duodenum, deglucuronidation by bacterial /3-glucuronidases 
and reabsorption of free morphine is to be expected; this 
data is, therefore, highly suggestive of an active 
enterohepatic circulation for morphine and its two major 
metabolites. However, the levels excreted are very low when 
compared to the dose administered, and the contribution that 
this process makes to prolonging the activity of a given dose 
of morphine is difficult to interpret. Previous suggestions 
that this process may significantly contribute to the 
increased relative potency of repeated-dose oral morphine 
(Hanks âi.» a 1987), and the prolonged and enhanced effect 
of morphine in patients with renal failure (Sawe, 1986), have 
been revised in the light of recent data on M6G (Hanks and 
Wand, 1989), In a study investigating the pharmacokinetics of 
morphine, M3G and M6G in normal volunteers, Osborne and 
coworkers (1990) observed a prolonged terminal elimination 
half-life for the glucuronides in some subjects. They 
proposed that, among other possible explanations, 
enterohepatic recirculation may contribute to these findings,
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and that, once the free morphine has been reabsorbed, it is 
metabolised so rapidly that it does not manifest itself as a 
secondary rise in morphine levels, but instead results in 
continued low level production of the metabolites. In another 
study, enterohepatic recirculation of morphine is implicated 
in the prolonged elimination half-life of morphine apparent 
in a patient with renal failure (Hasselstrom et al., 1989). 
On the basis of these findings, the data obtained in the 
present study has important clinical implications when 
considering the distribution of morphine, particularly in 
chronic use, and also suggests a potential adverse effect of 
antibiotics on the analgesic action of morphine, which 
warrants further investigation.
The data obtained in this study has formed the basis of 
a recent publication (Hanks et al., 1988; see Appendix III).
8.4. PLASMA PROTEIN BINDING OF MORPHINE AND MORPHINE- 
6-GLUCURONIDE
8.4.1. Introduction
Most drugs are carried in extracellular compartments, 
such as subcutaneous tissues, various organs, and blood, 
bound to macro-molecules, particularly plasma proteins. 
Binding to plasma proteins affects drug distribution and 
elimination, as well as the pharmacologic effects of the 
drug. The high molecular weight of the binding proteins 
restricts their passage across capillaries, and low lipid
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solubility prevents passage across cell membranes. Drugs 
bound to plasma proteins are, therefore, similarly 
restricted. Knowledge of a compound's protein binding
properties is also of use in the development of immunoassays 
for its measur^pent in plasma' as inaccuracy may occur in the 
unlikely event that the antiserum available has a similar 
binding affinity to that of the plasma proteins.
Of the plasma proteins, albumin, which comprises 50% of 
the total, binds the widest range of drugs, including
morphine and its surrogates. The most widely quoted estimate 
for percentage plasma protein binding of morphine in normal 
human plasma is between 34% and 37.5%, reported by Olsen 
(1975). A similar figure has also been reported in dog plasma 
by Garrett and Jackson (1979). In the same study, protein
binding of 14C-M3G was not demonstrated. However, no such
data is available for M6G, and it was the aim of this study 
to compare the extent to which morphine and M6G are bound to 
plasma proteins.
8.4.2. Methods
The extent to which morphine and M6G were bound to 
protein in the plasma was determined by the method of 
equilibrium dialysis (Horowitz and Barnes, 1983), Each small 
dialysis cell was composed of two compartments separated by a 
dialysis membrane. Plasma samples (1ml) were placed in one 
compartment, and the second compartment contained the same 
volume of assay buffer (pH 7.4). For each experiment, six
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cells were assembled: cells 1 and 2 contained pooled patient 
samples known to contain low and high levels of morphine 
respectively. Similarly, cells 3 and 4 contained pooled 
patient samples known to contain low and high levels of M6G; 
these pools had been prepared by mixing samples from patients 
that had been treated with i.v. M6G alone, and in which 
morphine 'Ka<^ not^detected. The passage of these two compounds 
through the dialysis membrane under the conditions used was 
assessed by inclusion of cells 5 and 6, which contained 1ml 
aliquots of assay buffer spiked with known quantities of 
[ 3H ]-morphine or [125I]-M6.G respectively. Samples were 
assayed in duplicate for morphine and M6G, before and 8 hours 
after dialysis with gentle agitation at ambient temperature. 
The time period allowed for dialysis had been pre-determined 
on the basis of that required to achieve complete 
equilibration. At the same time, duplicate aliquots from each 
buffer compartment were assayed to determine the amount of 
free drug that had dialysed through the membrane, bearing in 
mind that the free drug is expected to be at equilibrium 
between the two compartments.
8.4.3. Results
The results of these experiments are shown in Table 8.8. 
Equilibration of free radiolabelled morphine or M6G across 
the membrane was complete, as indicated by the results for 
cells 5 and 6. Up to 16% of morphine and 2.4% of M6G were 
bound to plasma proteins under these conditions. Comparison
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Table 8.8.
Plasma protein binding data for morphine and M6G
Sample Morphine/M6G cone.fnmol/1^
BufferBefore Plasma dialysis cell
Morphine 19.2 11.3patient pool (0.82) (0.44)(Low)
Morphine 754.0 445.8patient pool (70.0) (22.9)(High)
Buffer +
cell
8.72(0.45)
322.0(8.05)
35795.2 18247.2 18483.8[3H]-Morphine (5083.7) (2455.1) (2080.7)
(dpm)
%Bound %Free
12.9
16.1
87.1
83.9
M6G
patient pool (Low)
M6G
patient pool (High)
Buffer +[125IJ-M6G(cpm)
114.6(10.5)
461.7(44.1)
22929.8(2998.7)
56,6(4.79)
228.3(19.9)
10699.3(1663.1)
54.7 
(5.55)
217.7 (20.2 )
11162.8(2156.3)
1.71
2.38
98.3
97.6
mean ± (SEM); n = 3
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of the concentrations measured before dialysis, and in the 
two compartments after dialysis, indicates that these results 
were not due to low recoveries of morphine or M6G by the RIA, 
and that these assays do indeed measure total (free+bound) 
compound in the plasma.
8.4.4. Discussion
The extent to which morphine was found to bind to plasma 
proteins was lower than that reported previously (Olsen, 
1975). Olsen (1975) observed that binding was independent of 
drug concentration; a slight-increase in binding was apparent 
over a similar range of increasing concentrations in the 
present study. Conditions, such as buffer pH and period of 
dialysis, were similar in both these studies, although Olsen 
(1975) dialysed at a higher temperature. The present data is 
in agreement with the figure of 14% derived in dog plasma by 
Hug et (1981), who were unable to offer any explanation
for these apparent discrepancies. In another study, Olsen 
al. (1975) reported a decreased binding of morphine to plasma 
proteins in patients with uraemia, jaundice and/or 
hypoalbuminaemia. Relevant clinical details were unavailable 
for the patients whose plasma was used in this study, and the 
extent to which disease factors may have influenced the 
binding cannot be determined.
As expected, insignificant binding of M6G to plasma 
proteins was demonstrated, these results being comparable to 
those previously reported for M3G (Garrett and Jackson, 1979;
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Olsen et âi*/ 1988; Olsen ^  âi*/ 1989). This negligible
binding of metabolites, compared to the parent drug, is 
likely to be due to the lower lipid solubility of M3G and 
M6G. A similar pattern may be predicted for binding to other 
tissues in the body. The finding that greater quantities of 
free metabolite than morphine are present in the circulation 
has important implications in the pharmacokinetics of these 
compounds. It is the unbound fraction that is more readily 
available to cross membranes for rapid distribution, to be 
filtered at the glomerulus, and to gain access to 
drug-metabolising enzymes in_the liver. This is of particular 
importance when the availability to the CNS is considered. 
Indeed, Olsen al* (1975) concluded that the decrease in 
morphine binding in patients with hepatic and renal failure 
probably contributed to the increased CNS effects observed in 
these patients after usual clinical doses of morphine.
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CHAPTER JÜINE
GENERAL CONCLUSIONS
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9.1. Assay Methodology
The studies reported have attempted to examine the basic 
pharmacokinetics of morphine and its glucuronide metabolites
in both animals and man. One of the primary aims of these
studies was to clarify some of the confusing data that had 
arisen as a result of the use of non-specific assays in 
previous studies. In addition, in view of the quantitative 
significance of M6G after morphine treatment and its 
potential clinical activity in man, considerable importance 
was attached to the development of a sensitive and specific 
assay for the separate quantitation of morphine and its 
metabolites. The present studies have involved the assessment 
of the potential offered by RIA, and two different approaches 
have been pursued. Firstly, the use of three existing 
anti-morphine antisera, available at the start of the 
project, in a differential RIA technique designed to measure 
levels of morphine, M6G and M3G was investigated. A second
approach to measuring levels of M6G directly has involved 
attempts to raise a new antiserum specific for M6G. 
Unfortunately, to date, neither approach has proved to be
completely satisfactory.
The successful validation of a differential RIA 
technique enabling levels of morphine, M6G and M3G to be 
determined in a variey of biological fluids has been 
described. The use of a number of different radiolabels in 
these assays has been investigated and [3H]-morphine and 
[125IJ-M6G were eventually found to be the most suitable.
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It has long been realised that accurate assessment of
the characteristics of an antiserum are necessary before the 
procedures involved in the development of an immunoassay can 
be pursued. Of particular importance is the specificity of 
the antiserum, especially when the assay is required to 
measure levels of a drug in the presence of its metabolites. 
An excellent example of the problems that may arise in this 
situation is the use of a non-specific antiserum for morphine 
that was also found to cross-react with M6G (Moore gt &1«, 
1984b; Aherne and Littleton, 1986). The use of this antiserum
led to the publication of spurious results for morphine in a
number of pharmacokinetic studies, although this data 
indirectly provided some information on the importance of M6G 
as a metabolite of morphine.
Validation of the differential RIAs was achieved by 
performing extensive recovery studies for all the analytes of 
interest and, in the case of the assays for morphine and M6G, 
by correlation of the results obtained with a specific HPLC 
method. For both assays, accurate recoveries of low levels
from a number of matrices were evident, and good agreement 
with HPLC was also found. Indeed, the accuracy, reliability 
and sensitivity of the specific morphine RIA makes it an 
excellent choice for use in studies investigating the 
pharmacokinetics of morphine. Additional advantages of this 
RIA over existing chromatographic procedures include its 
ability to directly analyse small volumes of a range of 
biological fluids, combined with the high sample throughput
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that can be achieved in the absence of automation.
Greater caution is required when interpreting the 
metabolite data obtained using the differential RIA 
procedure. In the assay designed to measure levels of M6G, 
the potential problem of interference from high levels of M3G 
present was apparent. Better recoveries, leading to an 
improved correlation with HPLC, were achieved when [125I]-M6G 
was used as the radiolabel in place of [1251]-morphine. 
Additional attempts to improve the specificity and/or 
sensitivity of the assay for M6G, by increasing the assay 
incubation time, or by including an initial chromatographic 
separation stage to resolve the M3G and M6G components in 
plasma, did not offer immediate improvements. Comparison of 
the cross-reactivity and recovery data using this antiserum 
has revealed that, in a situation where mixtures of compounds 
compete for binding sites on antibodies with varying degrees 
of avidity, simple cross-reactivity standard curves are not 
sufficient. In these situations, detailed characterisation of 
the antiserum is required in the form of extensive recovery 
assessments. This information is particularly important when 
advantage is being taken of the broad specificity profile of 
an antiserum to enable a number of substances to be measured 
simultaneously within the same sample e.g. differential RIA. 
In the development of their assay. Hand et al. (1987a) 
reported that the antiserum they were using to measure 
combined levels of morphine and M6G cross-reacted with M6G by 
more than 100%. In an attempt to correct for this, and to
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allow for any inter-assay variation in M6G cross-reactivity, 
they divided each M6G result by a "cross-reactivity factor" 
determined by the inclusion of an M6G standard curve in each 
assay. However, this does not take into account any 
inter-sample variability in the cross-reactivity of M6G, 
which is likely to vary depending on the levels of morphine 
and M3G present. In the method reported in this thesis, 
similar cross-reactivity data was found with an equivalent 
antiserum, but accurate recoveries of morphine and M6G over a 
wide range of concentrations were evident. There appeared to 
be no requirement for a correction factor to be introduced. 
Reliable recovery of M6G was obtained when M6G was used as 
the standard and radiolabel. M6G results determined using 
this differential RIA technique showed good agreement with 
those obtained using a specific HPLC method.
The use of antiserum GR6 in a differential RIA to 
measure levels of M3G has also been investigated. This assay 
has been shown to be capable of providing reasonable 
estimates for the levels of M3G present, and has been used 
for this purpose in a small number of the studies reported 
here. It is possible that the specificity of this assay could 
be improved by adopting some of the modifications described 
for the differential RIA ; for M6G. Significant
improvements and further validation steps would be required 
before it could be used in more detailed pharmacokinetic 
studies.
A number of potential M6G-protein conjugates have been
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considered as candidates for use in the production of a 
specific M6G antiserum. Unfortunately, subsequent attempts 
to synthesise the haptens required have been far from 
successful, due mainly to the difficulties experienced in the 
chemical modification of the M6G molecule. The availability 
of specific antisera for morphine, raised to morphine 
conjugates prepared using 2-substituted and N-substituted 
haptens (Hand êÈ. al., 1987a; Morris gi , 1974), indicated 
that immunisation with similar M6G conjugates, could give 
rise to a specific M6G antiserum. - Initial studies
involved the preparation and -characterisation of an antiserum 
raised to a 2-directed morphine conjugate. The use of this 
antiserum in an assay for morphine indicated that high levels 
of M3G and M6G interfered in this assay and, as such, these 
results confirmed the findings of some earlier studies 
employing similar anti-morphine antisera (Spector et al., 
1973). It was therefore decided to abandon any plans to 
prepare a 2-substituted M6G hapten in favour of an 
N-substituted hapten. Unfortunately, although attempts have 
been made to prepare two such haptens, only 
N-aminobutylnormorphine had been successfully synthesised by 
the end of this project. Immunisation of a rabbit, using a 
conjugate prepared from this hapten and thyroglobulin, has 
given rise to antibodies to M6G for which encouraging data on 
titre and specificity has been obtained. This antiserum 
warrants further investigation and may offer an exciting 
potential as a reagent for a specific immunoassay for M6G.
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The present trend is away from the use of radioisotopes, 
and a number of alternative immunoassays have been described 
using enzyme and chemiluminescent labels. The use of morphine 
and M6G haptens for the preparation of conjugates for use in 
non-isotopic assays warrants investigation. In particular, 
the 2-substituted morphine hapten, and the antiserum 
subsequently raised to the resulting immunogen, have 
potential roles in the development of a general opiate 
screening ELISA, bearing in mind the specificity profile of 
this antiserum (Smith, R.N., personal communication).
In the absence of a suitable specific antiserum for M6G, 
differential RIA remains the only immunoassay technique 
available for the determination of M6G and M3G. Further 
validation of this, and any future immunoassays for M6G, 
should include an assessment of the cross-reactivity of 
morphine-3,6-diglucuronide, if a supply of this metabolite 
becomes available. In the meantime, HPLC remains the method 
of choice for the simultaneous determination of the 
metabolites of morphine. The method of Svensson and 
colleagues (Svensson êt âl*/ 1982; 1986; Joel et / 1988) 
has found the most widespread use, although its poor 
reliability and inflexibility make differential RIA an 
attractive alternative, particularly when dealing with 
tissues, other than plasma, for which this HPLC method has 
not been validated and may even be unsuitable. The potential 
offered by the HPLC method for the same compounds, recently 
published by Venn and Michalkiewicz (1990), warrants
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investigation.
9.2. Pharmacokinetics and Distribution of Morphine and 
MorDhine-6-glucuronide
One of the major aims of this thesis was to assess the 
pharmacokinetics of morphine and M6G after conventional 
routes of administration using reliable and properly 
validated assay techniques. At the same time, the effects of 
a novel, and potentially useful, route of dosing on morphine 
and M6G behaviour has also been investigated.
After intravenous and oral routes of administration, the 
behaviour of morphine was seen to resemble the findings of 
other workers who had also employed accurate analytical 
techniques. Marked individual variation in pharmacokinetic 
parameters following a single dose was apparent in the 
healthy subjects studied. However, there was a consistent 
correlation between administered dose of morphine and plasma 
AUG. The extensive first pass metabolism of morphine, and the 
resulting low bioavailability to the systemic circulation, 
was clearly demonstrated. No difference in bioavailability 
was demonstrated between oral morphine administered as an 
aqueous solution, or in the form of a controlled release 
tablet (MST Continus), with the relative bioavailability of 
these tablets ranging between 80% and 94%. However, the 
results obtained in these studies emphasise the need to take 
into account the considerable quantities of M6G that are 
produced after oral administration when interpreting the
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pharmacodynamie significance of the bioavailabilty data. The 
studies performed here provide the first available data on 
the relative quantities of morphine and M6G occurring after 
common routes of morphine administration, permitting 
meaningful speculation about the relative potency of 
parenteral and enteral dosing. Indeed, it was of interest to 
note that similar quantities of M6G were produced after an 
equivalent dose of morphine administered i.v. or orally. The 
relative quantities of morphine and M6G found after single 
oral doses in these studies were similar to those observed in 
cancer patients after chronic oral dosing (Poulain et al., 
1988), indicating that significant accumulation of these 
compounds does not occur after repeated administration. 
However, this may reflect the differences in assay techniques 
used, and further study of repeated dosing is required to 
compare metabolite production and other pharmacokinetic 
parameters so that the relevance of this single dose data can 
be extended to everyday practice.
The time course of the ■ occurrence and elimination of 
morphine and M6G after conventional doses of morphine explain 
the limited success of previous attempts that have been made 
to relate the analgesia experienced after morphine dosing 
solely on the pharmacokinetics of the parent drug. The 
present data supports the hypothesis that M6G, as well as 
morphine, is important in producing the observed clinical 
effects in man. A far more satisfactory pharmacodynamic/ 
pharmacokinetic correlation may be forthcoming if the
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disposition of morphine and M6G is taken into account.
When morphine was administered to volunteers as a 
sustained release buccal formulation, bioavailability was not 
improved. Unfortunately, this preparation was poorly 
tolerated and was simply swallowed by a number of the 
subjects. Nevertheless, this part of the study re-emphasises 
the importance of measuring morphine and M6G after morphine 
dosing, since, if an increase in bioavailability had been 
observed, it is likely that this would have been accompanied 
by a reduction in the quantity of M6G produced, and the total 
"quantity of analgesic" available after this treatment may 
not be significantly increased. From the present data, it 
would therefore appear that the buccal route does not offer 
an advantage over the oral route.
The studies discussed above have established basic 
pharmacokinetic parameters for the standard morphine 
formulations currently used, although more detail is required 
following chronic oral dosing. At the same time, information 
is required on the pharmacokinetics of morphine during its 
continuous subcutaneous infusion or after its rectal 
administration, both popular alternative routes in 
circumstances where oral medication is unsuitable.
Following the direct demonstration of the analgesic 
activity of M6G in man (Osborne et al., 1988), the studies
described in Chapter Six were carried out to provide some 
details on the behaviour of this compound after i.v. and oral 
dosing. In general, the pharmacokinetic data obtained
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following i.v. dosing was in good agreement with that 
reported in earlier studies investigating the disposition of 
M3G in animals and man. There was a large inter-individual 
variation in the results obtained, particularly in the 
patient groups studied. Following i.v. dosing, M6G appeared 
to obey dose-independent kinetics. The mean terminal 
elimination half-life for M5G in normal subjects was slightly 
shorter than that observed in patients, but was similar to 
that calculated for morphine and M6G in volunteers treated
with morphine (Chapter Five). The differences found in the 
patient data are likely to-reflect the importance of renal 
function on M6G elimination. In addition, values for plasma 
clearance in these patients were found to be 
dose-independent, confirming previous results obtained in the 
dog and providing further evidence that renal excretion is 
the major route of M6G elimination. Values for clearance of 
morphine following i.v. dosing were considerably higher than 
those calculated for M6G, reflecting the high hepatic
extraction ratio of the parent drug. Morphine was also found 
to be more widely distributed than M6G. These differences in 
values for volume of distribution would be predicted from the 
physicochemical properties of these compounds, which are also 
responsible for the differences in plasma protein binding
observed (Chapter Eight).
In another experiment, the details of which are not
included in this thesis, high levels of morphine, M6G and M3G 
were found in a selection of malignant effusions (pleural
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fluid and ascites fluid) collected from cancer patients at 
steady-state on chronic oral morphine. The ratios of 
morphine:M3G:M6G in these fluids were of the same order as 
would be expected in the plasma. Unfortunately, only a small 
number of patients were studied and the levels of these 
compounds were measured using the differential RIA techniques 
developed for use in plasma. It is therefore difficult to 
draw any firm conclusions from the results, although the 
fluids collected appeared to represent a considerable pool 
for the distribution of morphine, M3G and M6G in cancer 
patients and, as such, could contribute to altered drug 
distribution and influence dose requirements.
In contrast to earlier studies, significant increases in 
terminal half-life, or delayed secondary plasma peaks, for 
morphine or M6G were not observed in the subjects 
participating in the studies reported here. However, the 
significant quantities of morphine and its glucuronide 
metabolites detected in the bile of patients receiving 
chronic oral morphine are strongly suggestive of an 
enterohepatic circulation for morphine, the relative 
importance of which is, as yet, unclear. Nevertheless, this 
cycle could result in the persistance of significant levels 
of morphine and/or M6G in the plasma and, therefore, 
experiments investigating the biliary kinetics of morphine 
and its metabolites in patients receiving both single and 
multiple doses would be of use.
Wide individual variation was apparent in the
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pharmacokinetic data calculated for the volunteers who were 
given M6G as an oral solution. Following administration, low 
levels of M6G were quickly detected in the plasma of these 
subjects, but the lack of urinary excretion data precluded 
any discussion on the efficiency of absorption of this 
compound. The appearance of two plasma peaks was noted in 
most of the subjects, with an initial absorption peak 
occurring approximately 2 hours after dosing and a delayed 
peak observed between 8 and 10 hours. This late peak could 
be the result of intra-intestinal deglucuronidation, and 
subsequent reglucuronidation_of morphine by the intestine 
and/or liver before its reappearance in the plasma. The 
delivery of M6G by this route may be improved by the use of 
"ion-pairs" (Houston and Wood, 1980), or by the concurrent 
administration of other medications or food, as has been 
demonstrated for oral morphine (Chapter One). Bearing in mind 
the potential of M6G as an analgesic drug in its own right, 
and the popularity of the oral route in cancer patients, 
further studies investigating this route of administration 
are required, including the use of ia vitro intestinal models 
to study the absorption characteristics, and the collection 
of urine for a 24 hour period after dosing for subsequent 
analysis. Alternatively, the potential use of sublingual, 
buccal, or controlled*-release buccal tablets as alternative 
formulations for the enteral delivery of M6G deserves 
consideration, in view of the known absorption of M3G by the 
buccal route (Al-Sayed-Omar ^  al., 1987).
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The metabolic fate of systemically administered M6G has 
been partly defined in these studies. Morphine and M3G were nsb 
found in the plasma of the subjects dosed with i.v. or oral 
M6G, These findings are in agreement with those of Osborne 
and colleagues (1988), and confirm that the analgesia
experienced following the administration of this compound is 
due to the unchanged M6G itself, as was first suggested by 
Yoshimura et al,. (1973). Further detail on the
biotransformation of M6G is required, but is unlikely to 
become available until an assay capable of quantitating 
morphine-3,6-diglucuronide in plasma and urine is developed. 
Further modification of existing HPLC or RIA methods to 
include the detection of this compound is likely to prove
rather difficult. However, the structure of this metabolite 
indicates that it would be unlikely to contribute to the 
analgesia experienced after M6G administration.
In view of the problems observed in renal failure 
patients after treatment with morphine (Osborne et al.,
1986), and the important role of renal excretion in the 
elimination of M6G mentioned earlier, it is highly likely 
that significant accumulation of M6G would occur during renal 
failure, leading to persistence of the toxic effects of 
morphine in these patients. The consequences of this
phenomenon have been reported following morphine 
administration. Severe problems have arisen due to the 
prolonged respiratory depression experienced, and following 
the incorrect diagnosis of this increased narcosis as being
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the result of cerebral damage. In the event of M6G being used 
as an analgesic in its own right, its pharmacokinetics in 
renal failure requires extensive investigation to enable it 
to be safely prescribed to such a patient population.
The experiments described in Chapters Seven and Eight 
have provided useful information on the distribution of 
morphine and its glucuronide metabolites in animal tissues 
and human body fluids. In the past, a number of studies had 
failed to successfully correlate the clinical effects of 
morphine with its plasma pharmacokinetic data. Thus, it was 
of particular interest in these experiments to obtain some 
information on the distribution of these compounds in the 
CNS, i.e. closer to their site of action.
The experiments conducted in rats showed that following
i.p. administration, morphine and M6G follow similar 
distribution and elimination patterns within the serum and 
brain compartments. Both compounds were rapidly absorbed from 
the injection site and quickly entered the brains of the 
animals, with peak levels of both compounds found after 5 
minutes. Comparatively more morphine than M6G entered the 
brain, in agreement with the earlier studies of Yoshimura sb 
al. (1973). These findings would be predicted from the 
different lipophilicity characteristics of the two compounds. 
However, the half-lives for the terminal elimination phases 
from both these compartments were similar for morphine and 
M6G. This suggests that the passage of M6G into the brain 
compartment is restricted in terms of the relative quantities
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that can cross the blood-brain barrier, but that the rate at 
which this process occurs does not appear to be significantly 
longer than that observed for the less polar parent drug.
Morphine was not detected in the serum or brain of 
animals dosed with M6G, indicating that significant 
deglucuronidation does not occur in these tissues and that 
the analgesia observed in studies in rats treated with M6G 
was due to M6G alone. However, significant quantities of 
morphine were found in the organs of excretion collected from 
these animals. A good deal of conflicting data has been 
presented in previous reports investigating the in vivo 
disposition of glucuronidated compounds in animals. Verbeeck
(1982) has suggested that deglucuronidation may occur when 
significant quantities of drug glucuronides accumulate, and 
the influence that this process has on the behaviour of the 
glucuronide metabolites of morphine in vivo requires further 
investigation.
The data obtained in Chapter Eight provides further 
evidence confirming the presence of significant quantities of 
morphine, M6G and M3G, or M6G alone, in human CSF following 
treatment with morphine or M6G respectively. Wide 
inter-individual variation was found in the patients studied. 
In patients treated with morphine, levels of the metabolites 
present in the CSF were lower than those found in plasma, in 
keeping with their more polar characteristics; M6G had 
greater availability than M3G. In the patients receiving 
chronic oral morphine therapy, high CSF;plasma ratios for
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morphine did not necessarily correlate with high ratios for 
the glucuronides, whereas better agreement was apparent 
between M3G and M6G. These findings indicate different 
transport mechanisms for the parent drug and metabolites. 
However, the data obtained from the patients receiving single 
doses of morphine and M6G was in agreement with the animal 
data discussed above, and indicated that one of the factors 
governing the quantity of these substances entering the CSF 
was their relative plasma concentrations, suggesting that 
they compete for the same transport system across the 
blood-brain barrier. Information is not available on this 
topic, although it is possible that these compounds either 
share a transport process specifically designed for opioid 
compounds, or that the glucuronide metabolites share the 
active transport pathway(s) by which a number of other small, 
polar molecules (notably glucose) are known to gain access to 
the CNS. It has been demonstrated in rats that the more 
lipophilic compounds, heroin and monoacetylmorphine, can 
function as carriers to enhance morphine access to the brain, 
but that this access becomes limited as the animals develop 
and their blood-brain barrier becomes more effective (Way, 
1967). Further studies investigating the processes) 
responsible for the transport of morphine and its metabolites 
into the CNS by the use of suitable inhibitors/competitors 
would be of value.
Following a single i.v. dose of morphine or M6G, these 
compounds achieved peak concentrations within the CSF at
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around the same time. In addition, although the rate of 
disappearance from the CSF was marginally longer for M6G than 
morphine in most of the subjects studied, these differences 
were not significant. This data agrees with the animal data 
obtained (Chapter Seven). Similarly unexpected results had 
been obtained for the terminal elimination half-lives for 
morphine and M6G from plasma (Chapters Five and Six), where 
similar values were obtained for both compounds, despite 
their polarity differences. However, these CSF results are 
not consistent with the kinetics observed following 
intrathecal morphine, M3G and M6G (Hanna et âi., 1990). Other 
groups have suggested that the explanation for the increased 
intra-cerebral potency of M6G over morphine, despite their 
apparently similar binding affinities for the opioid 
receptors, is due to the differences in their distribution 
within the CNS, combined with the longer residence time of 
the glucuronide. However, the relationship between overall 
CNS kinetics and CSF compartment kinetics is not well 
understood, and meaningful comparison of these studies is 
difficult. The present studies have only investigated CSF 
kinetics in a limited number of patients. In addition, the 
concentrations within the CSF frequently approached the 
limits of sensitivity of the RIAs employed. More detailed 
information on the distribution and elimination of morphine 
and M6G within the CSF compartment is required from studies 
using larger numbers of patients studied over a longer time 
period, and who are receiving a wider range of doses of
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morphine or M6G. At the same time, accurate data for the 
lipid/aqueous partition coefficients of morphine and M6G are 
required so that an accurate assessment of the relationship 
between plasma and CSF pharmacokinetics and lipophilicity can 
be carried out.
The potential of immunocytochemistry using existing 
anti-morphine antibodies for the localisation of morphine in 
rat brains has also been investigated during the course of 
these studies, with rather limited success. However, the use 
of improved staining procedures both with the existing 
antisera and with the antiserum raised to M6G, requires 
further investigation. Another in vitro tissue localisation 
technique that deserves investigation, and may provide useful 
information on the distribution of morphine and its
metabolites in animal and human post-mortem tissues, is 
autoradiography. For this purpose, the iodinated morphine and 
M6G radioligands, prepared for use in the RIAs (Chapter Two), 
might prove to be of use.
To complement the CSF distribution data discussed above, 
consistent opiate receptor binding data is required for
morphine, M3G and M6G. At the same time, details concerning 
the binding characteristics of other 6-substituted morphine 
analogues would be of interest, in particular 
6-monoacetylmorphine and morphine-6-ethereal sulphate (which 
is believed to be more potent than M6G). This data could be
complemented by information on the same compounds derived
from computer modelling studies carried out as an extension
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to the preliminary studies already performed for morphine, 
M3G, and M6G (Appendix II). This data may provide information 
on how the presence of a particular chemical group at the 
6-position on the morphine molecule influences the subsequent 
binding affinity, and could aid the design of future 
analgesic agents with an improved toxicity profile.
In summary, the pharmacokinetic data obtained in this 
thesis has provided the first reliable evidence that 
abundant quantities of M6G are produced after single doses of 
morphine administered intravenously or enterally. Indeed, the 
AUC (0-co) for M6G following^lOmg i.v. or oral morphine were 
similar to that obtained after lmg/70kg i.v. M6G, strongly 
suggesting that part of the analgesic effect observed after 
conventional morphine treatment is mediated by the active 
metabolite. In the light of this information, further studies 
relating the observed clinical effects, following the 
administration of morphine or M6G, to the plasma and CSF 
pharmacokinetics of these two compounds are required to 
define the pharmacodynamics of M6G more securely. More detail 
on the metabolic fate of systemically administered M6G is 
also required, notably the formation of
morphine-3,6,-diglucuronide, as well as information on the 
urinary excretion pattern for M6G and its metabolites.
The availability of suitable RIA techniques has- proven 
invaluable during the course of this work, and it is hoped 
that an improved immunoassay employing the anti-M6G antiserum 
will overcome some of the disadvantages of the differential
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RIA technique. In the meantime, the studies reported here 
have highlighted a number of clinically relevant features of 
morphine pharmacokinetics and metabolism, in particular the 
importance of the analgesically active metabolite, M6G. Data 
describing the distribution and elimination of morphine and 
M6G from the CSF have also provided useful information that 
will be of value when comparing the relative toxicitites of 
these compounds, with particular reference to the problem of 
respiratory depression. The insight gained in these studies 
will be invaluable in further studies investigating the 
potential of M6G as an analgesic in its own right, and will 
also ultimately result in a more rational use of morphine in 
the clinical situation, with a consequent improvement in 
patient care.
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APPENDIX I; IMMUNOCYTOCHEMISTRY METHOD 
Reagents
Tris-saline buffer 9.Ig tris methylamine 25.5g NaCl 3 ml Tween 20Dissolve above in 3 litres of distilled water, adjust to pH 
7.5 with HCl. Store at 4°C for 1 month.
Citric acetate solutiona) Dissolve 5.3g citric acid in 500 ml distilled water.b) Dissolve 1.2g ammonium acetate in 300 ml distilled water. Add a) to b) with warming until pH=5.0. Store at 4°C for 1 month.
Peroxidase substrateDissolve 125mg diaminobenzidine (DAB) (BDH Chemicals Ltd.) in 340 ml warm citric acetate solution. Add 200jul Preparefresh before use.
Procedure ;
1. Dewax sections
2. Rinse in running water.
- Histoclear- 100% alcohol70% alcohol 50% alcohol
3. Block endogenous peroxidase activity with H^PC/methanol.
4. Rinse in running water.
5. Cover slides with 1% non-immune serum.
6. Tip non-immune serum off and replace with 1st antibody. Incubate at 4“C in humidity chamber
7. Wash in tris-saline buffer.
8. Incubate with peroxidase-labelled 2nd antibody at room temperature.
9. Wash in tris-saline buffer.
10. Incubate in peroxidase substrate solution.
3 min 1 min 1 min1 min
10 min 
10 min
10 min 
30 min 
Overnight
2 X 10 min
4 0 min 2 hr.
2 X 10 min 
10 min
page 315
11. Wash in tris-saline buffer
12. Rinse in running water.
13. Rinse in distilled water
14. Counterstain
15. Dehydrate
- haematoxylin- running water- acid alcohol- running water
85% alcohol- 100% alcohol- xylene
2 X 10 min
10 min
1 min
5 min 1 min 5-10 sec 10 min
30 sec 1 min 1 min
16. Mount in DPX (xylene-based mounting fluid) and cover 
slide.
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APPENDIX II! MOLECULAR MODELLING STUDIES USING MET-ENKEPHALIN WITH MORPHINE-3- AND MORPHINE 6-GLUCURONIDES.
The following procedures were undertaken by Dr. D. Lewis 
of the Department of Biochemistry. University of Surrey.
Methods
Molecular structures of morphine 3- and 6-glucuronides 
were generated by the COSMIC modelling package (Vinter, J.G., 
Davis, A. and Saunders, M.R., Smith-Kline and French Ltd.). 
The met-enkephalin pentapeptide N-terminal sequence 
(Tyr-Gly-Gly-Phe-Met) was produced by an amino acid building 
routine within the COSMIC framework. Electronic structures 
were calculated by CNDO/2 method of Pople et aj.. ( 1965) on 
the minimised structures using COSMIC and then the 
met-enkephalin pentapeptide was modelled via conformational 
fitting with each glucuronide. All calculations were executed 
on a MicroVAX II minicomputer at the University of Surrey.
Results
Figures I-III show the results of computer modelling of 
the fitted structures. The atomic colour coding is as 
follows: Yellow = Sulphur; Red = Oxygen; Blue = Nitrogen. The 
hydrogen atoms have been removed for clarity.
In the case of M6G, the degree of molecular fitting with 
the pentapeptide is greater than for M3G. In particular, 
although the phenolic rings overlay quite readil .y in both 
cases (morphine and tyrosine phenolic functions), the
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disposition of carboxylic acid group of the 6-glucuronide 
ring permits overlap with the isosteric amide moiety of the 
met-enkephalin. When the glucuronide function is in the 
3-position of the morphine molecule, this overlap does not 
occur due to the different spatial arrangement of the 
molecule. These observations imply that the 6-glucuronide is 
more likely to mimic met-enkephalin activity than the 
3-glucuronide.
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Fig.I. Molecular structure of met-enkephalinN-terminal sequence (Tyr-Gly-Gly-Phe-Met). pentapeptide
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iFig.II. Morphine-6-glucuronide overlayed on met-enkephalinpentapeptide N-terminal sequence.
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Fig. III. Morphine-3-glucuronide overlayed on met-enkephalinpentapeptide N-terminal sequence.
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